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ABSTRACT
With the onset of the rapidly increasing population, the impact of age related
neurodegenerative diseases including Amyotrophic lateral sclerosis, Alzheimer’s disease,
Creutzfeldt-Jakob disease, Parkinson’s disease, Huntington’s disease and frontotemporal
dementia is becoming a predominant health and economic concern. Amyotrophic lateral
sclerosis (ALS) is a devastating neuromuscular degenerative disease that currently has no
effective treatment or therapeutics. ALS is characterised by a focal onset of motor neuron
loss, followed by contiguous outward spreading of pathology throughout the nervous system,
resulting in paralysis and death generally within a few years after diagnosis. The mechanisms
underlying neurodegeneration of motor neurons and disease progression are currently
unknown; however, current evidence implicates a range of cellular mechanisms. These
mechanisms include, deficient protein quality control, aberrant RNA metabolism, oxidative
stress, endoplasmic reticulum stress, glutamate excitotoxicity, mitochondrial dysfunction,
fragmentation of the Golgi apparatus, activated glia, axonal transport defects and
neuroinflammation. These dysfunctional cellular pathways may be associated with the
protein aggregates that are hallmarks of ALS pathology. However, the dysfunction in several
cellular processes does not explain the spreading of pathology, here the aberrant release and
uptake of toxic proteins including SOD1 and TDP-43 and their subsequent accumulation and
deposition in motor neurons may contribute. Given this hypothesis, the work presented in this
thesis aimed to further examine the role of SOD1 and TDP-43 in the propagation of
neurodegeneration in ALS, and investigate whether the proteins exhibit prion-like properties.
The term “Prion-like” as used here refers to the misfolding and aggregation of a disease
specific protein that subsequently escapes the cellular environment and seeds aggregation in a
naïve cell.
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The main aims of this thesis were to: investigate the mechanisms underpinning the uptake of
SOD1 aggregates into murine NSC-34 cells (Chapter 2); Examine the subsequent release of
SOD1 into the cytosol, detect released extracellular SOD1, and observe for secreted SOD1
internalisation into NSC‐34 motor neurons, then identify and quantify seeding activity in
recipient cells expressing SOD1 and characterise this interaction using a novel flow
cytometry method to quantify protein aggregation; Flow cytometric characterisation of
inclusions and trafficking (FloIT) (Chapter 3); determine whether exogenous recombinant
SOD1 protein aggregates can induce and/or contribute to TDP-43 pathology (Chapter 4);
determine if SOD1 aggregates can enter humanised models of motor neurons via the same
mechanism of action using both iPSC derived motor neurons and primary neurons (Chapter
5).
In Chapter 2, the aggregation and internalisation of SOD1 proteins, inhibition of SOD1
aggregates; macropinocytosis-associated membrane protrusions, fluid-phase uptake and
activation of RAC1 in NSC-34 motor neurons were investigated using transmission electron
microscopy,

pharmacological

inhibitors,

flow

cytometric

measurements,

confocal

microscopy, field emission scanning electron microscopy and enzyme‐linked immunosorbent
assays (ELISAs). Flow cytometric measurements indicated that SOD1 aggregates could enter
into naïve NSC‐34 cells in vivo. Furthermore, internalisation of SOD1 aggregates into NSC34 cells was shown to be mediated via a macropinocytosis pathway. SOD1-induced the
activation of macropinocytosis in NSC-34 cells, which was dependent on the activation of
RAC1 as assessed by ELISA. This in turn triggered the formation of ruffles and blebs in the
plasma membrane as assessed by field emission scanning electron microscopy and
fluorescent measurements of the FM1-43FX membrane binding dye. This resulted in the
uptake of SOD1 aggregates and fluid from the extracellular environment as assessed by
fluorescent measurements of 10 kDa dextran conjugated to Alexa Fluor. Significant cell
xxviii

death in NSC-34 motor neurons was not observed during this process. Collectively, this data
suggests that SOD1 aggregates are capable of mediating the activation of macropinocytosislike pathways to facilitate their entry into in NSC-34 cells.
In chapter 3, spontaneous aggregation of SOD1WT and mutant SOD1G93A-EGFP proteins in
NSC-34 motor neurons was measured using the flow cytometric characterisation of
inclusions and trafficking (FloIT) technique. The transient expression of SOD1WT and mutant
SOD1G93A-EGFP in NSC-34 motor neurons was shown to correlate with cell death over time,
indicative of toxicity. SOD1 aggregate release from transiently transfected NSC-34 cells was
examined by immunoblotting pelletable fractions of conditioned media from these cells at
end point (72 h). Although the mechanisms of release were not confirmed, an increase in cell
death was observed concomitant with inclusion formation; consistent with a possible role for
passive release from SOD1 transfected NSC-34 cells. The now extracellular (released) SOD1
aggregates were internalised into naïve NSC-34 cells as demonstrated by confocal
microscopy and immunoblotting of cell lysates. Next, the transfer of SOD1WT tdTomato and
mutant SOD1G93A-EGFP from transfected NSC-34 cells was assessed by flow cytometry and
the FloIT technique. The transfer of SOD1WT tdTomato and mutant SOD1G93A-EGFP proteins
was confirmed by the detection of dual fluorescent NSC-34 cells, indicating the presence of
both proteins. Furthermore, immunoblotting and microscopic observations following the
uptake of SOD1 aggregates suggested that recombinant WT and mutant SOD1 aggregates
were found to escape membrane bound vesicles and enter into the cytosol; a similar process
has previously been observed during virus entry. The ability of SOD1 to rupture membrane
bound compartments was confirmed by haemoglobin red blood cell assay, the use of
liposomes, and fluorescent measurements of the Galectin-3 protein. The seeding activity of
mutant SOD1 was assessed by co-culturing NSC-34 cells expressing either SOD1WT
tdTomato or mutant SOD1G93A-EGFP. Flow cytometric analysis and FloIT measurements
xxix

indicated that mutant SOD1G93A-EGFP induced the aggregation of SOD1WT tdTomato
proteins at 72 h, in a prion like fashion. The FloIT analysis of two colour aggregates also
demonstrates that SOD1G93A-EGFP and SOD1WT tdTomato are co-aggregating. The seeding
activity of mutant SOD1 was further confirmed, when recombinant mutant SOD1 G93A
aggregates were found to enhance the number of inclusion bodies containing SOD1WT
tdTomato red aggregates as assessed by flow cytometric analysis and FloIT measurements.
Together, this data supports a role for SOD1 in the infectious prion-like spread of protein
aggregation in neuronal cells.
In Chapter 4, spontaneous aggregation of TDP-43WT tdTomato and mutant TDP-43G124AEGFP fusion proteins in NSC-34 motor neurons was demonstrated using flow cytometry and
measured using the flow cytometric characterisation of inclusions and trafficking (FloIT)
technique. However, a significant reduction in the number of inclusions was observed at 72 h,
indicating loss of cells containing inclusions, likely through cell death. The transfer of TDP43WT tdTomato and mutant TDP-43G124A-EGFP from transfected donor to recipient NSC-34
cells was assessed by flow cytometry and the FloIT technique. The transfer of TDP-43WT
tdTomato and mutant TDP-43G124A-EGFP proteins was confirmed by the detection of dual
fluorescent NSC-34 cells, indicating the presence of both proteins. Furthermore, the seeding
activity of mutant TDP-43 was assessed by co-culturing NSC-34 cells expressing either TDP43WT tdTomato or mutant TDP-43G124A-EGFP. Flow cytometric analysis and FloIT
measurements indicated that mutant TDP-43G124A induced the aggregation of TDP-43WT from
48 to 72 h. These data also demonstrate that TDP-43G124A and TDP-43WT tdTomato are coaggregating. Incubation of TDP-43WT tdTomato transfected NSC-34 cells with recombinant
SOD1 aggregates was found to induce the mislocalisation and aggregation of TDP-43WT into
the cytosol at 2 h and 72 h. To confirm these results, flow cytometric analysis and FloIT
measurements were used to quantify inclusion formation. Recombinant mutant SOD1 G93A
xxx

aggregates were found to significantly enhance the number of inclusion bodies containing
TDP-43WT tdTomato red aggregates. Furthermore, confocal microscopy demonstrated that
recombinant SOD1 aggregates could induce the same TDP-43 pathology in TDP-43WT
tdTomato transfected human embryonic kidney (HEK-293) cells. Collectively, this data
suggests that TDP-43 can spontaneously form aggregates, transfer between cultured motor
neuron cells and induce the aggregation of TDP-43WT mediated by mutant TDP-43G124A. This
is similar to those observed for SOD1. Furthermore, this study suggests a role for the
interplay between SOD1 and TDP-43 where SOD1 aggregates may contribute to TDP-43
pathology.
In Chapter 5, a role for macropinocytosis in humanised models was studied. Human iPSC
derived motor neurons and human primary neurons were both used to confirm the ability of
protein aggregates to stimulate macropinocytosis using confocal microscopy and flow
cytometry. Incubation of human iPSC derived motor neurons and neurons with WT and
mutant G93A SOD1 recombinant aggregates were found to internalise into these cells, and
this could be significantly inhibited by pre-incubation with inhibitors of macropinocytosis
including EIPA

and

RAC1W56. Furthermore, confocal

microscopy observations

demonstrated that SOD1 aggregate internalisation into these cells induced the formation of
membrane ruffling and blebbing, as assessed by field emission scanning electron microscopy
and fluorescent measurements of the FM1-43FX membrane binding dye. In addition, the
internalisation of SOD1 aggregates was shown to coincide with the uptake of extracellular
fluid as assessed by fluorescent measurements of 10 kDa dextran conjugated to Alexa Fluor.
This data supports a role for SOD1 aggregate mediated activation of macropinocytosis in
human neurons, demonstrating that similar mechanisms are possible in vivo. Moreover, the
role of macropinocytosis in other protein aggregates including recombinant TDP-43,
Huntingtin (Httex146Q) and α-synuclein associated with ALS/FTLD, Huntington’s and
xxxi

Parkinson’s disease was assessed in NSC-34 motor neurons. Incubation of NSC-34 motor
neurons with TDP-43, Huntingtin (Httex146Q) and α-synuclein recombinant aggregates was
found to result in aggregate internalisation, which could be significantly inhibited by preincubation with inhibitors of macropinocytosis including EIPA (exception in the case of αsynuclein). Furthermore, internalisation of these aggregates into these NSC-34 motor neurons
induced the formation of membrane perturbations as assessed by field emission scanning
electron microscopy; this coincided with the activation of RAC1 as assessed by ELISA and
the uptake of extracellular fluid as assessed by fluorescent measurements of 10 kDa dextran
conjugated to Alexa Fluor. Furthermore, the model proteins α-lactalbumin reduced and
carboxymethylated (RCM) and amorphous proteins were also able to internalize into NSC-34
motor neurons, induce membrane perturbations and fluid uptake from the extracellular
environment, in a similar manner to that of SOD1, however, this occurred in the absence of
the activation of RAC1 suggesting that a broad range of aggregated proteins, both amorphous
and amyloid-like, may be able to induce varied macropinocytosis-like pathways to facilitate
their cellular uptake. Overall, this data suggests that activation of macropinocytosis-like
pathways induced by a range of protein aggregates including SOD1, TDP-43, Huntingtin
(Httex146Q) and α-synuclein aggregates may facilitate their entry into motor neurons in vivo,
similar to those observed during the propagation of aggregation during ALS progression.
Collectively, this thesis demonstrated that SOD1 and TDP-43 protein aggregates, as well as
other protein aggregates including Huntingtin (Httex146Q) and α-synuclein aggregates are
capable of being internalising by neuronal cells, through stimulating the activation of
macropinocytosis, an endocytic pathway also commonly employed by viruses during
infection. Once internalised, SOD1 and TDP-43 aggregates were shown to behave in a prionlike manner, propagating aggregation between motor neuron cells in culture, a mechanism
that potentially contributes to the progression of disease in ALS. However, given that an
xxxii

array of other genes have been recently implicated in disease pathogenesis and the multisystemic and multifactorial nature of ALS, findings from this thesis may only represent one
pathway which may act in concert with other pathways and mechanisms to induce motor
neuron degeneration. Given this, further research into the pathological mechanisms
underlying the progressive cycle of disease progression of ALS is necessary for viable
therapeutic treatments of ALS.
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Chapter 1
LITERATURE REVIEW
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1.1

Amyotrophic Lateral sclerosis: A common motor neuron disorder

Amyotrophic lateral sclerosis (ALS) was first described by Jean-Martin Charcot in 1869, as a
paralytic disorder associated with lesions observed in the central nervous system (CNS)
(Goetz, 2000). ALS is the most common form of motor neuron disease with adult onset. It is
a progressive and fatal neurodegenerative disease characterised by the selective degeneration
of both the upper and lower motor neurons which extend through the brainstem and spinal
cord to innervate skeletal muscle (Boillée et al., 2006) (Figure 1.1). Premature degeneration
and death of these motor neurons leads to progressive spasticity, exaggerated reflexes of
facial muscles (bulbar onset) or limbs (spinal onset), muscle weakness and atrophy that
affects the muscles of mobility, speech, swallowing and respiration, eventually resulting in
paralysis and death of the patient generally within 3-5 years from clinical onset (Cleveland
and Rothstein, 2001; Tandan and Bradley, 1985). Although in general cell loss in ALS is
specific for motor neurons, thus sparing cognitive ability, in approximately 5-10% of ALS
cases, patients also develop frontotemporal lobar dementia (FTLD) (Lomen-Hoerth et al.,
2002).
1.2

Clinical features and disease course in ALS

Diagnosis of ALS is achieved by clinical examination and electromyography (EMG) analysis
(Redler and Dokholyan, 2012). ALS is a heterogeneous disorder, characterised by variations
in i) the region(s) of onset, ii) contribution of upper and lower motor neuron deficits and iii)
the rate of disease progression between affected individuals (Ravits and Spada, 2009).
Irrespective of this, the majority of ALS cases are defined by a focal site of clinical onset of
motor neuron degeneration, followed by outward spreading of pathology through adjacent
contiguous anatomic paths, affecting motor neurons that are proximal to the region of onset,
followed by more distal pools of motor neurons and other cells within the interconnected
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regions (Ravits et al., 2007; Ravits and Spada, 2009). Recent evidence however, suggests that
onset of motor neuron degeneration can start at one or more focal points (multifocal) (Braak
et al., 2013), followed by local propagation of pathology from these regions (Sekiguchi et al.,
2014). Although contiguous propagation of pathology through the neuroaxis is considered the
most significant clinical feature of ALS (Ravits and Spada, 2009), the molecular mechanisms
underlying anatomical spread are currently unknown. Given the progression and spread
observed in ALS cases, it is likely disease pathology is spread cell to cell and region to region
by a yet to be understood mechanism.

Figure 1.1 ALS disease onset and regional spread of pathology involves the anato my of
the motor system. The functional motor system consists of upper motor neurons (UMNs), lower motor
neurons (LMNs), and regional skeletal muscles. Upper motor neurons (solid red line) are located in the primary
motor cortex of the brain with their axons projecting to the brainstem or spinal cord to form synapses with LMN
cell bodies (blue dots). LMN axons then extend from the brainstem or the spinal cord to communicate with
target muscles of the head and neck or trunk and proximal limb muscles through synaptic connectivity
respectively (blue line). At the initiation of disease in ALS, pathology is observed to have propagated and
distributed within the functional motor system, followed by propagation of pathology by regional contiguous
spread (Ravits, 2014; Ravits and Spada, 2009), affecting muscle tissues responsible for controlling voluntary
movements (Rowland and Shneider, 2001), and therefore resulting in the progressive paralysis.
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1.3

Incidence, Risk factors and therapeutics

ALS has an incidence of approximately 2-3 people per 100,000 (Logroscino et al., 2010;
Strong and Rosenfeld, 2003), with a slight male predominance in Caucasian populations
(Logroscino et al., 2010), although the incidence between men and women is relatively
similar in familial ALS (Kiernan et al., 2011). The major risk factors for ALS are age, with
onset commonly occurring at 45-65 years, and family history of the disease (Kiernan et al.,
2011). There is increasing evidence to suggest that specific environmental factors may have a
role in the etiology of some ALS cases. Such environmental factors thought to increase the
risk of developing ALS include engaging in a lifetime of intensive physical activity
(Scarmeas et al., 2002; Veldink et al., 2005) and geographically limited populations including
Gulf War veterans (Haley, 2003) and Italian soccer players (Chio et al., 2005). The overall
population-based lifetime risk of ALS is 1:350 and 1:400 for men and women respectively
(Kiernan et al., 2011), with a rapid decrease in incidence after the age of 80 (Logroscino et
al., 2010).
Currently, ALS is managed by limited pharmacological treatments which have prioritised the
symptoms rather than the causes of ALS, with more potentially supportive therapies being
investigated, such as Tauroursodeoxycholic acid (Elia et al., 2016; Lu et al., 2016). Despite
this, there are no definitive treatment options to cure or even significantly slow ALS disease
progression. Riluzole is the only clinically approved disease-modifying therapeutic treatment
available (Orsini et al., 2015). However this drug only provides modest improvement in
survival (3-6 months) attributed to its transient effects on modulating excitotoxicity
(Geevasinga et al., 2016). Consequently, understanding the pathological mechanisms of
neurodegeneration in ALS disease progression is necessary for better treatment options that
aim to improve disease course and potentially lead to preventative treatments for ALS that
will act as specific disease targets.
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1.4

Disease Aetiology

The aetiology of ALS is currently unknown, however, it is suggested that the complexity of
ALS is attributed to the multi-factorial and multi-systemic nature of the disease, some of
which will be outlined below. Previous findings from studies of ALS patients, transgenic
animal models and in vivo cell culture systems implicate several pathological processes that
may potentially be responsible for, or contribute to, the pathogenesis of ALS resulting in it
being classed as either a proteinopathy, a ribonucleopathy, an axonopathy, or a disease
related to the neuronal microenvironment (Riancho et al., 2016).
There are currently multiple and interconnected molecular and pathological mechanisms
implicated in ALS. These mechanisms include, deficient protein quality control, aberrant
RNA metabolism, oxidative stress, endoplasmic reticulum stress, glutamate excitotoxicity,
mitochondrial dysfunction, fragmentation of the Golgi apparatus, axonal transport defects and
neuroinflammation (reviewed in Harikrishnareddy et al., 2015; Redler and Dokholyan, 2012).
However, recent work presents convincing evidence to suggest that these mechanisms are
occurring simultaneously, rather than individually, to mediate motor neuron degeneration and
death (reviewed in Soo et al., 2011), and therefore are potential targets for therapeutic
intervention.
1.5

Protein misfolding and aggregation

Neurodegenerative diseases are closely linked to the formation and deposition of protein
aggregates, quite often fibrillar, that accumulate intracellularly, such as α-synuclein in
Parkinson’s disease, or extracellularly, such as the Aβ peptide plaques associated with
Alzheimer’s disease (Chiti and Dobson, 2006). Although the peptides and proteins that
aggregate are seemingly unrelated in terms of primary or tertiary structure, often the resulting
deposits are remarkably similar, often sharing a rope-like fibrillar morphology, a common
5

cross-β core structure, and the ability to bind specific dyes such as thioflavin T and Congo
red (Dobson, 2003).
Protein aggregation, or more specifically fibril formation, can be described as a nucleated
self-assembly reaction. In this context, misfolded monomeric proteins or peptides must first
aggregate to form stable nuclei from which fibril growth can occur via addition of further
monomer. In vivo, using bulk measurements such as light scattering or thioflavin T
fluorescence, protein aggregation reactions display sigmoidal growth kinetics (Figure 1.2).
Initially, there is a lag phase which is thought to reflect the time it takes for the nuclei to
form, and throughout which time the formation of fibrils is below the threshold of detection
(Pedersen et al., 2004; Serio et al., 2000). In solution, there are two predominant species;
monomer and fibrils (Figure 1.2A), while oligomeric aggregates are thought to be present in
small amounts (< 2% of total species). However, during the elongation phase the
concentration of fibrils increases dramatically as the monomer concentration decreases. This
is thought to be due to increasing numbers of actively growing fibrils via fragmentation of
fibrils creating new ‘growing ends’ and/or secondary nucleation (Figure 1.2B; where
available sites on existing fibrils catalyse the nucleation of new aggregates)(Arosio et al.,
2014; Knowles et al., 2014). This rapid growth proceeds until such time as the process
reaches a plateau where the equilibrium between available monomer and fibrillar protein is
reached (Figure 1.2A) (Chiti and Dobson, 2006; Wilson et al., 2008). The lag phase can be
circumvented by the addition of exogenous nuclei or ‘seed’ in the form of preformed fibrils
(Jarrett and Lansbury, 1993). As a consequence of seeding, the lag time is eliminated (Jarrett
et al., 1993) resulting in a first-order growth polymerisation (Figure 1.2C).
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Figure 1.2 Schematic representation of amyloid fibril formation. (A-B) Fibril formation can be
characterised by a lag phase where nucleation events occur, following critical nucleation a growth/elongation
phase is observed which can proceed via primary (monomer addition) or secondary (fragmentation/secondary
nucleation) events. During the latter stages, mature fibrils are formed which often display strong ThT emission
signals. (C) Addition of fibrils or other functional seeds to the start of the reaction allows elongation to proceed
without the requirement for primary nucleation removing the lag phase.

1.6

Genetic factors

While the majority of clinical ALS is sporadic (sALS; 90-95%) with no known obvious
cause, the remainder of cases are familial or inheritable in nature (fALS; 10%) (Haverkamp
et al., 1995) and are predominantly associated with Mendelian-inherited mutations in genes
encoding Cu/ Zn superoxide dismutase (SOD1), 43-kDa trans-activating response region
DNA-binding protein (TDP-43), fused in sarcoma/translocated in liposarcoma (FUS/TLS),
and C9ORF72 (Belzil et al., 2009; Brettschneider et al., 2012; Mackenzie et al., 2007; Rosen,
1993). Familial ALS is commonly inherited in an autosomal dominant pattern (Li and Wu,
2016). Furthermore, some gene mutations have been identified in sALS cases including the
ataxin-2 repeat expansions (Elden et al., 2010) and more recently loss-of-function NEK1
variants have been associated with approximately 3% of ALS cases (Kenna et al., 2016). In
addition, there is accumulating evidence to suggest that that mutations in these genes
associated with fALS are also identified in sALS cases (Al-Chalabi et al., 2012). Given the
similarities in pathological and clinical features between sporadic and familial forms of ALS,
it is suggested that similar downstream pathogenic mechanisms are involved in the final
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pathway for ALS (Al-Chalabi et al., 2012; Kabashi et al., 2007), and therefore information
into mechanistic insights and therapeutic advances may be translatable to all forms of ALS
and increase our understanding of the aetiology of ALS.
To date, at least 19 major genes with mutations and various functions including DNA and/or
RNA processing, and protein transport, trafficking and degradation have been directly linked
to fALS, in which a summary of these main genes are outlined in Table 1.1 (see Li and Wu,
2016). Although other studies and genome wide analysis databases have reported
approximately 125 genes as potential modifiers of ALS susceptibility (ALS Online Genetics
Database; http://alsod.iop.kcl.ac.uk), mutations in most of these genes are only identified in a
small fraction of ALS patients and therefore contribute minimally to the development of ALS
disease (Li and Wu, 2016). Furthermore, some polymorphisms identified in ALS patients
may represent genetic risk factors rather than causative mutations including mutations in the
neurofilament-heavy subunit (NFH), vascular endothelial growth factor (VEGF) and ciliary
neurotrophic factor (CNTF) (see Redler and Dokholyan, 2012).
The first causative gene was identified in 1993 as Cu2+, Zn2+ superoxide dismutase 1 (SOD1)
(Rosen, 1993). SOD1, a well-studied gene linked with several variants of familial ALS, and
has contributed significantly to the current understanding of the molecular mechanisms of
other forms of ALS. Mutations in SOD1 are very common, accounting for approximately
20% fALS and 1-2 % sALS cases (Deng et al., 1993; Rosen, 1993). The majority of these
SOD1 mutations are missense mutations, with an autosomal dominant inheritance, with the
exception of the D90A polymorphism, which can also result in a recessive inheritance pattern
(Al-Chalabi et al., 1998). In addition to SOD1, TDP-43, which binds RNA and DNA, is an
additional key player in ALS, with mutations in TDP-43 identified in approximately 5%
sALS and 3% fALS (Rutherford et al., 2008; Sreedharan et al., 2008).
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Table 1.1 The genetics of familial amyotrophic lateral sclerosis
Gene

Protein

Clinical presentations

Function

Mode of
Inheritance

ALS 2

Alsin

UMN, LMN, Bulbar

DNA/RNA processing

AR

ANG

Angiogenin

UMN, LMN, Bulbar

DNA/RNA processing

AD

ATXN2

Ataxin 2

UMN, LMN

DNA/RNA processing

AD

C9orf72

Chromosome 9 open
reading frame 72

UMN, LMN, Bulbar

Protein degradation

AD

CHMP2B

Charged multivesicular
body protein 2B

UMN, LMN, Bulbar

DNA/RNA processing

AD

CHMP2B

Charged multivesicular
body protein 2B

UMN, LMN, Bulbar

DNA/RNA processing

AD

CCNF

cyclin F

UMN

Protein degradation

AD

DCTN1

Dynactin

UMN, LMN, Bulbar

Axonal transport and
vesicle trafficking

-

FUS

Fused in sarcoma

UMN, LMN, Bulbar

DNA/RNA processing

AD,AR,DN

NEFH

Neurofilament heavy chain

UMN, LMN, Bulbar

Cytoskeletal network

AD

OPTN

Optineurin

UMN, LMN

Protein degradation
(autophagy)-

AD, AR

PRPH

Peripherin

LMN, Bulbar

Cytoskeletal network

-

PFN1

Profilin 1

LMN, Bulbar

Cytoskeletal network

AD

SETX

Senataxin

UMN, LMN, Bulbar

DNA/RNA processing

AD

SOD1

Cu2+, Zn2+ superoxide
dismutase 1

UMN, LMN, Bulbar

Antioxidant

AD,AR,DN

SQSTM1

Sequestosome 1

UMN, LMN, Bulbar

Protein degradation

-

TAF15

TAF15 RNA polymerase II,

UMN, LMN

DNA/RNA processing

AD, AR

TARDBP

TAR DNA binding protein

UMN, LMN, Bulbar

DNA/RNA processing

AD, AR

UBQLN2

Ubiquilin 2

UMN, LMN, Bulbar

Protein degradation

SD

VAPB

Vesicle‐associated
membraneprotein‐
associated protein B

UMN, LMN, Bulbar

Axonal transport and
vesicle trafficking

AD

VCP

Valosin‐containing protein

UMN, LMN, Bulbar

Protein degradation

AD

Mode types: AD, autosomal dominant; AR, autosomal recessive; DN, de novo; (‐) unknown information at current.
Information obtained from ALSoD database (http://alsod.iop.kcl.ac.uk/) and from the following literature (Al-Chalabi et al.,
2012; Chen et al., 2013; Li and Wu, 2016; Marangi and Traynor, 2015; Webster et al., 2016; Williams et al., 2016).
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1.6.1

Superoxide dismutase 1 (SOD1) in ALS

SOD1 is a ubiquitously expressed, cytosolic 32 kDa homodimeric enzyme, which plays an
important role as a cellular antioxidant to prevent oxidative stress. The primary function of
SOD1 is to convert (dismutase) the highly reactive free-radical superoxide formed during
biological processes, to a less damaging species (hydrogen peroxide) (Beckman and
Koppenol, 1996). More than 180 disease-associated mutations have been described in ALS
patients, mainly identified as point mutations present throughout all 5 exons of the SOD1
gene (http://alsod.iop.kcl.ac.uk/; Tortelli et al., 2013). Although some of these SOD1
mutations can impair enzymatic function, others are not associated with a loss of dismutase
function, rather they retain enzymatic activity comparatively similar to wild-type levels
(Bruijn et al., 1997; Gurney et al., 1994). However, these mutations may result in varying
dimer stability, aggregation propensity, metal ion binding affinity, intracellular protein
trafficking and rates of disease progression (Kaur et al., 2016).
Some of the most common SOD1-ALS mutations include G93A, G37R, G85R, A4V and
D90A (Al-Chalabi et al., 1998; Bruijn et al., 1997; Polling et al., 2014; Robertson et al.,
2007; Weisberg et al., 2012). To further characterise the role of SOD1 in ALS, in vivo models
including transgenic mice and rats have been engineered to over-express fALS associated
mutated forms of either the human or murine SOD1. These genetically engineered
(transgenic) animal models subsequently develop progressive motor neuron degeneration,
reminiscent of human ALS disease, and are therefore used as in vivo experimental ALS
models (reviewed in Turner and Talbot, 2008). To more accurately analyse SOD1 behaviour
in vivo, recent studies have developed mice expressing both human WT and mutant SOD1
protein, since most patients with familial ALS exhibit heterozygous mutations (Fukada et al.,
2001; Jaarsma et al., 2000). Interestingly, co-expression of WT SOD1 accelerated disease
phenotypes of mutant SOD1 expressing mice (Deng et al., 2006; Wang et al., 2009).
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Increasing evidence implicates a toxic gain of function acquired by mutant forms of SOD1,
which is directly responsible for motor neuron death (Andersen et al., 1995; Gurney et al.,
1994; Yim et al., 1996). This idea was initially supported by observations that transgenic
mice lacking SOD1 do not develop an ALS-like motor neuron disease or do not die
prematurely at least up to 6 months of age (Reaume et al., 1996). Conversely, rodents
expressing mutant SOD1 develop a progressive motor neuron disease, recapitulating many
features of ALS including motor neuron loss, deficient axonal transport, mitochondrial
dysfunction as well as pathological hallmarks (Gurney et al., 1994; Nagai et al., 2001; Ripps
et al., 1995) similar to that observed in human ALS patients (Dal Canto and Gurney, 1997).
However, the development of ALS-like symptoms in these mice varies depending on the type
of SOD1 mutation; transgene expression level, gender and genetic background (HeimanPatterson et al., 2011; Mancuso et al., 2012). Although it is widely accepted that different
mutants of SOD1 exert their toxicity through a gain of function, the precise cytotoxicity of
mutant SOD1 and its specificity for motor neurons remain to be elucidated.
A common feature that nearly all forms of mutant SOD1 exhibit is a higher propensity to
misfold and/or aggregate compared to WT SOD1 (Andersen et al., 1995; Furukawa and
O’Halloran, 2005; Gurney et al., 1994). Indeed, the relative aggregation propensities among
variants of mutant SOD1 has been reported to vary significantly in culture (Prudencio et al.,
2009), with certain mutations in SOD1 that exhibit aggressive clinical phenotypes having a
higher propensity to aggregate (Radunovic and Leigh, 1996). Although protein aggregation is
central to mutant SOD1 pathogenesis, it is unclear how mutation in SOD1 results in protein
misfolding and thus disease. However, aggregation-prone segments that interact to induce
aggregation in SOD1 have recently been identified, indicating that protein destabilisation of
the native fold may play a role in SOD1 mutant pathogenicity (Ivanova et al., 2014).
Furthermore, dimer disassociation has been reported to be a critical step for triggering SOD1
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aggregation, thus making aggregation prone residues more accessible (Rakhit et al., 2004).
However, additional factors such as RNA granule dysregulation and dysfunction of protein
degradation pathways may also underlie aggregation more generally in ALS (see Blokhuis et
al., 2013). Using in vivo analysis of mutant SOD1 aggregation profiles and survival time of
fALS patients, it has been reported that a higher protein instability and aggregation rate
correlate inversely with survival time (Bystrom et al., 2010; Wang et al., 2008). In addition,
under certain denaturing conditions, WT SOD1 has also been shown to form aggregates in
vivo (Chia et al., 2010), suggesting that aberrant oligomerisation of SOD1 could be a shared
pathogenic feature of ALS, irrespective of genotype (Redler and Dokholyan, 2012).
1.6.2

TDP-43 in ALS

In addition to SOD1, pathogenic forms of TDP-43, that are mislocalised to the cytoplasm,
hyperphosphorylated, and ubiquitinated within protein inclusions are a significant
pathological characteristic of motor neurons in ALS where SOD1 mutations are excluded.
TDP-43 is a heterogeneous RNA/DNA binding protein that is ubiquitously expressed and
involved in a range of processes in RNA metabolism including mRNA splicing and
localisation and gene regulation (Ayala et al., 2008; Johnson et al., 2009). Specifically, TDP43 has been implicated in ALS as a key player due to its presence in neuronal cytoplasmic
inclusions found in the spinal cord of sporadic ALS patients (Arai et al., 2006; Neumann et
al., 2006). In addition, mutations in TDP-43 have been associated with both familial and
sporadic ALS disease (Kabashi et al., 2008; Sreedharan et al., 2008; Van Deerlin et al.,
2008). Of note, most mutations identified in the TARDBP gene are located in the exon
encoding the C-terminal domain (Rutherford et al., 2008; Sreedharan et al., 2008), which has
been suggested to be highly aggregation prone (Zhang et al., 2009). It remains to be
determined if mutations in TDP-43 cause a gain or loss of function, with current evidence
suggesting both a toxic gain of function, a loss of function or a combination thereof (Lee et
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al., 2012). Similar to other misfolding disease related proteins, a gain of toxic function may
result from the mislocalisation of TDP-43 from the nucleus to the cytosol, where it fragments,
aggregates and forms inclusions (Johnson et al., 2009). However, it has been proposed that
the sequestration of functional TDP-43 into cytoplasmic inclusions may deplete nuclear TDP43 and result in the toxic loss of function of nuclear TDP-43 (Budini et al., 2015).

1.7
1.7.1

Cytoplasmic inclusion bodies in ALS
Overview

The central pathological hallmark of ALS is the presence of cytoplasmic proteinaceous
deposits known as inclusion bodies in degenerating motor neurons and neighbouring cells
(Blokhuis et al., 2013). The most common types of aggregates identified in ALS patients are
ubiquitinated aggregates in the form of Lewy body-like hyaline inclusions, skein-like, or
round ubiquitin positive inclusions (Kato, 1999; Murayama et al., 1989). In addition, Bunina
bodies and round hyaline inclusions (without a halo) are also found is ALS (Mizusawa, 1993;
Okamoto et al., 2008). Multiple proteins have been found associated with these inclusions
including; SOD1, TDP‐43, FUS/TLS, optineurin (OPTN), Ubiquilin‐2 (UBQLN2) and
C9ORF72 (reviewed in Blokhuis et al., 2013). Of note, TDP-43 is thought to be the major
component of ubiquitinated inclusions in most cases of ALS and many cases of FTLD (Arai
et al., 2006; Neumann et al., 2006). Therefore, not only are these misfolded protein
aggregates a significant pathological hallmark of ALS, but also have an important role in
mediating disease initiation and progression (see section 1.4).
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1.7.2 Misfolded SOD1 in inclusion bodies
Inclusion bodies containing aggregated SOD1 have been detected in human most-mortem
spinal cord tissues from both familial and to a lesser extent sporadic ALS patients (Bosco et
al., 2010; Forsberg et al., 2010; Shibata et al., 1994) and in spinal cord tissues from SOD1
ALS mouse (Bruijn et al., 1997; Shibata et al., 1994; Watanabe et al., 2001). However, these
cytoplasmic inclusions are not limited to the spinal cord, rather are found in other brain
regions including the hippocampus, cerebellum and frontal and temporal cortices (reviewed
in Al-Chalabi et al., 2012). The appearance of these inclusion bodies coincide with disease
onset in mouse models and are therefore thought to be an early pathological event in ALS,
which then accumulate progressively throughout the course of the disease (Turner et al.,
2003; Wang et al., 2002). Furthermore, recent studies have used conformation specific
antibodies to show that misfolded WT SOD1 can be detected in human post-mortem tissues
from non-SOD1 sporadic ALS individuals (Bosco et al., 2010; Forsberg et al., 2010;
Pokrishevsky et al., 2012).
While SOD1 misfolding and/or aggregation are features of pathogenesis in both familial and
sporadic ALS, including non-SOD1 linked familial and sporadic ALS (Matias-Guiu et al.,
2008), the role of SOD1 misfolding in motor neuron death has not yet been conclusively
determined. A study of transgenic familial ALS mice over time reported that soluble
misfolded SOD1 is concentrated in motor neurons from birth (Rakhit et al., 2007; Zetterstrom
et al., 2007), and that large insoluble aggregates are detected primarily in the later stages of
disease (Karch et al., 2009). Its thus appears that smaller soluble or misfolded SOD1 species
may be responsible for initial toxicity, and eventually begin to cause symptoms once a
disease-specific threshold has been reached. However, the relative toxicities of small soluble
oligomers and large-scale aggregates of SOD1 remain to be directly proven. It has been
postulated that oligomeric species present in solution prior to the appearance of fibrils are
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more likely to be responsible for cellular toxicity more generally (Kayed et al., 2003).
However, it is probable that all aggregate species provoke some level of cellular stress. One
potential mechanism of toxicity is through exposed hydrophobic residues found on protein
aggregates that have been shown to interact with cell receptors and membranes (Bolognesi et
al., 2010; Stefani and Dobson, 2003), leading to membrane disruption and inappropriate
signaling cascades. Moreover, the toxicity exerted by misfolded and aggregated SOD1 has
been reportedly linked with a range of pathological cellular effects including organelle
dysfunction (mitochondria, endoplasmic reticulum and the Golgi), cytoskeletal disruption,
caspase activation and dysfunction of proteasomal and autophagic pathways (Bendotti et al.,
2012).
Evidence from post mortem tissue demonstrates that protein aggregation is linked closely to
motor neuron death in ALS (Brettschneider et al., 2014).However, nucleation of protein
aggregation appears to be a stochastic process (Hortschansky et al., 2005), suggesting that
protein aggregation alone should cause a random pattern of cell death. In contrast, cell death
in ALS occurs in an ordered and progressive manner in human ALS patients, and therefore
protein aggregation contained within individual cells is not likely the sole cause of this
spread. Rather, one way to explain such an ordered progression is the prion-like propagation
of protein misfolding and aggregation between adjacent cells.
1.8

Patterns of Neurodegenerative Pathology in Humans

Major neurodegenerative diseases, such as ALS, Alzheimer’s disease, Tauopathies such as
Frontotemporal Dementia, Parkinson’s disease, Huntington’s disease, and transmissible
spongiform encephalopathies (TSEs), have common pathological changes such as loss of
neurons and the presence of pathological protein aggregates into either intracellular
inclusions bodies or extracellular plaques. However, generally speaking, the main
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aggregating protein is disease specific; for example SOD1, β-amyloid, α-synuclein,
Huntingtin and the prion protein (PrP) aggregate in ALS, Alzheimer’s disease, Parkinson’s
disease, Huntington’s disease and Creutfeldt-Jakob disease respectively (reviewed in Brundin
et al., 2010). Distinctive anatomical patterns of disease spread are consistent with a spreading
of pathology from one part of the brain to another in all of these neurodegenerative diseases
(Brundin et al., 2010).
The progression of these disorders, which is also associated with increasing clinical severity,
has enabled the development of several staging systems based on location of protein
aggregates (Braak et al., 2006; Braak et al., 2003; Brettschneider et al., 2014; Brettschneider
et al., 2013). The resulting patterns suggest that pathology is not only propagated between
nearby cells, but that it also remotely connects regions of the brain along axonal pathways
(Brettschneider et al., 2015; Brundin et al., 2010). Together these data are consistent with a
propagation of protein misfolding and aggregation reminiscent of those underpinning prion
diseases (reviewed in Zeineddine and Yerbury, 2015).
1.9
1.9.1

Prion-like propagation of aggregation in neurodegenerative diseases
Prion Disease

Over 30 years ago, a significant development in the field of infectious diseases and protein
biochemistry research was made, it was identified that “infectious” proteins known as prions,
could transmit disease between organisms without the requirement of nucleic acid (Prusiner,
1998). The mammalian prion protein is a self-propagating transmissible agent that mainly
consists of the abnormal misfolded/aggregated form of the prion protein (Prion Protein
Scrapie; PrPSc), known to transmit between cells and between individuals of the same species
(species barriers) (Diener et al., 1982; Prusiner, 1984). Prions can exhibit multiple
phenotypes

(prion

strains)

and

are

responsible

for

a

spectrum

of

aggressive
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neurodegenerative diseases in humans including Kuru and Creutzfeldt-Jakob disease (CJD),
and in animal populations in the form of scrapie in sheep and bovine spongiform
encephalopathy (BSE), also known as mad cow disease in cattle, and several other species
have their own version of prion-opathies (Diener et al., 1982; Prusiner, 1982). In these prion
diseases, the PrPSc protein can replicate by inducing the misfolding and aggregation of the
recruited natively folded cellular prion protein (PrPC), resulting in the aggregation of the
newly formed pathological prion protein converting it the protease resistant and insoluble
state. Therefore, prions act as abnormal templates that induce template-directed protein
misfolding and progressive aggregation (Prusiner, 1998).
There are two hypotheses on the molecular mechanisms of PrPSc-induced conversion of PrPC,
including template-directed refolding or nucleated polymerisation. Template-directed
misfolding involves a cyclical propagation whereby PrPSc induces PrPC (substrate) formation,
and these newly formed pathogenic proteins go on to convert subsequent PrPC proteins, thus
amplifying infectious agents (Aguzzi and Calella, 2009). The nucleated polymerisation
hypothesis suggests that the misfolding of PrPC to PrPSc is a reversible process and the PrPSc
can be stabilised by contact with PrPSc protein aggregates (Aguzzi and Calella, 2009).
1.9.2

Prion-like activity in neurodegenerative disease

1.9.2.1 Overview
Misfolded proteins associated with common neurodegenerative diseases are thought to be
capable of propagating the misfolding and aggregation of their natively folded counterparts,
potentially contributing to the transmission and spread of pathology from cell to cell within
and between tissues beyond the site of original protein conversion (reviewed in
Brettschneider et al., 2015). Mounting evidence has implicated a ‘prion-like’ mechanism in
the propagation of a pathology associated with common neurodegenerative diseases also
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known collectively as proteinopathies including; ALS, Alzheimer’s, Parkinson’s and
Huntington’s disease. Proteins known to aggregate in these disorders including SOD1, 𝛽amyloid, tau, α-synuclein and fibrillar polyQ aggregates (K2Q44K2), a model for polyQ
expansion, are all thought to share a “prion-like” mechanism of cell to cell spread, to
propagate misfolding (see Aguzzi and Calella, 2009; Brundin et al., 2010).
Prion-like propagation involves these protein aggregates entering into cells, crossing cellular
membranes to transmit pathogenic proteins in a ‘prion-like’ manner through the triggering of
the misfolding of their normally structured counterparts in cells, tissues, and animal models
(Brettschneider et al., 2015). The precise mechanism by which pathogenic proteins gain
access to the cytoplasmic compartment to propagate misfolding and aggregation remains
incompletely understood (Clavaguera et al., 2009; Desplats et al., 2009; Grad et al., 2014;
Ren et al., 2009).
These non-infectious proteopathies do not involve the prion protein but typically their disease
specific misfolded protein (Marciniuk et al., 2013). However, it is useful to model the
progression of neurodegenerative diseases associated with protein aggregation on the spread
of prion diseases within a host. It may provide an explanation for the apparent clinically
observed patterns of pathology in ALS, Parkinson’s, Alzheimer’s and Huntington’s disease.
There is indeed evidence amassing that suggests this might be the case (Table1.2).
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Table 1.2 Evidence of Prion-like mechanisms of disease specific proteins in models of
common neurodegenerative disorders.
Disease

Transmissible
prion
encephalopathie
s

Disease
specific
protein
Prion

Cellular location
of misfolded
protein
Intracellular
(Yamasaki et al.,
2012)
Extracellular
(Fevrier et al.,
2004)
Intracellular
(Bick et al., 2008;
Eisbach and
Outeiro, 2013)
Extracellular
(Desplats et al.,
2009; Gustafsson et
al., 2016; Loov et
al., 2016; Ren et
al., 2016)
Intracellular
(Moon et al., 2012)
Extracellular
(Kumar et al.,
2011)
Extracellular
(Schwab et al.,
1998; Yamaguchi
et al., 1991)

Parkinson’s

𝛼Synuclei
n

Alzheimer’s

𝛽amyloid

Alzheimer’s

Tau

Huntington’s

Huntingti
n (Poly
Q)

Intracellular
(Petrasch-Parwez et
al., 2007)

ALS

SOD1

ALS

TDP-43

Intracellular
(Cereda et al.,
2013)
Extracellular
(Grad et al., 2011;
Turner et al.,
2005a; Urushitani
et al., 2006)
Intracellular
(Nonaka et al.,
2009b)

*

Cell to cell
spread

Selfpropagation

Disease
transmission

Yes

Yes

Yes

Yes
(Luk et al.,
2012a)

Yes
(Desplats et al.,
2009; Ibrahim
and McLaurin,
2016; Pinotsi et
al., 2016)

Yes
(Li et al., 2008;
Luk et al., 2012a;
Luk et al.,
2012b)

Yes
(Nath et al.,
2012; Tasaki et
al., 2010)

Yes
(Kane et al.,
2000; Tjernberg
et al., 1999)

Yes
(Kfoury et al.,
2012;
Mohamed et
al., 2013;
Saman et al.,
2012)
Yes
(Herrera et al.,
2011; Pearce et
al., 2015)
Yes
(Grad et al.,
2014; Münch et
al., 2011)

Yes
(Frost et al.,
2009; Stancu et
al., 2015; Stohr
et al., 2012;
Vasconcelos et
al., 2016)
Yes
(Ren et al.,
2009; Yang et
al., 2002)
Yes
(Chia et al.,
2010; Grad et
al., 2011; Grad
et al., 2014;
Münch et al.,
2011)

Yes
(Kane et al.,
2000; MeyerLuehmann et al.,
2006)
Yes
(Iba et al., 2013;
Lasagna-Reeves
et al., 2012)

No

Yes
(Ayers et al.,
2014; Ayers et
al., 2016)

Yes
(Feiler et al.,
2015; Nonaka
et al., 2013)

Yes
Yes
(Feiler et al.,
(Nonaka et al.,
2015; Furukawa
2013)
et al., 2011;
Nonaka et al.,
2013;
Shimonaka et
al., 2016)
* Self propagation refers to the ability of the disease proteins to seed the aggregation of soluble
endogenous proteins.
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1.9.2.2 Parkinson’s Disease
Parkinson’s disease is a movement disorder characterised by the formation of Lewy bodies
and Lewy neurite inclusions, containing predominately α-synuclein, which has been
implicated as a key mediator in vesicular transport (Braak et al., 2003; Uversky, 2007).
Mutations within the α-synuclein gene is linked with inherited forms of Parkinson’s disease
and over expression of the wild-type form of α-synuclein has been reported to induce
toxicity, similar to that observed in the disease (Dauer and Przedborski, 2003).
Similar to ALS, in Parkinson’s disease α-synuclein aggregates have been reported to spread
in a topographically predictable manner as disease pathology progresses through the CNS
(Braak et al., 2006; Braak et al., 2003). Furthermore, previous studies have observed the
propagation of α-synuclein aggregates from cell to cell in human cultured human neurons and
in animal models, initiating the formation of Lewy body- like aggregates in naïve cells
(Desplats et al., 2009; Hansen et al., 2011; Lee et al., 2010). Cell culture studies have shown
that extracellular α-synuclein in various forms (fibrils, oligomers, and monomers) can be
internalised by cultured neuronal cells (Lee et al., 2010). Furthermore, mouse cortical
neuronal stem cells were shown to internalise extracellular aggregated α-synuclein either
applied as recombinantly produced protein aggregates or from co-culture with cells
overexpressing and subsequently releasing α-synuclein aggregates (Steiner et al., 2011). In
addition, CNS injections of brain homogenates derived from mice exhibiting α-synuclein
pathology or recombinant 𝛼-synuclein amyloid fibrils induced the formation of intracellular
inclusions and the onset of Parkinson’s symptoms in recipient transgenic and wild-type nontransgenic mice (Luk et al., 2012a; Luk et al., 2012b).
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The most startling evidence for a prion-like mechanism of α-synuclein involves the
observation that healthy tissue transplants grafted into the brains of people with Parkinson’s
disease acquire (as early as four years) intracellular deposits of α-synuclein, known as Lewy
bodies (Li et al., 2008). This was further demonstrated in post mortem studies that showed
that approximately 2-5% of normal embryonic neurons transplanted in the brains of
Parkinson’s disease patients acquired α-synuclein rich Lewy bodies over a period of 5 years
(Brundin et al., 2008; Hansen et al., 2011). The host to graft pathological 𝛼- synuclein cell-tocell transfer and seeding aggregation in recipient neurons (neuroblastoma cell line) and in
vivo in mice, where α-synuclein was shown to propagate from a mouse host brain cells to
grafted dopaminergic neurons (Hansen et al., 2011) and demonstrates the transmissibility of
𝛼- synuclein. A more recent study has been able to show, using more advanced imaging
techniques including super resolution microscopy, that 𝛼- synuclein can be taken up in its
monomeric form into neuronal cells, and nucleate the aggregation of endogenous 𝛼synuclein (Pinotsi et al., 2016).
1.9.2.3 Alzheimer’s Disease
Alzheimer’s disease is characterised by the formation of amyloid plaques which are
extracellular deposits composed primarily of insoluble β-amyloid aggregates and cytoplasmic
inclusion bodies containing hyperphosphorylated tau protein (Alonso et al., 1996). β-amyloid
is a proteolytic cleavage product of amyloid precursor protein (APP) which is a
transmembrane protein which may act as a signaling nexus, transducing information about
extracellular conditions (van der Kant and Goldstein, 2015). Cytoplasmic inclusion bodies
containing hyperphosphorylated tau protein aggregates or tangles are known to progressively
spread through the brain in an anatomically stereotypical manner (Alonso et al., 1996;
Goedert et al., 2006).
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In a similar paradigm to α-synuclein in Parkinson’s disease models, the transmissibility of 𝛽amyloid (A𝛽) peptide plaques have been initially shown to resemble a prion-like mechanism
in a study in which non-human primates were injected with human brain tissue derived from
AD patient (Baker et al., 1993; 1994). Similarly, injection of autopsy-derived brain extracts
from Alzheimer’s disease patients in to transgenic mouse models of Alzheimer’s disease
engineered to produce large amounts of APP, induces 𝛽-amyloid (A𝛽) peptide plaque
formation around the injection site indicating that a single inoculation of brain extract can
initiate β-amyloid plaque formation in vivo (Kane et al., 2000). In addition, one study
implanted steel wires coated with brain extracts derived from human Alzheimer’s disease
patients and demonstrated plaque formation which were observed to spread from the point of
seeding into neighbouring tissues (Eisele et al., 2009). This transmissibility was shown to be
inhibited by neutralising antibodies specific for 𝛽- amyloid, therefore indicating that the
agent responsible for this self-propagation mechanism is 𝛽-amyloid (Meyer-Luehmann et al.,
2006). Furthermore, intraperitoneal injections of β-amyloid rich transgenic brain
homogenates into transgenic mice induced widespread cerebral 𝛽-amyloidosis and associated
pathologies (Eisele et al., 2010), which was confirmed in another study which traced in vivo
A𝛽 propagation using bioluminescence imaging (Stohr et al., 2012).

In addition to 𝛽-amyloid, tau protein aggregates have been shown to self-propagate from cell
to cell in cultured cells (Kfoury et al., 2012). Similar to 𝛽-amyloid, injected brain extracts
containing misfolded tau into the brains of transgenic mice can seed the propagation of tau
misfolding and transmit this misfolding from the site of injection into neighbouring regions
of the brain (Clavaguera et al., 2009). More recently, pre-aggregated 𝛽-amyloid aggregates
were shown to directly induce Tau aggregation by cross-seeding in a prion-like manner and
therefore propagating Tau pathology in vivo (Vasconcelos et al., 2016).
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1.9.2.4 Huntington’s Disease
Huntington’s disease is a genetic autosomal dominantly inherited disease associated with
mutations in the gene encoding huntingtin and is characterised mainly by involuntary
movements and dementia. Huntingtin protein has been implicated in DNA transcription,
vesicle and axonal transport and synaptic function (Cattaneo et al., 2005). Mutations in the
huntingtin protein associated with disease are in the form of variable expansions within a
polyglytamine repeat (CAG) in exon 1 and induce the misfolding and aggregation of
Huntingtin resulting in the formation of inclusion bodies (Duyao et al., 1993). A direct
correlation between the extent of polyQ expansion with the propensity to misfold or
aggregate, disease severity and initiation of onset has been suggested (Davies et al., 1997;
Duyao et al., 1993; Scherzinger et al., 1997). Like α-synuclein, 𝛽-amyloid and tau,
Huntingtin has also been reported to exhibit prion-like mechanisms of propagation.
Aggregates of pathogenic polyQ expansion peptides have been shown to resemble scrapie
prions (fibrillar or ribbon-like morphology) (Scherzinger et al., 1997) and transmit from cell
to cell (Ren et al., 2009; Yang et al., 2002). Importantly, large aggregates of huntingtin
peptides have been shown to self-propagate through a seeding nucleation mechanism that
persists for several passages following the initial incubation of the cells with the extracellular
aggregates (Ren et al., 2009).
1.10 Regional spread of disease in ALS
1.10.1 Overview
It has been known for decades that fibril formation can be seeded in vivo through addition of
preformed fibrils, removing the rate limiting lag phase (see Figure 1.2). Just as in vivo fibril
formation of purified proteins is a nucleation dependent process, recent work using 2-photon
imaging demonstrates that Aβ plaque formation in the brain is also a nucleation dependent
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process (Burgold et al., 2014). This propagation is easily understandable given that Aβ
aggregates do not have to cross plasma membranes to seed further aggregation as amyloid
plaques are present outside of cells. It may be less likely that aggregates formed
intracellularly such as SOD1, could propagate aggregation inside another cell. However,
there is a wave of research that demonstrates that this is possible. At present, two major
proteins associated with pathogenesis of ALS have demonstrated intermolecular requirements
of prion-like activity: including SOD1 and TDP-43 (see Grad et al., 2015). In SOD1-ALS
disease models, the propagation of SOD1 protein aggregates from cell to cell in neuronal and
other cell lines and the template-directed seeding of SOD1 has been suggested as a possible
explanation for the toxic intercellular spread of pathology. (Furukawa et al., 2013; Grad et al.,
2014; Münch et al., 2011).
Given that ALS associated inclusions are intracellular, there are two vital steps that must
occur in order to propagate aggregation between cells; aggregates must first be released from
the originating neuron to the extracellular space and then the aggregates must cross the cell
membrane barriers to be taken up by neighbouring neuron cells to seed further aggregation in
the cytosol of naïve cells.
1.10.2 SOD1
1.10.2.1 SOD1 aggregates can be released from neurons
Misfolded SOD1 aggregates that are suggested to exhibit thermodynamic and conformational
stability are able to better thrive in the hostile extracellular environments (Grad et al., 2015).
SOD1 aggregates are generally found to be intracellular in human ALS patient samples,
however both WT and mutant SOD1 have been detected in the cerebrospinal fluid of ALS
patients (Zetterstrom et al., 2011) and in spinal cord cultured derived from transgenic SOD1
mouse models (Urushitani et al., 2006), suggesting that release of SOD1 occurs in vivo. In
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addition, SOD1 can also be secreted from motor neuron like-cells in culture (Gomes et al.,
2007). Although the mechanism of release of protein aggregates is incompletely understood,
SOD1 secretion can occur in both a passive manner associated with cell death or actively
through exocytosis pathways (Gomes et al., 2007; Grad et al., 2014). In addition, SOD1
associates with secretory chaperone-like proteins, including chromogranins which are
components of neurotransmitter enriched secretory vesicles, facilitating the release of SOD1
(Huttner et al., 1991; Urushitani et al., 2006). Of note, prior to secretion, mutant SOD1
aggregates can accumulate in the endoplasmic reticulum-Golgi compartments of the
endocytic pathways (Urushitani et al., 2008). Misfolded WT and mutant SOD1 have been
shown to be secreted from neuron-like cells in association with exosomes (Basso et al.,
2013), which are subsequently taken up by neuron-like cells in culture (Grad et al., 2014).
Furthermore, exosomes obtained from mouse astrocytes were observed to transfer mutant
SOD1 to spinal neurons, resulting in the selective death of motor neurons (Basso et al.,
2013). Collectively these data leaves open the possibility that both cell death and active
secretion mechanisms are acting in concert to promote aggregate release in vivo.
1.10.2.2 SOD1 uptake
In order to facilitate the propagation of intracellular aggregation in neurodegenerative
diseases, such as ALS, Parkinson’s, Alzheimer’s and Huntington’s diseases, active aggregate
nuclei or seeds must internalise into cells and gain access to the cytosol of naïve cells. Indeed,
a number of recent studies have observed that exogenously applied SOD1 aggregates derived
recombinantly or from conditioned media can be taken up efficiently and rapidly into living
cells (Furukawa et al., 2013), such as motor neuron like cells in a time dependant manner,
followed by localisation of SOD1 to the cytosol of neurons (Münch et al., 2011) and cultured
glial cells (Roberts et al., 2013). However, it is currently unknown how exogenous SOD1
aggregates gain access to the cytosol and subsequently accumulate in cytosolic inclusions
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(Sundaramoorthy et al., 2013). Moreover, exogenously added aggregated WT and mutant
SOD1 have been shown to be taken up into mouse NSC-34 and human SH-SY5Y neuronal
cells (Sundaramoorthy et al., 2013).
1.10.2.3 Prion-like action of SOD1
Increasing experimental evidence now indicate that misfolded SOD1 has the ability to induce
conformational changes from one molecule, seeding aggregation to another analogous to that
of prion-like propagation (Chia et al., 2010; Grad et al., 2011; Grad et al., 2014; Münch et al.,
2011).
Furthermore, similar to prions, there is evidence to suggest that propagation of misfolding
and aggregation of both mutant and WT SOD1 occurs via two mechanisms including,
nucleated polymerisation and template-directed misfolding (Grad et al., 2015). Given the
highly stable conformation of native SOD1 and its ability to stabilise mutant misfolded SOD1
(Prudencio et al., 2010), it has been suggested that this may enable native SOD1 to act as a
thermodynamically favourable substrate for template directed seeded polymerisation (Grad et
al., 2015). Furthermore, another study has also demonstrated that the intracellular conversion
of WT SOD1 potentially occurs via template-directed misfolding, using surface plasmon
resonance (Grad et al., 2011). However, it is possible that mutant SOD1 that is highly
aggregation prone may utilise both seeded polymerisation and template directed misfolding.
Moreover, newly formed misfolded SOD1 can act as template for propagation of misfolding,
given that the misfolding of SOD1 can persist in the absence of the misfolded seed in cell
culture (Grad et al., 2014).
Misfolded and aggregated forms of SOD1 derived from recombinant protein or from
homogenates of spinal cords of transgenic mice expressing human mutant SOD1 have been
observed to trigger the formation of SOD1 protein aggregates in naïve cells, thus acting as
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seeds (Figure 1.3) (Chia et al., 2010). In addition, the co-aggregation of mutant and WT
SOD1 have been detected in post-mortem tissue derived from familial ALS patients,
indicative of intermolecular conversion of protein misfolding (Bruijn et al., 1998). Supporting
this, familial associated mutations in SOD1 (G127X and G85R) expressed in human
mesenchymal and neural cell lines were observed to trigger the conversion of endogenous
wild-type native SOD1 to a misfolded form, revealed by conformation-specific antibodies
specific for epitopes present in SOD1 only when it is in a misfolded state. The conversion of
human WT SOD1 to a misfolded form was shown to be dependent on a tryptophan (Trp)
amino acid residue at position 32 (Grad et al., 2011). Interestingly, the same study showed
that SOD1 mutations containing a serine substitution at position 32 failed to trigger the
misfolding of WT SOD1 in human cell lines. Similarly, expression of these human SOD1
mutants in cells lines did not induce the misfolding of endogenous murine WT SOD1 which
inherently exhibits a serine at position 32, indicating species specific barriers. Similarly,
prions also have species specific barriers that limit their transmission of disease between
different species (Raymond et al., 2000), therefore further supporting the prion-like behaviour
of SOD1 ALS.
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Figure 1.3 Proposed model of the role of SOD1 propagation of aggregation in amyotrophic
lateral sclerosis. Protein aggregates form in neurons (primary nucleation) and have the potential to further
nucleate the aggregation of other proteins. These protein aggregates can transfer directly from cell to cell
through synaptic transfer, or be actively released via secretion mechanisms (e.g. exosomes) or in their naked
forms from newly dying/dead motor neurons which is suggested to occur in the easily stages of the diseases to
neighbouring interconnecting neurons. The uptake of such aggregates nucleates aggregation in naïve cells, a
process that resembles the prion-like propagation of aggregation.

To further support this, murine SOD1 protein is not associated with inclusions of human
mutant SOD1 in SOD1 mice (Deng et al., 2006; Prudencio et al., 2009; Wang et al., 2009).
Furthermore, human WT SOD1 does not exacerbate motor neuron disease in mice expressing
murine mutant SOD1 G86R (Audet et al., 2010). In addition, recombinant G127X aggregates
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were able to trigger the misfolding of recombinant human WTSOD1 in a cell-free system
under reducing conditions, supporting the idea of “protein-only” conversion. This therefore
provides direct evidence of intermolecular conversion of natively structured WT SOD1 by
misfolded SOD1 in a physiological intracellular environment (Grad et al., 2011).
Furthermore, other work has observed that exogenously applied mutant SOD1 aggregates can
induce the misfolding of soluble transgenically expressed mutant protein in mouse
neuroblastoma cells, transmitting the pathology from cell to cell, indicative of selfpropagation of aggregation, similar to the disease mechanics in prion diseases (Münch et al.,
2011). Similarly, exogenously applied recombinant human mutant SOD1 fibrils can
internalise into mouse neuroblastoma cells that are engineered to express the same human
SOD1 mutant and subsequently induce intracellular aggregation (Furukawa et al., 2013)
These findings are supported by the results of two other studies which demonstrate for the
first time, in vivo evidence for prion-like transmission of SOD1 toxic aggregate species in
mediating pathology in ALS. Recently, it has been demonstrated that spinal cord
homogenates derived from symptomatic (paralysed) SOD1G93A mice when injected into the
spinal cords of genetically vulnerable mice (newborn) expressing low amounts of another
form of mutant SOD1 (SOD1G85R-YFP) triggered a spinal inclusion pathology and ALS-like
disease phenotype (Ayers et al., 2014). Interestingly, when second passage homogenates
derived from these mice were injected into new SOD1G85R mice, an early onset of clinical
disease was observed, again featuring abundant SOD1G85R inclusion‐like pathology (Ayers et
al., 2014). Furthermore, it was observed in this study that spinal cord homogenates derived
from WT SOD1 transgenic mice injected into transgenic mice triggered widespread
SOD1G85R containing inclusion‐like pathology in one third of inoculated SOD1G85R mice,
implicating WT SOD1 in the pathogenesis of disease progression in sporadic ALS. In a more
recent study that extends these findings, spinal homogenates from paralysed mutant
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SOD1G93A mice were injected into the sciatic nerves of adult SOD1G85R expressing mice
(rather than newborn) (Ayers et al., 2016). Similar to the previous study above, these mice
developed ALS-like disease characterised by rapidly spreading SOD1G85R containing
inclusion pathology and motor neuron loss, similar to clinical and pathological findings in
human ALS.
1.10.3 TDP-43
In addition to SOD1, propagation of TDP-43 aggregation has also been suggested to resemble
that of a prion-like seeding mechanism. TDP-43 pathology in ALS is clinically similar to
SOD1 pathology in SOD1 familial ALS, with ubiquitinated inclusions throughout the spinal
cord and motor cortex. There is also evidence of regional spreading of TDP-43 associated
pathology occurring in a sequential pattern through the neuroaxis (Brettschneider et al.,
2013). Recent evidence suggests that phosphorylated and ubiquitinated TDP-43 aggregates
may be able to propagate from cell to cell in cultured neuroblastoma cells and induce TDP-43
aggregation in the cells expressing human TDP-43 in a self-templating fashion (Nonaka et
al., 2013). Similar to SOD1, TDP-43 and its C-terminal fragments have a high propensity to
misfold in vivo (Johnson et al., 2009) with mutations enhancing aggregation (Guo et al.,
2011; Johnson et al., 2009). Furthermore, aggregated full length TDP-43 has been detected in
exosome fractions derived from conditioned media of human neuroblastoma cells treated
with seeds from ALS disease patient brain extracts, similar to prions and therefore this gives
evidence for the prion-like properties of pathological TDP-43 aggregates from diseased
brains (Nonaka et al., 2013). It has been suggested that TDP-43 contains a yeast prion-like
domain in the C-terminal region which is highly aggregation prone (Mousavi and Hotta,
2005). Specifically, one study has reported that the prion-like domain of TDP-43 is critical
for aggregation, cytoplasmic mislocalisation and toxicity (Johnson et al., 2008). Pathological
aggregates of TDP-43 also contains aggregates of its C-terminal fragment (Arai et al., 2006)
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which have been characterised as fibril-like structures (Hasegawa et al., 2008). Other studies
have demonstrated that recombinant exogenously applied fibrillar aggregates of full-length
TDP-43 can internalise into human embryonic kidney cells, and triggered the mislocalisation
of endogenous nuclear TDP-43 to the cytoplasm, where it is found to co-localise with the
seeding aggregates and form inclusions via prion-like nucleated polymerisation (Furukawa et
al., 2011). These induced aggregates are ubiquitinated, similar to that observed in ALS
disease and therefore supporting an important role for pathological TDP-43 in disease
progression. More recently, it was observed that TDP-43 fibrils triggered the seed-dependant
aggregation of WT TDP-43 or TDP-43 lacking a nuclear localisation signal, and different
peptides sequences of TDP-43 were able to produce fibrils that induced different TDP-43
associated pathologies (Shimonaka et al., 2016).
A role for a prion-like propagation of WT SOD1 misfolding induced by toxic TDP-43 has
recently been reported. Aberrant accumulation of mislocalised cytosolic TDP-43 has been
shown to induce the misfolding of SOD1 (Pokrishevsky et al., 2012). Misfolding-specific
antibodies revealed misfolded SOD1 in both spinal cord tissue derived from SOD1-familial
ALS and in sporadic ALS with cytoplasmic TDP-43 inclusions. In addition, this was also
supported by in vivo evidence using human neuroblastoma SH-SY5Y cells and murine spinal
neural cultured cells transgenic for human WT SOD1. However, misfolded SOD1 was not
co-localised with cytosolic TDP-43, suggesting an indirect induction of SOD1 misfolding,
followed by the propagation of SOD1 misfolding (Pokrishevsky et al., 2012). Similar to the
prion protein, tissue-derived TDP-43 aggregates are resistant to protease digestion, heat and
formic acid (Nonaka et al., 2013), however, it remains to be determined whether propagated
aggregation persists in the absence of the seed. In addition, induced aggregates of TDP-43 are
toxic to cultured neuroblastoma cells (Nonaka et al., 2013).
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1.11 Endocytosis
The mechanisms involved in the propagation of misfolded proteins from cell to cell or from
region to region in CNS tissues are not completely understood. However, there may be
several mechanisms involved in disease-associated protein aggregate entry into recipient
neurons depending on the nature of the protein aggregate, activation of signals and the fate of
the internalised material (Mercer and Helenius, 2009).
Endocytosis can occur by multiple mechanisms that are generally classified into two broad
categories, including pinocytosis which involves the uptake of fluid and solutes, and
phagocytosis which involves the uptake of large particles (see Conner and Schmid, 2003).
Phagocytosis is used to internalise large particles like bacteria and viruses, but only a few cell
types have the ability to use this mechanism. Pinocytosis is characterised by a range of
unrelated and highly regulated mechanisms including clathrin-mediated endocytosis,
cavelolar-mediated endocytosis, clathrin and cavelolar-independent endocytosis, lipid raft
mediated endocytosis and macropinocytosis (Mercer and Helenius, 2009).
1.11.1 Clathrin-mediated endocytosis
Clathrin mediated endocytosis previously known as receptor mediated endocytosis involves
concentrating transmembrane receptors and their bound soluble ligands into coated pits
formed by the arrangement of cytosolic clathrin proteins embedded in the plasma membrane,
which eventually invaginate and pinch off to form endocytic vesicles which are transported
into the cell (Brodsky et al., 2001; Schmid, 1997).
1.11.2 Caveolae -mediated endocytosis
Similarly, caveolae-mediated endocytosis involves caveolin which is a dimeric protein found
on the surface of most cells and represents a cholesterol-rich microdomain on the plasma
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membrane, which facilitates the import of molecules (including pathogens) and transports
them to specific locations within the cell. Caveolin binds cholesterol and inserts into the inner
leaflet of the plasma membrane where it self-associates, forming the caveolin coat on the
surface of the membrane invagination, in which many signalling molecules and membrane
transporting molecules are concentrated (Anderson, 1998).
1.11.3 Clathrin and caveolin dependant -mediated endocytosis
Clathrin and cavelolar-independent endocytosis occurs in neurons and neuroendocrine cells
which may constitute a specialised high capacity endocytic pathway for fluids and lipids,
including recovering secreted membrane proteins, however, this remains poorly understood
(Artalejo et al., 2002; Kirkham and Parton, 2005). Lipid-raft mediated endocytosis involves
lipid rafts which are microdomains embedded in the plasma membrane characterised by a
unique lipid environment enriched in cholesterol and sphingolipids, which concentrate
receptors and therefore regulate the induction of signalling pathways (Marmor and Julius,
2001).
1.11.4 Macropinocytosis
Macropinocytosis, also known as a form of fluid-phase endocytosis, is a unique and transient
actin dependent process that leads to the non-selective internalisation of extracellular fluid,
membrane and other particles (Watts and Marsh, 1992).
Fluid-phase and receptor-mediated endocytosis have been implicated in the cellular uptake of
protein aggregates associated with neurodegenerative diseases. Extracellular α-synuclein
fibrils and oligomers are thought to enter into neuronal cells via receptor mediated
endocytosis (Lee et al., 2008), with more recent evidence that α-synuclein fibrils bind
heparan sulfate proteoglycans (HSPGs) to mediate their entry into in cultured cells and

33

primary neurons (Holmes et al., 2013). Similarly, tau aggregates bind HSPGs to trigger their
cellular uptake via macropinocytosis, although how this relates to activation of
macropinocytosis and to entry of other neurodegenerative disease aggregates is unclear
(Holmes et al., 2013). However, monomeric α-synuclein and mutant huntingtin aggregates
have been observed to directly translocate and penetrate the plasma membrane, respectively,
without passage though endocytic compartments (Lee et al., 2008; Ren et al., 2009).
Several studies now suggest that macropinocytosis may be involved in the uptake of protein
aggregates associated with various neurodegenerative diseases (Grad et al., 2014; Holmes et
al., 2013; Münch et al., 2011; Sundaramoorthy et al., 2013). Interestingly, endocytic uptake
of the pathogenic prion protein can be mediated by lipid-raft dependant macropinocytosis
(Wadia et al., 2008). Collectively these data show that, despite their size, aggregates from a
range of neurodegenerative diseases can be efficiently taken up by cells and most importantly
this can occur in neurons. Given the similar structure and large size of these aggregates it is
likely that similar mechanisms are used by various subsets of neurons to engulf such large
aggregates.
1.12

Hijacking macropinocytosis for SOD1 aggregate entry into cells

Fluid phase endocytosis has been gaining importance in SOD1-ALS pathogenesis, where
large SOD1 aggregates have been shown to enter into cells through macropinocytosis (Grad
et al., 2014; Münch et al., 2011; Sundaramoorthy et al., 2013; Zeineddine and Yerbury,
2015). Supporting this, the large size of the protein aggregates argues against neuronal entry
by caveolae (generally used for particle sizes from 50 - 100 nm) (Richter et al., 2008) or
clathrin-coated pits (for particle sizes < 200 nm) (Traub, 2009) and the fact that neurons are
incapable of phagocytosis.
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Specifically, macropinocytosis is a signal-dependent process generally triggered by growth
factors but can be triggered by a variety of other particles such as bacteria, apoptotic bodies,
necrotic cells and viruses (Mercer and Helenius, 2012). The activation of macropinocytosis is
a result of a number of cell‐specific downstream signalling events including activating
receptor tyrosine kinases that in turn trigger a signalling cascade that induces changes in the
dynamics of actin filaments and trigger plasma membrane ruffling (or membrane extensions
and blebbing). Membrane ruffles can take the form of planar lamellipodia, circular ruffles or
blebs, dependant on the nature of the cell type and ligand (reviewed in Mercer and Helenius,
2009). These ruffles can then fold back onto themselves to fuse with the plasma membrane
creating large, fluid filled randomly sized vacuoles (0.5-10 µM) termed macropinosomes that
lack supporting coating molecules (Meier et al., 2002).
Various factors and signalling pathways are required for macropinocytosis, including the Ras
superfamily GTPases which activate the RAC1, Rab5, Arf6, and the phosphatidylinositol‐3kinase (PI(3)K) signalling pathways (Bar-Sagi et al., 1987). Kinases, including p21-activated
kinase 1 (Pak1) activated by RAC1, regulate cytoskeleton dynamics and motility, and are
required throughout the whole process of macropinocytosis (Dharmawardhane et al., 2000).
In addition, other factors including Na+/H+ exchangers that maintain pH required for GTPase
activity are vital for macropinocytosis (West et al., 1989). Following these signalling events,
macropinosome closure occurs, which involves fusion of membrane folds (Swanson, 2008)
regulated by kinases, myosins and GTPases (Sun et al., 2003). Once macropinosomes are
formed they are trafficked into the cytoplasm of the cell, however some macropinosomes are
recycled to the cell surface, where their contents are released into the extracellular space
(Hewlett et al., 1994), although the fate of macropinosomes is not completely understood, the
trafficking process depends on the cell type and mode of induction (Mercer and Helenius,
2009).
35

Studies on the propagation of SOD1 aggregation by Münch et. al were the first to show that
mutant SOD1 ALS protein aggregates enter into N2A cells via endocytic vesicles mediated
by ATP and lipid raft dependent macropinocytosis (Münch et al., 2011), through the use of a
large panel of inhibitors of a range of cellular functions to systematically rule out specific
pathways of endocytosis including as caveolin and clatherin dependent endocytosis.
Specifically, inhibitors of Na+/H+ exchangers (EIPA), kinases (rottlerin), phosphoinositide
3-kinase and a cholesterol depleting agent were able to strongly diminish the uptake of
aggregates composed of mutant SOD1 protein into neuronal cells (Münch et al., 2011).
Furthermore, these mutant SOD1 aggregates were capable of transiently co-localising with
fluorescent dextran, a marker of fluid phase uptake and therefore together suggests that
mutant SOD1 aggregates selectively use macropinocytosis to enter the cells. Interestingly, it
was proposed that once internalised, these mutant SOD1 aggregates can rapidly exit the
macropinocytic compartment to enter into the cytosol, where these aggregates seed the
aggregation of their soluble counterparts in a prion-like fashion (Münch et al., 2011).
In addition, a recent study demonstrated that that uptake of both extracellular WT and mutant
SOD1 soluble forms into NSC-34 cells can be inhibited by the small molecule EIPA which is
sometimes considered a specific inhibitor of macropinocytosis (Sundaramoorthy et al., 2013).
EIPA (ethylisopropylamiloride) is an analogue of amiloride that is an inhibitor of Na+/H+
exchangers and is thought to be specific to macropinocytosis due to the susceptibility of
GTPases such as RAC1 to pH changes (Koivusalo et al., 2010). Further, the protein kinase C
inhibitor, rottlerin, was also able to inhibit SOD1 uptake consistent with macropinocytosis
facilitating the uptake of WT and mutant SOD1 (Sundaramoorthy et al., 2013). Following the
internalisation of the aggregated WT and mutant SOD1 via macropinocytosis, these
aggregates were observed to form SOD1 containing foci or inclusions which inhibited
transport from the endoplasmic reticulum to the Golgi apparatus. This resulted in the
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induction of neurodegenerative pathways reminiscent of ALS pathology, including
endoplasmic reticulum stress and fragmentation of the Golgi resulting and subsequent
neuronal cell death (Sundaramoorthy et al., 2013). This further supports the role of misfolded
WT SOD1 in ALS and therefore the idea that similar mechanisms of neurodegeneration
spread may be occurring in familial and sporadic ALS.
Viruses, including vaccinia virus (Huang et al., 2008) and the Adenovirus 3 (Meier et al.,
2002), are known to hijack macropinocytosis pathways to enter cells and likely rupture the
unsupported and unstructured vacuole to gain entry to the cytosol, including the Japanese
encephalitis virus that infects neurons (Kalia et al., 2013). The African swine fever virus also
uses macropinocytosis to internalise into host cells (Sanchez et al., 2012). Interestingly, this
virus is able to directly stimulate macropinocytosis through induction of cytoplasmic
membrane perturbation in the form of blebbing and ruffles, fluid (measured using dextran)
uptake, actin reorganisation, activity of Na+/H+ exchangers and signalling events required
for macropinocytosis including Pak1 kinases and the Rho-GTPase RAC1 activation. Similar
to previous studies, EIPA significantly reduced virus entry and infection (Sanchez et al.,
2012).
Although there is now growing evidence that fluid phase endocytosis and in particular
macropinocytosis may play a role in SOD1- mediated ALS, the mechanisms by which SOD1
aggregates utilise macropinocytosis to gain entry into cells and potentially nucleate the
aggregation of endogenous soluble proteins and if the form of pinocytosis is constitutive or
stimulated is currently unknown (Figure 1.4).
1.13

Overview

It is becoming increasingly evident that the propagation of protein aggregation is a key event
in the progressive nature of several neurodegenerative diseases such as ALS, Alzheimer’s
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disease, Parkinson’s disease and Huntington’s disease. This may be explained by the
nucleation of aggregation in nearby or connected neurons. In the cases where protein
aggregates are intracellular, in order for this propagation to occur aggregates must be able to
gain access to the cytosol of naïve neurons. It is; however, clear that SOD1 protein
aggregates are able to spread to naïve cells in culture gaining access to the cytosol in an
unknown manner linked with fluid phase endocytosis. Evidence is accumulating that
implicates neuronal macropinocytosis in the uptake of protein aggregates. Although this
process is very complex and may involve other processes and factors, the literature published
to date on the role of macropinocytosis in ALS allows for further detailed investigations into
the role of SOD1 and macropinocytosis in the propagation of aggregation in neuronal cells in
a prion-like manner. Furthermore, the involvement of fluid phase endocytosis in the prionlike propagation of disease proteins in Parkinson’s, Alzheimer’s and Huntingtons disease
implicates a unifying mechanism of pathogenesis in these proteinopathies. Overall, it appears
that misfolded disease proteins associated with neurodegenerative disorders exhibit similar
patterns of disease propagation to prion protein, and interestingly may use similar
mechanisms of uptake to that of viruses. It is there vital then to understand this mechanism to
identify targets that will halt passage of the “infectious” particle in a strategy analogous to
drugs blocking viral entry.
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Figure 1.4 Proposed mechanism for aggregate uptake via macropinocytosis. Aggregates may
interact with cell surface receptors (such as HSG) (1) and promote the clustering and activation of signalling
receptors such as receptor tyrosine kinases. This may result in the activation of signalling pathways such as
those regulated by RAC1 (2), PAK1 and PKC and subsequent mobilisation of actin and formation of
ruffles/blebs (3). Upon macropinosome closure (4) the structure is internalised (5). Given the unstructured
nature of the macropinosomes it is likely that rigid aggregate structures may cause rupture (6) and allow access
of the aggregates to the cytosol where nucleation of aggregation can proceed (7).

1.14

Summary

ALS is a deadly adult-onset neurodegenerative disease affecting thousands of people
globally. With no effective or promising therapies available at present, the need to understand
and decipher the mechanisms involved in disease progression is important. This knowledge
may help slow or halt the propagation of disease in ALS, and eventualy manage quality of
life and survival rates.
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Emerging evidence implicates the prion-like activity of SOD1 and processes such as
macropinocytosis as important players in the propagation of disease in ALS. The uptake of
aggregates via macropinocytosis may have broader implications as a common mechanism
facilitating spread of protein misfolding in neurodegenerative diseases of aging. Although it
has been well established previously that common proteinopathies cannot spread between
humans, reports from post-mortem studies now revealed that some patients who developed
iatrogenic Creutzfeldt-Jakob disease (CJD) as a result of treatment with human cadaveric
pituitary-derived growth hormone contaminated with prions exhibited parenchymal and
vascular amyloid-beta deposition. Given that none of these patients had pathogenic mutations
or other high risk alleles associated with easrly onset of Alzheimer’s disease, these findings
are consistent with iatrogenic transmission of amyloid-beta pathology in addition to CJD
(Jaunmuktane et al., 2015).
The major difference between PrP and SOD1 is that the pathological PrP is highly stable and
protease resistant, compared to misfolded SOD1 which becomes protease sensitive (Grad et
al., 2011), and thus less likely to be able to transmit from one person to another. However, the
ability of misfolded SOD1 to transmit from cell to cell and region to region posssibly via
macropinocytosis is thought to be critical for disease progression. However, further detailed
research is required to understand how SOD1 aggregates are internalised into neuronal cells
via macropinocytosis. Further understanding is also required around how these aggregates
can gain access to the cytosol. It is likely that elucidating these mechanisms will provide
rational therapeutic targets that could stop the spread of pathology and halt ALS and
potentially other progressive neurodegenerative diseases in their tracks.
The overarching aim of this project is to investigate the roles of WT and mutant SOD1 in the
macropinocytosis dependent propagation in ALS, through the use of the motor neuron‐like
40

cell line, NSC‐34, Human primary neurons and Human iPSC derived motor neuron cultures.
Specifically, this project aims to:
1. Investigate the mechanism of uptake of SOD1 into neuronal cells, in particular to
determine the mechanisms and processes involved in, and leading up to the uptake of
SOD1 proteins in their soluble and aggregated form;
2. Examine the mechanisms of SOD1 aggregate release, uptake and propagation in
NSC‐34 motor neurons.
3. Determine whether exogenous recombinant SOD1 protein aggregates can induce
and/or contribute to TDP-43 pathology, specifically its mislocalisation and
aggregation and;
4. Determine if SOD1 aggregates can enter human neurons via the same mechanism of
action using both iPSC derived motor neurons and primary neurons.

These aims will be addressed in Chapters 2‐5, respectively.
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Chapter 2
SOD1 PROTEIN AGGREGATES
STIMULATE
MACROPINOCYTOSIS IN
NEURON-LIKE CELLS TO
FACILITATE THEIR
PROPAGATION
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2.1 Background
The hallmark of Amyotrophic Lateral Sclerosis (ALS) is the selective death of upper and
lower motor neurons in the motor cortex, brainstem and spinal cord, leading to loss of
voluntary muscle control, muscle atrophy and invariably death. The specific causes of most
cases of ALS are undefined, although approximately 10% are inherited. The best-studied
familial ALS (fALS) cases are from families possessing mutations in the gene encoding
copper/zinc superoxide dismutase (Cu/Zn SOD, SOD1) (Rosen et al., 1993). There is,
however, a rapidly growing list of other genes in which mutations have been implicated in
fALS. These include ALS2, SETX, FUS, VAPB, ANG, TARDBP, OPTN, VCP, UBQLN2,
PFN1, SQSTM1, and a hexanucleotide repeat in a non-coding region of C9ORF72 (Renton et
al., 2014). Current clinical practices are such that by the time that a diagnosis is confirmed
disease progression is well under way and as many as 50% of motor units may already have
been affected (Aggarwal and Nicholson, 2002). There is now very strong evidence in humans
that neurodegeneration in ALS begins focally and then spreads amongst adjacent motor
neurons and neighbouring cells or through axonal pathways to other cells throughout the
three dimensional anatomy of the central nervous system (CNS) (Brettschneider et al., 2014;
Ravits and La Spada, 2009; Shaw, 2002). More detailed knowledge of the action of this
spreading is crucial, as is identifying a means of early detection of the disease if we are to
therapeutically slow disease progression.
In common with other neurodegenerative diseases, such as Alzheimer’s Disease (AD) and
Parkinson’s Disease (PD) (Chiti and Dobson, 2006; Knowles et al., 2014), there is growing
evidence that disruptions to proteostasis, protein misfolding and aggregation are the
underlying mechanisms driving neurodegeneration in ALS (Pasinelli and Brown, 2006). Of
particular interest is the fact that, although nucleation of protein aggregation appears to be a
stochastic process (Abdolvahabi et al., 2016; Hortschansky et al., 2005), suggesting that
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protein aggregation should cause a random pattern of cell death, cell death in ALS occurs in
an ordered and progressive manner. One way to explain this ordered progression is the prionlike propagation of protein misfolding and aggregation between adjacent cells. In addition,
recent work has indicated that secondary processes, notably nucleation (Cohen et al., 2013;
Knowles et al., 2009; Knowles et al., 2011), takes place on the surface of aggregates, and
along with other diffusional or active transport of protein aggregates between cells can give
rise to cell-to-cell propagation of the type that is often defined as prion-like behaviour.
Clues to understanding the entry of aggregates into cells comes from studies that show uptake
of aggregates of SOD1 can be blocked with EIPA, wortmannin, IPA-3 (Munch et al., 2011)
and rottlerin (Grad et al., 2014; Sundaramoorthy et al., 2013), which inhibit Na+/H+
exchangers, phosphoinositide 3-kinases (PI3K), P21 protein (Cdc42/Rac)-activated kinase 1
(PAK-1) and protein kinase C (PKC), respectively (suppressing signalling events that
promote actin rearrangement and pinosome closure), findings to date that suggest the
involvement of fluid phase pinocytosis, possibly macropinocytosis, in the aggregate uptake
process.
Macropinocytosis is a form of non-selective endocytosis used by cells to engulf large
amounts of solute macromolecules (fluid phase) or particles too large for other forms of
endocytosis. Macropinocytosis is typically defined as a transient, externally induced, actindependent endocytic process associated with vigorous perturbations, such as ruffles and
blebs, in the plasma membrane (Swanson and Watts, 1995). The activation of this process
results in a transient increase in receptor-independent fluid phase endocytosis in large
vesicles or vacuoles (0.5-10 µm) termed macropinosomes (Mercer and Helenius, 2009;
Swanson and Watts, 1995). Macropinosomes do not have a coat to guide their formation and
are heterogeneous in size and shape. Macropinocytosis provides non-phagocytic cells with
the ability to take up large particles, but the process must be triggered by an external
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stimulus. Bacteria, viruses, apoptotic bodies and necrotic cells have all been shown to induce
the ruffling behaviour typical of macropinocytosis resulting in their uptake along with fluid
(Swanson and Watts, 1995).
There is emerging evidence that prions and prion-like proteins may also enter cells via
macropinocytosis allowing the propagation of their aggregation (Grad et al., 2014; Holmes et
al., 2013; Munch et al., 2011; Sundaramoorthy et al., 2013; Wadia et al., 2008). However, the
small molecule inhibitors utilized to define macropinocytosis, such as EIPA, are not specific
to a single cellular event and depending on the cell type can prevent various forms of
endocytosis (Ivanov, 2008). However, whether SOD1 aggregates stimulate macropinocytosis
in neuronal cells has not been reported.
2.1.1 Aims
Recent evidence suggests a role for SOD1 in ALS disease progression through a prion-like
propagation of protein misfolding and aggregation between neighbouring cells (Münch et al.,
2011; Zeineddine and Yerbury, 2015). Given the potential role for SOD1 in mediating
disease progression in ALS, this work initially aimed to further investigate the mechanism of
uptake of SOD1 into neuronal cells. In particular, the current study aimed to investigate the
mechanism(s) involved in the uptake of SOD1 in both its soluble and aggregated form.
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2.2 Methods
2.2.1 Reagents and Antibodies
DMEM/F-12 medium, DMEM/F-12 without phenol red, 0.05% trypsin-EDTA, GlutaMAX,
SuperSignal West Pico Chemiluminescent Substrate, SYTOX Red dead cell stain, FM® 143FX, fixable analog of FM® 1-43 membrane stain, 10 kDa 647-dextran, Image-iT ™ LIVE
Red caspase detection kit and Lab-Tek chambered coverglass 8 well with cover were
purchased from ThermoFisher Scientific (Waltham, USA). Any kD Mini-PROTEAN TGX
Precast Protein Gels and Precision Plus Protein dual color protein standard were from BioRad (California, USA). Foetal Bovine Serum (heat-inactivated prior to addition in media;
FBS) was from Bovogen Biologicals (East Keilor, Australia). Amersham Hyperfilm was
obtained from GE Healthcare (Little Chalfont, Buckinghamshire, UK). RedDot 2 was from
Biotium (Hayward, CA). Sterile cell culture plates were form Greiner Bio-One
(Frickenhausen, Germany). Casein (heat denatured before use; HDC), dimethyl sulfoxide
(DMSO), bovine serum albumin (BSA), β-mercaptoethanol, Brilliant blue R concentrate,
paraformaldehyde (PFA), biotinamidohexanoic acid 3-sulfo-N-hydroxysuccinimide ester
sodium salt, Bicinchoninic Acid Kit, Glutaraldehyde solution (50% in H2O), Propidium
iodide, Osmium tetroxide solution (4 WT. % in H2O) and dithiothreitol (DTT) were from
Sigma-Aldrich (St. Louis, MO). Ethylenediaminetetraacetic acid (EDTA) was from Amresco
(Solon, USA). Uranyl acetate and 19 mm glass coverslips were from ProSciTech (Kirwan,
Australia). Protease inhibitor cocktail tablets (complete, Mini, EDTA-free) was from Roche
Diagnostics (Penzberg, Germany). RAC1 G-LISA Activation Assay Kit (Colorimetric Based)
was purchased from Cytoskeleton (Denver, CO). All other reagents including salts, powders
and chemicals were from Amresco, Sigma-Aldrich or Astral Scientific (Gymea, Australia).
All reagents used were endotoxin free. Antibodies (Abs) and inhibitor compounds and their
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respective manufacturing companies used in this current study are listed in Table 2.1 and
Table 2.2 respectively.
Table 2.1 Antibodies used in this study to investigate the effect of SOD1 proteins on TDP-43
pathology
Host species
(clonality)1
Mouse (mAb)

Anti-body target
(Immunogen)2
Beta Actin [AC-15]

Rabbit (pAb)

Conjugate
-

Manufacturer
(product number)3
Abcam (ab8226)

Vimentin

-

Abcam (ab137321)

Sheep (pAB)

SOD1

-

Mouse (mAb)

RAC1

-

Goat (pAB)

Mouse IgG

Alexa Fluor 488

Goat (pAB)

Rabbit IgG

Alexa Fluor 488

Donkey (pAb)

Sheep IgG

Alexa Fluor 488

ThermoFisher Scientific
(PAI-30817)
Cytoskeleton
(ARC03)
ThermoFisher Scientific
A-(11001)
ThermoFisher Scientific
( A-11008)
Abcam (150177)

Goat (pAb)

Mouse IgG

Alexa Fluor 633

Donkey (pAb)

Sheep IgG

HRP

ThermoFisher Scientific
( A-21052)
Abcam (97125)

Goat (pAb)

Mouse IgG

HRP

Merck Millipore (12-349)

1

pAb, polyclonal anti-body, mAb, monoclonal anti-body; 3 Abcam, Cambridge, USA; ThermoFisher Scientific
(Waltham,MA, USA); BD Biosciences San Jose, CA, USA; Merck Millipore, Billerica, Massachusetts, USA; Cytoskeleton
(Denver, CO,USA)

Table 2.2 Pharmacological inhibitors used in this study to investigate the mechanisms of SOD1
uptake
Compound

Manufacturer
(product number)1

5-N-ethyl-N-isopropyl-amiloride (EIPA)
Chlorpromazine

hydrochloride

Sigma (A3085)

(Chlorp Sigma (C8138)

HCL)Genistein (Gen)

Sigma (G6649)

Rottlerin (Rot)-

Sigma (R5648)

RAC1 inhibitor W56

Tocris Bioscience (2221)

1

Sigma, (St. Louis, MO, USA), Tocris Bioscience (Avonmouth, Bristol,UK)

47

2.2.2 Cell Lines
The mouse neuroblastoma x spinal cord hybrid cell line (NSC-34 cells) (Cashman et al.,
1992) were routinely cultured in DMEM/F12 supplemented with 10% (v/v) FBS and 2 mM
GlutaMAX. Cells were maintained in an incubator at 37°C under a humidified atmosphere
containing 5% (v/v) CO2.
2.2.3 Aggregation and biotinylation of WT and mutant G93A SOD1 proteins
WT and G93A SOD1 were expressed and purified from E.coli as previously outlined
(Lindberg et al., 2002; Roberts et al., 2013). SOD1 aggregation was performed in vivo as
previously described (Roberts et al., 2013). Briefly, solutions of purified WT or G93A mutant
SOD1 protein (1 mg/ml) in PBS were co-incubated with 20 mM dithiothreitol (DTT) and 5
mM ethylenediaminetetraacetic acid (EDTA) for 72 h at 37 °C with shaking using a orbital
shaker (universal IKA® MS 3, 230 V) (Sigma, St. Louis, MO). The aggregated SOD1 was
then labelled with biotin amidohexanoic acid 3-sulfo-N-hydroxysuccinimide ester sodium
salt (40 mg/ml) in DMSO for 2 h at RT. The unconjugated biotin was then separated from the
aggregates by centrifugation (21 000 x g for 30 min) and washed three times with PBS (300 x
g for 5 min). The purified aggregates free of unconjugated biotin were then resuspended in
PBS (1 mg/ml). A bicinchoninic acid (BCA) protein assay was performed to determine the
amount of protein in solution.
2.2.4 SOD1 protein Immunoblotting
Purified SOD1 proteins in their soluble and aggregate form (1 μg protein/lane) were
separated under reducing conditions (5% β-mercaptoethanol) using Any kD Mini-PROTEAN
TGX Stain-Free™ Precast Gels (Bio-Rad, Hercules, CA). Proteins were then transferred onto
nitrocellulose membranes using the Trans-Blot Turbo Transfer System (Bio-Rad).
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Membranes were blocked with heat denatured casein (HDC) in for 1 h at 37°C. To confirm
immunoreactivity of SOD1 and confirm the aggregation and biotinylation of the SOD1
proteins, sheep anti-SOD1 pAb (1:500) and streptavidin−peroxidase (1:400) (Sigma, St.
Louis, MO) diluted in HDC/PBS was incubated with membranes for 1 h at 37°C, to detect
SOD1 soluble and biotinylated-aggregated protein respectively. The following day, the
membrane containing soluble proteins was washed three times over 15 min with PBS
containing 0.1% Triton X-100. The membrane was then incubated with peroxidaseconjugated to anti-sheep IgG Ab (1:1000) for 1 h at 37°C. Membranes were washed three
times over 30 min with PBS containing 0.1% Triton X-100 and membranes were visualised
using chemiluminescent substrate and Amersham Hyperfilm ECL (GE Healthcare). The
processing of films was achieved using GBX Developer and Replenisher and GBX Fixer and
Replenisher (Kodak Australiasia, Collingwood, Victoria Australia). Images of the films were
collected using a GS-800 Calibrated Densitometer (Bio-Rad).
2.2.5 Transmission electron microscopy of SOD1 aggregates
Negative staining transmission electron microscopy (TEM) was performed using substrate
carbon-coated nickel grids (Proscitech Kirwan, Australia). Initially, 2 µl aliquots of SOD1
WT and G93A proteins (1 mg/ml) were loaded onto carbon-coated nickel grids (Proscitech
Kirwan, Australia) for 1 min at RT. Grids were washed 3 times with filtered Milli-Q water.
Grids were then negatively stained using 2% (w/v) uranyl acetate (ProsciTech Kirwan,
Australia) diluted in Milli-Q water for 2 min at RT. Grids were then dried using filter paper
blotting and then left at RT for 5 min, until processing. Protein structure and morphology was
then analysed using a JEOL 2011 TEM (Tokyo, Japan) operated at 200kV. Images were
taken using a Gatan Microscopy Suite (Version 2.30.542.0) (California, USA).
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2.2.6 Internalisation of SOD1 by flow cytometry
NSC-34 cells were incubated with 20 μg/ml of aggregated SOD1 or PBS (no protein;
negative control) for 60 min at 4°C. Cells were then washed twice in PBS, harvested using 5
mM EDTA (5 min, 37°C) and then washed again using centrifugation (300 x g for 5 min).
Cells were fixed with 4% PFA in PBS for 20 min at RT, and then washed again using
centrifugation (300 x g for 5 min). Cells were washed once with ice-cold PBS and then
incubated with Triton X-100 for 30 min at 4°C. Cells were washed again in ice cold PBS
(300 x g for 5 min) and incubated with blocking solution (5% FCS, 1% BSA and 0.3% Triton
X-100) for 20 min at RT. Cells were incubated with anti- SOD1 IgG Ab (1:500; diluted in
4% BSA and 0.1% Triton X-100) for 30 min at 4°C. Cells were washed again in ice cold PBS
(300 x g for 5 min) and incubated with anti-sheep IgG conjugated to Alexa Fluor 488 (1:500
diluted in 1% BSA and 0.1% Triton X-100) for 30 min at 4°C protected from light. Cellular
events were collected using a LSR II flow cytometer (BD Biosciences) (Excitation 488 nm,
emission collected with 515/20 band-pass filter). The live cells were analysed using gating
methods with forward and side scatter parameters. Mean fluorescence intensity (MFI) was
then determined using FlowJo software (Tree Star, Ashland, OR).
2.2.7 Detection of internalised SOD1 aggregates by immunoblotting
In separate experiments, NSC-34 cells were treated with biotin conjugated-SOD1 aggregates
as previously outlined above. Post incubation, cells were washed (300 x g for 5 min) twice
with PBS and harvested using 0.05% trypsin-EDTA (5 min, 37°C) and then washed again
using centrifugation (300 x g for 5 min). Cells were lysed (1.5 x 106 - 1.5 x 108 cells/ml) over
15 min at 4°C in ice-cold lysis buffer (10 mM Tris, 150 mM NaCl, 5 mM EDTA, 1% Triton
X-100 and protease inhibitor cocktail, pH 7.0). Cell debris was then cleared (21,000 × g at
4°C for 30 min) and supernatants (75 μg protein/lane) were collected and separated under
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reducing conditions (5% β-mercaptoethanol) using Any kD Mini-PROTEAN TGX StainFree Gels (Bio-Rad, Hercules, CA). Proteins were then transferred to nitrocellulose
membranes using a Trans-Blot Turbo Transfer System (Bio-Rad). The membrane was
blocked with heat denatured casein (HDC) in for 1 h at 37°C. The nitrocellulose membrane
was then incubated with mouse anti-actin mAb (1:5000), diluted in HDC/PBS for 1 h at
37°C. The membrane was washed three times over 15 min with PBS containing 0.1% TritonX-100. The membrane was then incubated with peroxidase-conjugated anti-streptavidin
(1:400) (Sigma, St. Louis, MO) and goat anti-mouse IgG Ab-HRP diluted in HDC/PBS for 1
h at 37°C for aggregates and actin respectively, and then washed as above. Internalised SOD1
aggregates were visualised using chemiluminescent substrate and Amersham Hyperfilm ECL
(GE Healthcare). Images of films were collected using a GS-800 Calibrated Densitometer
(Bio-Rad). Actin was used as a loading control.
2.2.8 Rapid detection of aggregated SOD1 by flow cytometry
NSC-34 cells were incubated with 20 μg/ml of soluble and aggregated SOD1, GST or PBS
(no protein, control) for 30 min at 37°C/5% CO2. Cells were then washed twice in ice-cold
PBS, harvested using 5 mM EDTA (5 min, 37°C) and then washed again using centrifugation
(300 x g for 5 min). Cells were fixed with 4% PFA for 20 min at RT, and then washed again
(300 x g for 5 min) with ice-cold PBS. Cells were then incubated with Triton X-100 for 30
min at 4°C. Cells were washed again in ice cold PBS (300 x g for 5 min) and incubated with
blocking solution (5% FCS, 1% BSA and 0.3% Triton X-100) for 20 min at 4°C. Cells were
then incubated anti-SOD1 IgG Ab (1:500 diluted in 4% BSA and 0.1% Triton X-100) for 30
min at 4°C. Cells were washed again in ice cold PBS (300 x g for 5 min) and incubated with
anti-sheep IgG conjugated to Alexa Fluor 488 (1:500 diluted in 1% BSA and 0.1% Triton X100) for 30 min at 4°C protected from light. Cellular events were collected using a LSR II
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flow cytometer (BD Biosciences) (Excitation 488 nm, emission collected with 515/20 bandpass filter). The live cells were analysed using gating methods with forward and side scatter
parameters. Mean fluorescence intensity (MFI) of these cells was then determined using
FlowJo software (Tree Star, Ashland, OR).
2.2.9 Rapid detection of aggregated SOD1 by confocal microscopy
NSC-34 cells (2–3 x 104 cells/0.2 ml/chamber) were cultured in chamber slides at 37°C/5%
CO2 overnight. Cells were incubated with 20 μg/ml of aggregated SOD1 or PBS (no protein
control) for 30 min at 4°C to slow endocytosis. Cells were fixed with 4% PFA in PBS for 20
min at RT and washed twice with ice cold PBS over 5 min. Cells were then incubated with
Triton X-100 for 30 min at 4°C. Cells incubated with blocking solution (5% FCS, 1% BSA
and 0.3% Triton X-100) for 20 min at RT. Cells were incubated with anti- SOD1 IgG Ab
(1:500 diluted in 4% BSA and 0.1% Triton X-100) for 30 min at 4°C. Cells were washed
again in ice cold PBS and incubated with anti-sheep IgG conjugated to Alexa Fluor 488
(1:500 diluted in 1% BSA and 0.1% Triton X-100) for 30 min at 4°C protected from light. An
inverted microscope (DM IBRE) and a Leica TCS SP confocal imaging system were used to
visualise and image cells (excitation 488, emission collected at 520-545). Fluorescence,
bright field (differential interference contrast; DIC) and merged images were captured using
Leica confocal software.
2.2.10 Permeabilisation of NSC-34 cells
NSC-34 cells were incubated in chamber slides with 20 μg/ml of aggregated-biotin
conjugated SOD1 for 60 min at 4°C. Cells were fixed with 4% PFA in PBS for 20 min at RT
and washed twice with ice cold PBS over 5 min. Cells were then incubated with Triton X-100
(permeabilised) or PBS (not permeabilised) for 30 min at 4°C. Cells were incubated with
blocking solution (5% FCS and 1% BSA ) for 20 min at RT. Cells were incubated in 1 µg/ml
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Alexa Fluor 488 streptavidin (diluted in 1% BSA and 0.1% Triton X-100) for 1 hr at RT
protected from light. An inverted microscope (DM IBRE) and a Leica TCS SP confocal
imaging system were used to visualise and image cells (excitation 488, emission collected at
520-545). Fluorescence, bright field (differential interference contrast; DIC) and merged
images were captured using Leica confocal software.
2.2.11 Treatment with trypsin
NSC-34 cells (2–3 x 104 cells/0.2 mL/chamber) were cultured in chamber slides at 37°C/5%
CO2 overnight. Cells were incubated with 20 μg/ml labelled aggregated SOD1 for 1 h at
37°C/5% CO2. Cells were incubated with 0.25% trypsin or PBS (control) for 5 min at
37°C/5% CO2. Cells were washed (300 x g for 5 min) and the resulting suspended cells were
re-cultured in complete DMEM culture medium for a total of 6 h at 37°C/5% CO2 to allow
cells to recover. Cells were then immediately fixed with 4% PFA in PBS for 20 min at RT
and washed twice with PBS over 5 min. Cells incubated with 0.5% Triton X-100 for 30 min
at 4°C. Cells were then incubated with blocking solution (5% FCS, 1% BSA and 0.3% Triton
X-100) for 20 min at RT. Cells were then incubated with Alexa Fluor 488 streptavidin
(1:1000 diluted in 1% BSA and 0.1% Triton X-100) for 1 h at RT. Sytox Red (5 µM) was
used as a counter stain, and incubated with cells for 10 at RT. An inverted microscope (DM
IBRE) and a Leica TCS SP confocal imaging system were used to visualise and image cells
(excitation 488, emission collected at 520-545 and excitation 633, emission collected at 635650). Fluorescence, bright field (differential interference contrast; DIC) and merged images
were captures using Leica confocal software. Mean fluorescence intensities (MFI) per cell of
SOD1 aggregate uptake were quantified from confocal images using ImageJ software
(Version 1.48) (National Institutes of health, Bethesda, MD).
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2.2.12 Pre-treatment of NSC-34 cells with trypsin
NSC-34 cells were harvested using either 5 mM EDTA (control) or 0.25% trypsin-EDTA (10
min, 37°C) and then washed again using centrifugation (300 x g for 5 min). Cells were then
incubated with 20 μg/ml of aggregated SOD1 or PBS (no protein, control) for 30 min at
37°C/5% CO2. Cells were then washed twice in ice-cold PBS (300 x g for 5 min), and fixed
with 4% PFA for 20 min at RT, then washed again with ice-cold PBS using centrifugation
(300 x g for 5 min). Cells were then incubated with Triton X-100 for 30 min at 4°C. Cells
were washed again in ice cold PBS (300 x g for 5 min), incubated in solution (5% FCS, 1%
BSA and 0.3% Triton X-100) for blocking for 20 min at RT. Cells were incubated with antiSOD1 IgG Ab (1:500 diluted in 4% BSA and 0.1% Triton X-100) for 30 min at 4°C. Cells
were washed again in ice cold PBS (300 x g for 5 min) and incubated with anti-sheep IgG
conjugated to Alexa Fluor 488 (1:500 diluted in 1% BSA and 0.1% Triton X-100 ) for 30 min
at 4°C protected from light. Cellular events were collected using a LSR II flow cytometer as
described above.
2.2.13 Inhibition of SOD1 uptake - confocal microscopy
Internalisation of aggregated SOD1 was measured in the presence or absence of a range of
compounds that inhibit various internalisation mechanisms. NSC-34 cells (4 x 104 cells/.35
ml/well) were incubated in 24-well culture plates fitted with sterile 19 mm glass coverslips
(1.5 ml/ well) and incubated at 37°C/5% CO2 overnight to allow time to adhere. Cells were
pre-treated with various endocytic inhibitors including 100 µM 5-N-ethyl-N-isopropylamiloride (EIPA), 5 µM chlorpromazine hydrochloride (Chlorp HCl), 10 µM genistein (Gen)
or 3 µM rottlerin (Rot) diluted in 1% BSA/PBS or PBS (no inhibitor, diluted in 0.1% DMSO
or 20% acetonitrile in water) for 30 min at 37°C/5% CO2. Cells were then co-incubated with
by 20 μg/ml soluble or aggregated SOD1 for an additional 30 min at 37°C/5% CO2. Cells
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were immediately fixed with 4% PFA in PBS for 20 min at RT and washed twice with PBS
over 5 min. Cells were incubated with Triton X-100 for 30 min at 4°C. Cells were then
incubated with blocking solution (5% FCS, 1% BSA and 0.3% Triton X-100) for 20 min at
RT. Cells were incubated with anti-SOD1 IgG Ab (1:500 diluted in 4% BSA and 0.1% Triton
X-100) for overnight at 4°C. Cells were subsequently washed again in PBS and incubated
with anti-sheep IgG conjugated to Alexa Fluor 488 (1:500 diluted in 1% BSA and 0.1%
Triton X-100) for soluble proteins and with Alexa Fluor 488 streptavidin (1:1000 diluted in
1% BSA and 0.1% Triton X-100) for 1 h at RT. Sytox Red (5 nM) was used as a counter
stain, and incubated with cells for 10 min at RT. An inverted microscope (DM IBRE) and a
Leica TCS SP confocal imaging system were used to visualise and image cells (excitation
488, emission collected at 520-545). Fluorescence, bright field (differential interference
contrast; DIC) and merged images were captured using Leica confocal software.
2.2.14 Inhibition of SOD1 uptake - flow cytometry
Cells were harvested using 5 mM EDTA (5 min, 37°C) and then washed again using
centrifugation (300 x g for 5 min). Cells were pre-treated with various endocytic inhibitors
including 100 µM EIPA, 5 µM Chlorp HCl, 10 µM Gen, 3 µM Rot or RAC1 inhibitor W56
(200 µM) diluted in 1% BSA/PBS or PBS (no inhibitor, diluted in 0.1% DMSO or 20%
acetonitrile in water) for 30 min at 37°C/5% CO2. Cells were then washed twice in PBS (300
x g for 5 min) and then co-incubated with by 20 μg/ml soluble or aggregated WTSOD1 for an
additional 30 min at 37°C/5% CO2. Cells were then washed twice in PBS (300 x g for 5 min)
and immediately fixed with 4% PFA in PBS for 20 min at RT. Cells were then washed twice
in PBS (300 x g for 5 min) and then incubated with Triton X-100 for 30 min at 4°C. Cells
were washed twice in PBS (300 x g for 5 min) and incubated with blocking solution (5%
FCS, 1% BSA and 0.3% Triton X-100) for 20 min at RT. Cells were then washed twice in
PBS (300 x g for 5 min) and incubated with anti-SOD1 IgG Ab (1:500 diluted in 4% BSA
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and 0.1% Triton X-100) for 30 min at 4°C for 1 h at RT. Cells were washed again (300 x g
for 5 min) in PBS and incubated with anti-sheep IgG conjugated to Alexa Fluor 488 (1:500
diluted in 1% BSA and 0.1% Triton X-100 ) for soluble proteins and with Alexa Fluor 488
streptavidin (1:1000 diluted in 1% BSA and 0.1% Triton X-100) for 1 h at RT. Cells were
then washed twice in PBS (300 x g for 5 min). Cellular events were collected using a LSR II
flow cytometer (excitation 488 nm, emission collected at 515/20 nm) and the MFI of relative
SOD1 uptake into NSC-34 cells was determined using FlowJo software. Results are the
average of at least five independent experiments.
2.2.15 Field emission scanning electron microscopy (FESEM)
Detached NSC-34 cells (7x104 cells/ml/well) were incubated in 24-well culture plates fitted
with sterile 19 mm glass coverslips (1.5 ml/well) and incubated at 37°C/5% CO2 overnight to
allow time to adhere. Cells were then serum starved in DMEM F12 phenol red free culture
medium for 24 h at 37°C/5% CO2. Cells were then washed once with PBS and incubated with
20 µg/ml soluble or aggregated proteins in PBS or PBS containing 200 nM phorbol 12myristate 13-acetate (PMA) for 2 h at 37°C/5% CO2. Post incubation, cells were washed
three times in PBS then fixed in 2.5% glutaraldehyde/4% PFA in 0.1 M phosphate buffer for
3 h at 4°C. Cells were then washed three times in phosphate buffer and postfixed in 2%
OsO4/water at RT for 1 h. After washing with water, the cells were dehydrated using a
gradient of ethanol at 30%, 50%, 70%, 80%, 90% and 100% (30 min per incubation) at RT.
The cells were then critical point dried for 2 h using a LEICA CPD030 (Vienna, Austria) and
coated with graphite-gold in a sputter coater. Cellular structures were visualised with a JEOL
6490LV SEM (Tokyo, Japan) microscope operated at 10 kV at a 10 mm working distance
and a spot size setting of 35.
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2.2.16 Membrane activity quantification
NSC-34 cells (2–3 x 104 cells/0.2 ml/chamber) were cultured in 8-well chamber slides in
DMEM/F12 media supplemented with 10% FCS and were incubated overnight at
37°C/5%CO2. Cells were incubated with 20 µg/ml of SOD1 proteins, PBS alone, or PMA
(200 nM) in PBS for 1 h at 37°C/5% CO2. Cells were then washed twice in PBS and
incubated with 10 µM of FM 1-43FX membrane stain diluted in PBS for 7 min at 37°C/5%
CO2. Excess dye was removed by several washes in PBS and cells were returned to the
incubator (37°C/5% CO2) for 4 min. This procedure was repeated to give a total of 8 min of
incubation in PBS. Post incubation, ice-cold PBS was added to stop endocytosis and prepare
cells for fixation in 4% PFA in PBS for 20 min at 4°C. Post fixation, cells were washed twice
in PBS and incubated with 1x Red Dot 2 for 10 min at RT.
2.2.17 Fluid phase uptake - confocal microscopy
Pinocytosis involves uptake of solutes from the extracellular medium. One well established
solute is dextran. To quantify the amount of fluid phase solute uptake NSC-34 cells (2–3 x
104 cells/0.2 ml/chamber) were incubated in chamber slides with 20 µg/ml of SOD1 proteins
in PBS alone or PMA (200 nM) for 30 min at 37°C/5%CO2. Prior to harvesting or fixation,
cells were then co-incubated for 15 min with 0.5 mg/ml 10 kDa dextran conjugated to Alexa
Fluor 647 at 37°C/5% CO2. The cells were then placed on ice to stop dextran uptake and cells
were washed three times with ice cold PBS and once with low pH buffer (0.1 M sodium
acetate, 0.05 M NaCl, pH 5.5) for 10 min. The cells were then incubated with anti-SOD1 IgG
Ab (1:500 diluted in 4% BSA and 0.1% Triton X-100) overnight at 4°C. Cells were washed
again in PBS and incubated with anti-sheep IgG conjugated to Alexa Fluor 488 (1:500 diluted
in 1% BSA and 0.1% Triton X-100) for soluble proteins and Alexa Fluor 488 streptavidin
(1:1000 diluted in 1% BSA and 0.1% Triton X-100) for 1 h at RT. An inverted microscope

57

(DM IBRE) and a Leica TCS SP confocal imaging system were used to visualise and image
cells (excitation 488, emission collected at 495-515 and 650-668). Fluorescence, bright field
(differential interference contrast; DIC) and merged images were captured using Leica
confocal software.
2.2.18 Fluid phase uptake - flow cytometry
NSC-34 cells (5 x 104 cells/0.5 ml/well) were incubated with 20 µg/ml of SOD1 proteins in
PBS alone or PMA (200 nM) for 30 min at 37°C/5% CO2. Cells were co-incubated with 0.5
mg/ml 10 kDa dextran conjugated to Alexa Fluor 647 for 15 min at 37°C/5% CO2. The cells
were then placed on ice to supress dextran uptake and cells were washed three times with ice
cold PBS (300 x g for 5 min) and once with low pH buffer (300 x g for 5 min) (0.1 M sodium
acetate, 0.05 M NaCl, pH 5.5) for 10 min. The cells were then incubated with anti-SOD1 IgG
Ab (1:500 diluted in 4% BSA and 0.1% Triton X-100) for 1 h at RT. Cells were washed
again (300 x g for 5 min) in PBS and incubated with anti-sheep IgG conjugated to Alexa
Fluor 488 (1:500 diluted in 1% BSA and 0.1% Triton X-100) for soluble proteins and Alexa
Fluor 488 streptavidin (1:1000 diluted in 1% BSA and 0.1% Triton X-100) for 1 h at RT.
Cellular events were collected using a LSR II flow cytometer as described above.
2.2.19 Inhibition of PMA induced dextran uptake
NSC-34 cells (5 x 104 cells/0.5 ml/well) were serum starved for 24 h. Cells were pre-treated
with various endocytic inhibitors including 100 µM EIPA, 5 µM chlorpromazine
hydrochloride (Chlorp HCL), 10 µM Gen and 3 µM Rot diluted in 1% BSA/PBS or PBS
(0.1% DMSO) for 30 min at 37°C/5% CO2. Cells were co-incubated with 200 nM PMA for
an additional 30 min at 37°C/5% CO2. Cells were co-incubated with 0.5 mg/ml 10 kDa
dextran conjugated to Alexa Fluor 647 for 15 min at 37°C/5% CO2. The cells were then
placed on ice to supress dextran uptake and cells were washed three times with ice cold PBS
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(300 x g for 5 min) and once with low pH buffer (300 x g for 5 min) (0.1 M sodium acetate,
0.05 M NaCl, pH 5.5) for 10 min. Cellular events were collected using a LSR II flow
cytometer (BD Biosciences) as outlined above.
2.2.20 RAC1 activation ELISA assay
NSC-34 cells were incubated in sterile 12-well culture plates (2 ml/well) and incubated at
37°C/5% CO2 overnight. Cells were then serum starved in phenol red free culture medium for
24 h at 37°C/5% CO2. Cells were then washed once with ice cold PBS and incubated with 20
µg/ml of soluble and aggregated SOD1 proteins for 30 min at 37°C/5% CO2. Cells were
washed twice with ice-cold PBS and harvested by treatment with 0.05% trypsin for 10 min at
37°C. Cells were washed again (300 x g for 5 min) in PBS. RAC1 activation was measured
using a G-LISA activation kit (Kit #BK128 Cytoskeleton, Inc. Denver, USA) as per the
manufacturer’s recommendations. Absorbance values of wells were recorded with a
SpectraMax Plus 384 Microplate Reader and SoftMax Pro software (Molecular Devices,
Silicon Valley, CA) (490nm).
2.2.21 RAC1 inhibition and membrane activity
NSC-34 cells (2–3 x 104 cells/0.2 ml/chamber) were cultured in 8-well chamber slides in
complete culture medium and were incubated overnight at 37°C/5% CO2. Cells were preincubated with RAC1 inhibitor W56 or PBS (in 20% acetonitrile in water) diluted in 1%
BSA/PBS for 1 h at 37°C/5% CO2. Cells were then co-incubated with PMA (200 nM) in PBS
for an additional 30 min at 37°C/5% CO2. Cells were then washed twice in PBS and
incubated with 10 µM of FM 1-43FX membrane stain diluted in PBS for 7 min at 37°C/5%
CO2. Excess dye was removed by several washes in PBS and cells were returned to the
incubator (37°C/5% CO2) for 4 min. This procedure was repeated to give a total of 8 min of
incubation in PBS. Post incubation, ice-cold PBS was added to stop endocytosis and prepare
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cells for fixation in 4% PFA in PBS for 20 min at 4°C. Post fixation, cells were washed twice
in PBS and incubated with 1x Red Dot 2 for 10 min at RT for imaging with confocal
microscopy.
2.2.22 Etoposide Assay
To confirm cell blebbing is not apoptosis related, a Caspase Detection kit was used according
to manufacturer’s instructions. Detached NSC-34 cells (10x104 cells/ml/well) were incubated
in 12-well culture plates fitted with sterile 19 mm glass coverslips (1 ml/well) and incubated
at 37°C/5%CO2 overnight to allow time to adhere. Cells were incubated with either 20 μg/ml
soluble and labelled aggregated SOD1 or 100 µM Etoposide for 2 h at 37°C/5% CO 2. Cells
were incubated with 1X FLICA reagent for 60 min at 37°C/5% CO2, protected from light.
Cells were washed gently with cell-culture medium (DMEM F12 phenol red free). Cells were
then incubated with SYTOX Green stain (5 µM) for 8 min at 37°C/5% CO2. The cells were
then washed with 2 ml of 1X wash buffer and coverslips were mounted on slides using one
drop of apoptosis fixative solution in 1X wash buffer according to manufacturer’s
instructions. An inverted microscope (DM IBRE) and a Leica TCS SP confocal imaging
system were used to visualise and image cells (excitation 488, emission collected at 495-515
and 650-668). Fluorescence, bright field (differential interference contrast; DIC) and merged
images were captures using Leica confocal software.
2.2.23 Presentation of data and statistical analyses
Data is presented as the mean ± SD. ANOVA paired with Tukey’s HSD multiple comparison
post-test tests were used to analyse and compare differences between multiple treatments.
Unpaired student’s t-tests were performed for single treatment comparisons. Prism 5 for
Windows (Version 5.01) (GraphPad Software, San Diego, CA) was used to generate these
statistical analyses. Differences were defined as significant for P < 0.05.
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2.3 Results
2.3.1 SOD1 aggregates associate with the cellular surface and internalise into neuronal
cells via membrane proteins
2.3.1.1 Aggregating WT and G93A SOD1 proteins
Given the identification of SOD1-positive lewy-body like hylaline inclusions and skein like
inclusions in surviving motor neurons derived from spinal cords of SOD1-related fALS
patients (Piao et al., 2003) it is now generally accepted that pathogenic mutations in SOD1
increases the propensity of SOD1 to aggregate (Bruijn et al., 1998), and that SOD1
misfolding and aggregation contribute to the underlying cause for pathology in SOD1 fALS
cases (Furukawa and O’Halloran, 2005). To investigate the effects of properly folded soluble
SOD1 and aggregated proteins on motor-neuron like cell lines, recombinantly produced,
properly folded (soluble SOD1) and dimeric human WT and G93A SOD1 was purified and
subsequently aggregated in vivo to form fibrillar structures, as previously described (Yerbury
et al., 2013). To investigate the morphology of these aggregates, negative staining TEM was
performed. Representative TEM images of endpoint aggregates for both the WT and G93A
SOD1 proteins displayed short fibril-like structures, similar to those seen in human fALS
cases (Figure 2.1)

Figure 2.1 SOD1 proteins aggregate in to fibril -like structures. Representative TEM image of
endpoint aggregates. WT and G93A (1 mg/ml) protein samples (2 µl) were loaded onto carbon-coated nickel
grids for 1 min at RT and negatively stained using 2% uranyl acetate for 2 min at RT. Bars represent 20 nm.
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2.3.1.2 Applying exogenous recombinant SOD1 aggregates to the extracellular environment
of NSC-34 mouse motor neuron like cells
Our group and others have previously shown that aggregated human SOD1 can be taken up
by neuronal cells (Grad et al., 2014; Münch et al., 2011; Sundaramoorthy et al., 2013). To
confirm these results and further investigate entry, preformed SOD1 aggregates were added
to the media of NSC-34 cells (Figure 2.2). Following incubation of the cells with the SOD1
aggregates for 60 min, the aggregates could be detected in association with the cells by flow
cytometry Figure 2.2A). Next, to further investigate whether the SOD1 aggregates had
entered into NSC-34 cells, cells were incubated with SOD1 aggregates for 60 min and lysed.
Immunoblotting of cell lysates resulted in bands corresponding to the size of SOD1,
including SDS resistant high molecular weight (HMW) species (Figure 2.2B).

Figure 2.2 SOD1 protein aggregates are internalised into NSC -34 cells. (A) NSC-34 cells were
incubated with 20 μg/ml of SOD1 aggregates (blue line) or PBS alone (no protein, gray line) for 60 min at 4°C.
Cells were harvested, labelled with anti-sheep IgG conjugated to Alexa Fluor 488. (B) (Right panel) Western
blot of cell lysates detecting human SOD1 (and actin as a loading control). Lysates from NSC-34 cells were
treated with SOD1 aggregates or PBS (control) for 60 min at 4°C and were separated by SDS-PAGE under nonreducing conditions, transferred to nitrocellulose membrane and probed with streptavidin-peroxidase and mouse
anti-actin mAb. Arrows indicate approximate size of each band. Results are representative of at least 2
independent experiments.

2.3.1.3 Uptake into NSC-34 cells is specific for SOD1 and occurs rapidly
To further characterise the entry of SOD1 aggregates into NSC-34 cells, putative uptake of
SOD1 was investigated (Figure 2.3). NSC-34 cells were incubated with soluble SOD1 or
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aggregates for 30 min and immediately examined by flow cytometry (Figure 2.3A).
Incubation with the soluble (properly folded) WT SOD1 and non-aggregated ALS associated
mutant G93A SOD1 resulted in a significant increase in fluorescence compared to control
cells in the absence of protein. Similarly, aggregated WT SOD1 also associated with cells
when compared to the cells incubated in the absence of protein. In contrast, there was no
statistically significant increase in immunofluorescence after incubation with an unrelated
control protein GST suggesting that the uptake of both soluble and aggregated forms of
SOD1 is relatively specific. Next, to examine whether these aggregates enter cells efficiently
and rapidly, cells were incubated with SOD1 aggregates at 4ºC for 30 min. SOD1 aggregates
were found associated with the surface of NSC-34 cells after the 30 min incubation (Figure
2.3B), suggesting that interaction occurs relatively rapidly, given that endocytosis is slowed
and or inhibited by ice cold temperatures. To show that the observed SOD1 aggregates
associated with the cell surface are taken up by NSC-34 cells, cells were incubated with the
aggregates and treated with Triton X-100 detergent which non-selectively permeabilises
membranes. Similar to the flow cytometry observations described above, SOD1 aggregates
were no longer detected on the cell surface at 60 min (Figure 2.3C nevertheless they were
detected following permeabilisation of cells with Triton X-100, consistent with their
internalisation (Figure 2.3D).
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Figure 2.3 SOD1 protein aggregate are internalised rapidly into NSC -34 cells. (A) NSC-34
cells treated with 20 μg/ml of soluble and aggregated WT SOD1, GST or PBS (no protein, control) for 30 min at
37°C, fixed with 4% PFA, permeabilised and labelled with Alexa Fluor 488 streptavidin. Uptake of proteins was
determined by flow cytometry and results shown as means ± SE, n = 3, ***P < 0.001 compared to corresponding
control. (B) NSC-34 cells treated with 20 μg/ml of aggregated SOD1 for 30 min at 4°C, fixed with 4% PFA, and
labelled with Alexa Fluor 488 streptavidin. Slides were analysed by confocal microscopy. Bars represent 20 µm.
(C-D) NSC-34 cells treated with 20 μg/ml of aggregated SOD1 for 60 min at 4°C, fixed with 4% PFA,
permeabilised (or not) and labelled with Alexa Fluor 488 streptavidin. Slides were analysed by confocal
microscopy. Outline of cells from transmission images are indicated with white dashed lines. Bars represent 20
µm. Results are representative of at least 3 independent experiments.

2.3.1.4 SOD1 protein aggregates are not solely bound to the cells surface
Next, the possibility that WT and G93A SOD1 aggregates were bound primarily to the cell
surface was investigated. Previous work has used trypsin digestion to remove surface-bound
proteins (Wu et al., 2013). Incubation with 0.25% trypsin post treatment with SOD1
aggregates induced no significant differences in SOD1 signal, with similar levels of WT and
G93A SOD1 aggregate uptake in the presence or absence of trypsin, indicating that signal
observed in the flow cytometry experiments was not solely due to SOD1 aggregates
associated with the cell membrane, rather SOD1 aggregates were inside cells (Figure 2.4A
and B).
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Figure 2.4 SOD1 aggregates are detected inside in NSC -34 cells. Adherent NSC-34 cells were
incubated with 20 μg/ml of aggregated SOD1 or PBS (no protein, control) for 1 h at 37°C. Cells were then
incubated with 0.25% trypsin or PBS (control) for 5 min at 37°C. Suspended cells were re-plated for 6 h at 37°C
before fixation and immunocytochemistry. Biotinylated aggregates were detected with streptavidin-Alexa488.
Sytox Red (5 µM) was used as a counter stain (10 min at RT). Outline of cells from transmission images are
indicated with white dashed lines. Bars represent 20 µm. Mean fluorescence intensities (MFI) of SOD1
aggregate uptake were quantified from these images using ImageJ software (Version 1.48) (National Institutes
of health, Bethesda, MD). Results shown as mean cellular fluorescence intensity means ± SD, n > 3, ***P <0.001
compared to corresponding control (no protein treatment).

2.3.1.5 Digestion of membrane proteins by trypsin inhibits SOD1 uptake
Since SOD1 aggregate uptake had been observed and quantified, the possible role of
membrane proteins in the uptake into NSC-34 cells was next investigated. To investigate
whether an association between SOD1 aggregate uptake and membrane proteins exists, cells
were pre-treated with trypsin prior to the addition of SOD1 aggregates (Figure 2.5). In the
absence of a pre-incubation step with trypsin, a significantly higher fluorescence intensity
was measured for both WT and G93A protein aggregate treatments, compared to cells preincubated with trypsin. This indicates that digestion of plasma membrane associated proteins
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result in significant inhibition of aggregate association with cells, suggesting that the uptake
of SOD1 aggregates is dependent upon cell surface proteins.

Figure 2.5 SOD1 protein aggregates associate with NSC -34 cells via membrane proteins.
Internalisation of aggregated WT and G93A SOD1 (20 µg/ml) proteins for 30 min at 37oC, in the absence
(control) or presence of a pre-incubation step with 0.05% trypsin for 10 min at 37°C. MFI of 10 kDa dextran
conjugated to Alexa Fluor 647 uptake was measured using flow cytometry. Results shown as geometric means ±
SD, n = 6. Results shown as mean cellular fluorescence intensity means ± SD, n > 30, *P < 0.05 compared to
corresponding control (no protein treatment).

2.3.2 SOD1 aggregates are internalised via macropinocytosis pathways in NSC-34 cells
2.3.2.1 Pharmacological inhibitors of Macropinocytosis reduce SOD1 aggregate uptake in
NSC-34 cells
Previous studies have shown that small molecules that inhibit actin rearrangement, Na+/H+
exchangers, Pak-1, PI3K, and PKC suppress aggregate uptake (Grad et al., 2014; Munch et
al., 2011; Sundaramoorthy et al., 2013), consistent with macropinocytosis. However, it
remains to be shown whether SOD1 triggers macropinocytosis through an interaction with
cells or whether aggregates are taken up by a constitutive process. To investigate the
involvement of macropinocytosis-like pathways in the uptake of SOD1 aggregates into NSC34 cells, cells were firstly incubated in the absence or presence of EIPA (an inhibitor of the
Na+/H+ exchanger and subsequent endocytosis) and rottlerin (an inhibitor of PKC), as
reported previously (Grad et al., 2014; Munch et al., 2011; Sundaramoorthy et al., 2013), and
assessed by confocal microscopy and the mean fluorescence intensity for SOD1 uptake
determined by flow cytometry (Figure 2.6).
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Similar to previous experiments (Grad et al., 2014; Münch et al., 2011; Sundaramoorthy et
al., 2013), incubation with rottlerin and EIPA resulted in a significant reduction in the uptake
of SOD1 aggregates by (37±5% and 76±4%, Figure 2.6B) and (49±1% and 44±1%, Figure
2.6D for the WT and G93A aggregate treated cells respectively, compared to cells incubated
in the absence of inhibitors. However, inhibitors of clathrin (chlorpromazine) or caveolin
(genistein) dependent endocytosis had no significant effect on the uptake process. Therefore,
similar results were found regardless of whether or not the aggregates were WT or mutant
G93A SOD1. When soluble (non-aggregated) WT SOD1 (Figure 2.6C) was applied to cells
(Figure 2.6A) pre-incubated with EIPA, a significant reduction in SOD1 uptake was also
observed (48±8%). Similarly, pre-incubation with rottlerin suppressed WT SOD1 uptake by
(50±9%), however, this was not statistically significant. Although rotterlin (44±6%), EIPA
(50±9%) as well as genistein (43±6%) had some effect on reducing the uptake of G93A
SOD1 proteins into cells, pre-incubation with chlorpromazine hydrochloride was able to
significantly suppress uptake by (65±0.5%). Likewise, immunocytochemical analyses
confirmed these flow cytometry results, whereby lower signals of immunofluorescence are
indicative of reduced uptake of SOD1 proteins.
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Figure 2.6 Small molecule inhibitors blo ck SOD1 uptake. NSC-34 cells treated with 20 μg/ml of
(A-C) soluble or (B-D) aggregated SOD1 proteins (20 µg/ml) for 30 min at 37 oC, in the absence (control) or
presence of a pre-incubation step with either rottlerin (3 µM) a PAK-1 and PKC inhibitor, EIPA (100 µM) a
Na+/H+ exchange inhibitor, genistein (10 µM) a caveolin mediated uptake inhibitor or chlorpromazine
hydrochloride (Chlorp HCL) (5 mM) a clathrin mediated endocytosis inhibitor, fixed with 4% PFA,
permeabilised and labelled with either (A-C) anti-human SOD1 Ab (soluble) or (B-D) Alexa Fluor 488
streptavidin. Slides were analysed by confocal microscopy. Outline of cells are indicated with white dashed
lines. Bars represent 20 µm. Results are representative of at least n = 3. Uptake of proteins under the same
conditions were determined by flow cytometry and results shown as mean fluorescence intensity ± SD, n = 6,
***
P < 0.001 or *P < 0.05 compared to corresponding control.
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2.3.3 SOD1 aggregates trigger cell surface ruffling and activate RAC1 in NSC-34 cells
allowing the exploitation of macropinocytosis as a route of entry into cells
2.3.3.1 SOD1 aggregates induce cell surface ruffles and blebs in the membrane to enter into
NSC-34 cells
Actin cytoskeleton restructuring and the formation of ruffles and blebs in the cellular surface
are required for macropinocytosis and are generally formed upon an external stimuli such as
growth factors but can be triggered by a variety of other particles such as bacteria, apoptotic
bodies, necrotic cells and viruses (Swanson and Watts, 1995; Mercer and Helenius, 2012).
Since macropinocytosis has been implicated in SOD1 uptake (Münch et al., 2011;
Sundaramoorthy et al., 2013), the possible role of SOD1 aggregates in stimulating cellular
ruffles and blebs was investigated. To test whether there were any perturbations to the cell
surface membrane caused by incubation with SOD1, cells were treated with either PMA
(positive control) or SOD1 (aggregated and non-aggregated), for 2 h and then the detailed
morphology of cells was examined by field emission scanning electron microscopy (FESEM)
(Figure 2.7). In the absence of protein treatment, little to no membrane perturbations were
observed (Figure 2.7A), however, incubation with 200 nM PMA resulted in an obvious
increase in membrane perturbations, including ruffles and blebs (Figure 2.7B), consistent
with an activation of macropinocytosis. Incubation with soluble WT (Figure 2.7C) and G93A
SOD1 (Figure 2.7D) did not induce such membrane perturbations. In contrast, incubation
with aggregated WT (Figure 2.7E) and G93A SOD1 (Figure 2.7F) induced pronounced
membrane ruffling and blebbing consistent with stimulated macropinocytosis. Subsequent
quantifiable investigations into membrane perturbations induced by SOD1 were therefore
carried out.
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Figure 2.7 Aggregated SOD1 induces ruffles in the plasma membrane of NSC -34 cells.
NSC-34 cells were serum starved for 24 h and were incubated with (A) PBS (control, no protein), (B) PBS
containing 200 nm PMA or 20 μg/ml of (C-D) soluble (non-aggregated) and (E-F) aggregated SOD1, for 2 h,
fixed with 2.5% glutaraldehyde/4% PFA in 0.1 M phosphate buffer for 3 h, postfixed in 2% OsO4/ water,
dehydrated using a gradient of ethanol (30-100%, 30 min per treatment), critical point dried for 2 h and coated
with graphite-gold. Increases in membrane perturbations can be observed, such as ruffles and blebs. Slides were
analysed by field emission scanning electron microscopy. Bars represent 1 µm. Results are representative of n =
2.

2.3.3.2 SOD1 protein aggregates induce significant membrane perturbations in the cellular
surface of NSC-34 cells
To visualise and quantify the extent of observed SOD1 aggregate-induced membrane
perturbation to the cellular surface of NSC-34 cells, cells were treated with either PMA or
SOD1 (aggregated and non-aggregated), prior to incubation with the membrane dye FM 143FX (Figure 2.8). FM1-43FX has been used in previously for studies of membrane
perturbation during growth cone ruffling (Kolpak et al., 2009). Fluorescence images of NSC34 cells were then acquired (Figure 2.8A) and quantified (Figure 2.8B). In cells treated with
PMA, a significant increase in membrane dye fluorescence was observed (57±2) compared to
cells incubated in the absence of protein (30± 0.7). Similarly, incubation with WT (63±1) and
G93A (69±3) soluble SOD1 also resulted in a significant increase in fluorescence.
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Nevertheless, there was a three-fold higher mean fluorescence intensity for membrane
fluorescence in cells incubated with WT (97±6) and G93A (93±3) SOD1 aggregates,
consistent with an increase in membrane perturbation.

Figure 2.8 SOD1 aggregates induce membrane perturbations in the cell surface of NSC -34
cells (A) NSC-34 cells were incubated with PBS alone, 200 nM PMA or 20 μg/ml of aggregated SOD1for 60
min at 37°C, incubated with the membrane dye FM1-43FX and fixed with 4% PFA. Outline of cells are
indicated with white dashed lines. Bars represent 20 µm. (B) Mean fluorescence intensities (MFI) of membrane
dye per cell were quantified from these images using ImageJ software (Version 1.48) (National Institutes of
health, Bethesda, MD). A minimum of 200 cells were scored per treatment. Results shown as mean cellular
fluorescence intensity means ± SD, n = 3, ***P <0.001 compared to corresponding control (no protein
treatment); †††P < 0.001 compared to corresponding soluble protein.

2.3.3.3 SOD1 aggregates interact with the cell surface to trigger fluid phase uptake
Macropinocytosis is a form of fluid phase endocytosis that engulfs solutes at whatever
concentrations they are found in the extracellular medium, rather than concentrating ligands
at the cell surface. Thus, activation of macropinocytosis is well known to induce a transient
increase in dextran, a fluid phase marker (Kerr and Teasdale, 2009). To investigate whether
the interaction of SOD1 aggregates with cells triggers an increase in fluid phase uptake,
NSC-34 cells were incubated in the presence of both SOD1 and 10 kDa dextran conjugated to
Alexa Fluor 647 and assessed by both confocal microscopy (Figure 2.9A) and flow cytometry
(Figure 2.9B). Firstly, cells incubated in the presence of both WT and G93A SOD1
aggregates displayed an increase in fluid uptake compared to the untreated cells, with little to
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no difference observed for the cells treated with soluble SOD1. Next, cells were then
analysed by flow cytometry. Again, incubation with both WT (16±0.1%) and G93A
(18±0.3%) SOD1 aggregates triggered a significant increase in dextran uptake compared to
that in the absence of treatment (9±0.2%) or following incubation with WT (13±0.2%) and
G93A (13±0.1%) soluble SOD1. Whilst there was a small increase in dextran uptake in cells
treated with the soluble SOD1 compared to those not treated, it was concluded that this was
thus not attributable to stimulated macropinocytosis as it occurred in the absence of
membrane ruffling (see above).

Figure 2.9 SOD1 aggregates trigger fluid phase uptake using fluorescently labelled
dextran. NSC-34 cells were incubated with PBS alone (control) or 20 μg/ml of soluble and aggregated SOD1
for 30 min at 37°C, co-incubated with dextran Alexa-647 for 15 min, fixed with 4% PFA, permeabilised and
labelled with either anti-human SOD1 Ab (non-aggregated/ soluble) or Alexa Fluor 488 streptavidin. Slides
were analysed by (A) confocal microscopy. Outline of cells are indicated with white dashed lines. Bars
represent 10 µm. Results are representative of at least n = 3. (B) Cells were firstly gated on forward (FSC) and
side (SSC) scatter to exclude dead cells and the mean fluorescence intensities (MFI) of dextran Alexa-647 in
NSC-34 cells was determined by flow cytometry. Results shown as means ± SD, n = 6; ***P < 0.001 compared
to corresponding control; †††P < 0.001 or †P < 0.05 compared to corresponding soluble treatment.
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2.3.3.4 Pharmacological Inhibitors of Macropinocytosis also inhibit dextran uptake into
NSC-34 cells
To confirm that inhibitors of macropinocytosis can suppress dextran uptake into NSC-34
cells, cells were pre-incubated in the absence (PMA) or presence of pharmacological
inhibitors of macropinocytosis or in the absence of PMA and inhibitors (mock) (Figure 2.10).
As above (Figure 2.6) EIPA and rottlerin inhibited fluid phase uptake (quantified as uptake of
10 kDa dextran conjugated to Alexa647) stimulated by PMA treatment of NSC-34 cells, but
genistein and chlorpromazine did not, demonstrating the specificity of the inhibitors to PKCdependent fluid phase uptake.

Figure 2.10 PMA induced dextran uptake is suppressed by inhibitors of macropinocytosis.
The induction of fluid phase uptake was measured using fluorescently labelled dextran. NSC-34 cells were
serum starved for 24 h and co-incubated with 200 nM PMA for 30 min, in the absence (PMA) or presence of a
pre-incubation step with either rottlerin (3 µM), EIPA (100 µM), genistein (10 µM) or in the absence of PMA
and inhibitors (mock) for 30 min, and co-incubated with dextran Alexa-647 for 15 min. Induced fluid uptake
was determined by flow cytometry and results shown as mean cellular fluorescence intensity means. Cells were
firstly gated on forward (FSC) and side (SSC) scatter to exclude dead cells and the mean fluorescence intensities
(MFI) of dextran Alexa-647 in NSC-34 cells was determined by flow cytometry. Results shown as means ± SD,
n = 6; ***P < 0.001 compared to corresponding PMA treatment.

2.3.4 RAC1-GTPase activation is required for SOD1 aggregate uptake into NSC-34 cells
2.3.4.1 SOD1 aggregates trigger RAC1 activation to enter into NSC-34 cells
To further characterise the role of SOD1 protein aggregates in stimulating macropinocytosis,
additional events downstream of macropinocytosis activation were investigated. This
included activation of the Rho GTPase RAC1, which is involved in triggering membrane
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ruffling on the cell surface (Ridley et al., 1992). To investigate the activation status of RAC1
during entry of SOD1 aggregates into NSC-34 cells, cells were incubated with SOD1 and
RAC1 activation was probed for using a G-LISA based assay (Figure 2.11). Incubation of
cells with soluble SOD1 and aggregated WT SOD1 had no significant effect on RAC1
activation. While incubation with G93A SOD1 aggregates resulted in an almost one and a
half–fold significant increase in the amount of activated RAC1 ( RAC1-GTP) in NSC-34
cells.

Figure 2.11 RAC1 has an important role in SOD1 aggregate entry into NSC -34 cells. NSC34 cells were serum starved 24 h, incubated with PBS alone (mock) or 20 μg/ml of soluble and aggregated
SOD1 for 30 min at 37°C and lysed. RAC1 activation was measured using a RAC1 activation G-LISA kit
activation assay that probes for RAC1-GDP. Absorbance values of anti- RAC1 HRP at 490 nm were determined
by spectrometry and results are shown as mean absorbances (490 nm) ± SD of 6 experiments, **P < 0.01
compared to corresponding mock.

2.3.4.2 Addition of RAC1 inhibitor reduces SOD1 uptake.
To further examine the role of RAC1 in the uptake of SOD1 aggregates, the effect of the
RAC1 inhibitor W56 on SOD1 aggregate uptake was investigated (Figure 2.12). Significant
WT (19±0.4%) and G93A (21±0.4%) SOD1 aggregate uptake was observed in cells
incubated in the absence of W56. However, pre-treatment with W56 significantly suppressed
the uptake of WT (12±0.1%) and G93A (17±0.2%) SOD1 aggregates into NSC-34 cells.
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Figure 2.12 RAC1 inhibitor W56 suppresses the uptake of SOD1 aggregates. NSC-34 cells
treated with 20 μg/ml of aggregated SOD1 proteins (20 µg/ml) for 30 min, in the absence (control) or presence
of a pre-incubation step with RAC1 inhibitor W56 (200 µM) for 1 hr, fixed with 4% PFA, permeabilised and
labelled with either anti-human SOD1 Ab (non-aggregated/ soluble) or Alexa Fluor 488 streptavidin. (A) Slides
were analysed by confocal microscopy. Outline of cells are indicated with white dashed lines. Bars represent 10
µm. (B) Mean fluorescence intensities (MFI) per cell of a minimum of 100 cells were quantified from these
images using ImageJ software (Version 1.48) (National Institutes of health, Bethesda, MD). Results shown as
mean cellular fluorescence intensity means ± SD, n = 3, ***P <0.001 compared to corresponding control
(absence of RAC1 inhibitor).

2.3.4.3 RAC1 inhibitor W56 suppresses the formation of Ruffles in the cell surface in NSC-34
cells
Lastly, the effect of the W56 on ruffle formation in NSC-34 was investigated. Cells were
incubated with PMA in the presence or absence of pre-treatment with W56 and then
examined for membrane perturbations using membrane dye FM1-43FX (Figure 2.13). PMA
induced ruffle formation (112±1%) was significantly inhibited upon incubation with W56
(72±2%). Collectively, these results confirm that RAC1 activation is upstream of membrane
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ruffling, which in turn is required for macropinosome formation and entry of SOD1
aggregates into NSC-34 cells.

Figure 2.13 RAC1 activation is upstrea m of membrane ruffling. (A) NSC-34 cells treated with
200 nM PMA for 30 min, in the absence (PMA) or presence of a pre-incubation step with RAC1 inhibitor W56
(200 µM) or absence of PMA and inhibitor (control) for 1 hr, incubated with the membrane dye FM1-43FX for
7 min and fixed with 4% PFA. 1X RedDot2 was used as a counter stain (10 min, RT). Outline of cells are
indicated with white dashed lines. Bars represent 10 µm. (B) Mean fluorescence intensities (MFI) of membrane
dye per cell were quantified from these images using ImageJ software (Version 1.48) (National Institutes of
health, Bethesda, MD). A minimum of 200 cells were scored per treatment. Results shown as mean cellular
fluorescence intensity means ± SD, n = 6, ***P < 0.001 compared to corresponding control (no protein
treatment); †††P < 0.001 compared to corresponding soluble protein.

2.3.5 SOD1 induced macropinocytosis activation is not associated with cell death under
experimental conditions, in NSC-34 cells
Membrane perturbations in the form of ruffling and blebbing are required for entry of
particles and macromolecules to enter cells via macropinocytosis. However, protrusions of
the plasma membrane in the form of blebs can also be found in association with cell injury,
including apoptosis (Trump et al., 1997). To exclude the possibility that cells were blebbing
due to apoptosis, cells were firstly incubated in the absence or presence of SOD1 proteins or
the positive control etoposide (Schonn et al., 2010), and then the cells were examined for
levels of activated caspase-3 over the 2 h time period of the experiment (Figure 2.14 ).
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Incubation with SOD1 proteins; WT (25±1%) and G93A (20±2%) soluble (non-aggregated)
and WT (9±0.3%) and G93A (10±1%) aggregates did not induce caspase 3 activation in cells
above basal (22±0.5%) levels (PBS treated) in the timeframe of this experiment.

Figure 2.14 Addition of SOD1 does not induce rapid apoptosis. (A) NSC-34 cells were incubated
with PBS alone (mock), 100µM etoposide or 20 μg/ml of aggregated SOD1 for 2 h at 37°C, followed by
incubation with FLICA reagent and fixed with apoptosis fixative solution. The levels of activated caspase-3
were tested using Image-IT kit. Outline of cells are indicated with white dashed lines. Bars represent 20 µm. (B)
Mean fluorescence intensities (MFI) of FLICA reagent per cell were quantified from these images using ImageJ
software (Version 1.48) (National Institutes of health, Bethesda, MD). Results shown as mean cellular
fluorescence intensity means ± SD, n = 3, ***P <0.001 compared to corresponding control (no protein
treatment).
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2.4 Discussion
The current study confirms a role for stimulated macropinocytosis in the uptake of SOD1
aggregates into NSC-34 cells. The morphology of SOD1 aggregates were assessed in the
current study and these short fibrillar aggregates were found to associate with NSC-34 cells
via membrane proteins and efficiently internalise into cells. In addition, the addition of
pharmacological inhibitors of macropinocytosis including EIPA, rottlerin and W56 disrupted
the uptake of SOD1 aggregates into cells. Furthermore, this study demonstrated for the first
time that aggregates of SOD1 trigger activation of the Rho GTPase RAC1, leading to the
formation of membrane ruffles on the cell surface and fluid phase uptake that defines
macropinocytosis. Collectively, this suggests that SOD1 aggregates are capable of
stimulating macropinocytosis to facilitate their entry into NSC-34 cells. This process would
facilitate further seeding of SOD1 aggregates similar to what is suggested to occur during
progression of disease in SOD1 ALS.
It has been suggested that extracellular misfolded or aggregated SOD1 plays an active role in
the spread of pathology among motor neurons (Grad et al., 2014; Münch et al., 2011),
contributing to disease progression via interactions with both the cell surface and
internalisation into cells in both fALS and sALS (Sundaramoorthy et al., 2013). In the current
study, exogenously applied WT and mutant G93A SOD1 fibril-like aggregates were taken up
efficiently by naïve motor neuron-like cells. Similarly, the uptake of extracellular WT SOD1
aggregates, recombinantly produced or derived from conditioned media has previously been
observed (Grad et al., 2014; Sundaramoorthy et al., 2013). The morphology of human
recombinant SOD1 proteins were amlyloid-like in structure, consistent with another study
which suggest SOD1 positive inclusions derived from fALS patients do not stain with
amyloid dyes (Kerman et al., 2010). Furthermore, the work presented here demonstrated that
uptake of SOD1 was selective and rapid. Incubation with the soluble (properly folded) WT
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SOD1 and non-aggregated ALS associated mutant G93A SOD1 resulted in their uptake into
cells, to a similar extent to that of WT SOD1 aggregates. In contrast, there was no statistically
significant increase in immunofluorescence after incubation with an unrelated control protein
GST, suggesting that the uptake of both soluble and aggregated forms of SOD1 is relatively
specific. Other studies have also utilised recombinant soluble SOD1 proteins and similarly
demonstrated the uptake of soluble WT and mutant SOD1 (Sundaramoorthy et al., 2013).
This may reflect the proposed role of non-classically secreted SOD1 in signal transduction
(Damiano et al., 2013; Turner et al., 2005).
In the current study, SOD1 aggregates were shown to associate with the neuronal cell surface
after 30 min incubation and after 60 min are no longer detected on the surface but instead are
only detected following permeabilisation of cells with Triton X-100, suggesting these entered
into cells with remarkable efficiency, consistent with reports from previous studies (Münch et
al., 2011). Furthermore, this current study suggests that uptake of aggregates is dependent
upon cell surface membrane proteins, since trypsinisation of potential endocytosis receptor
proteins prior to treatment with aggregates significantly inhibited aggregate association with
cells. This is consistent with another study which shows treatment of the cell surface with
trypsin, inhibited the uptake of α-synuclein (Sung et al., 2001).
A role for macropinocytosis in the uptake of extracellular native and aggregated WT and
mutant SOD1 into neuronal cells has been previously suggested (Grad et al., 2014; Münch et
al., 2011; Sundaramoorthy et al., 2013). In these studies, the addition of small molecules that
inhibit actin rearrangement, Na+/H+ exchangers, Pak-1, PI3K, and PKC was reported to
impair the uptake of SOD1 aggregates (Grad et al., 2014; Munch et al., 2011;
Sundaramoorthy et al., 2013), consistent with macropinocytosis. In the current study, EIPA
(an inhibitor of the Na+/H+ exchanger and subsequent endocytosis) and rottlerin (an inhibitor
of PKC), as reported previously (Grad et al., 2014; Munch et al., 2011; Sundaramoorthy et
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al., 2013), were used to confirm the involvement of macropinocytosis-like pathways in the
uptake of SOD1 aggregates into NSC-34 cells. EIPA and rottlerin inhibited the uptake of
SOD1 aggregates, however, inhibitors of clathrin (chlorpromazine) or caveolin (genistein)
dependent endocytosis had no significant effect on this process. Furthermore, this process
differs from that responsible for the uptake of soluble SOD1 proteins, which occurs
presumably via a constitutive form of pinocytosis in the case of the WTSOD1 and potentially
via a range of mechanisms in the case of soluble G93A SOD1. Thus, these results suggest a
primary role for macropinocytosis in the uptake of SOD1 aggregates
While previous work demonstrated a role for macropinocytosis in the uptake of SOD1
aggregates into neuronal cells, it had been unclear whether macropinocytosis is triggered
through an interaction of SOD1 with cells or whether aggregates are taken up by some other
constitutive process. SOD1 aggregate-mediated activation of macropinocytosis and
subsequent internalisation into NSC-34 cells was confirmed in the current study. Triggering
the activation of macropinocytosis leads to the entry of large amounts of solute
macromolecules or particles too large for other forms of endocytosis across the plasma
membrane (Swanson and Watts, 1995). Activation of macropinocytosis has been reported to
induce a number of downstream signaling events including the activation of a Rho GTPase,
RAC1 (Ridley et al., 1992), which contributes to the modulation of ruffle formation,
macropinosome closure and membrane trafficking (Lanzetti et al., 2004).
Activated RAC1, has been identified as an important and central player in triggering
membrane ruffles and blebbing in the form of lamellipodia, circular-shaped membrane
extensions (ruffles) and large plasma membrane extrusions (blebs) (Mercer and Helenius,
2009), associated with virus entry into cells and has been found to do so by activating
downstream effectors of actin polymerisation (Sanchez et al., 2012). While the precise role of
PKC in virus entry is still unclear, its activation with PMA (as used in this current study) can
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induce ruffling and fluid uptake in the absence of ligands that bind the cell surface (Swanson,
1989). The activation of RAC1 and subsequent membrane ruffling was supported in the
current study. Similarly, intracellular mutant SOD1 has been found to interact with and
activate RAC1 (Harraz et al., 2008). Of note, inhibition of RAC1, supressed the uptake of
SOD1 aggregates, thus implicating these membrane perturbations in SOD1 entry. As
expected, incubation with SOD1 aggregates induced increased membrane perturbations,
including ruffles (retracting) and blebs, consistent with the formation of large vacuoles
(macropinosomes) at the plasma membrane, thus further supporting uptake of SOD1
aggregates occurs as part of the activation of macropinocytosis process. Of note, the current
study confirmed that activation of RAC1 activation is upstream of membrane ruffling.
Macropinocytosis is a form of fluid phase endocytosis that engulfs fluids and solutes at
whatever concentrations they are found in the extracellular medium, rather than concentrating
ligands at the cell surface. The data presented here shows that the activation of
macropinocytosis mediated by SOD1 aggregates induced fluid uptake, coinciding with the
formation of membrane ruffling, attributable to stimulated macropinocytosis. EIPA and
rottlerin inhibited fluid phase uptake (quantified as 10 kDa dextran conjugated to Alexa Fluor
647uptake) stimulated by phorbol 12-myristate 13-acetate (PMA) treatment of NSC-34 cells,
but genistein and chlorpromazine did not, demonstrating the specificity of the inhibitors to
PKC-dependent fluid phase uptake.
In addition to SOD1 aggregates, various viruses, such as the vaccinia virus, adenovirus 3,
herpes simplex virus 1 and HIV, utilize macropinocytosis to gain entry to cells. This
phenomenon is likely to be due to the fact that macropinosomes are not restricted in size,
enabling even large virions to be internalised, and that many cell types, not just professional
phagocytes (such as macrophages), have the ability to activate the macropinocytosis
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pathways (Swanson and Watts, 1995). Indeed, macropinocytosis can be activated in neurons
by interactions with large viral particles (Kalia et al., 2013).
While it was not confirmed in this study whether addition of recombinant SOD1 induced
stress, previous studies have found that addition of extracellular recombinant mutant and/or
aggregated SOD1 to naïve neuronal cells induce ER stress (Sundaramoorthy et al., 2013). In
the current study, NSC-34 cell death was not observed following incubation with SOD1
aggregates in the short timeframe of the experiment, as apoptosis is likely to occur at a much
longer incubation period (least 10 hours). Collectively, this suggests that SOD1 aggregates
are capable of mediating macropinocytosis, independent of cell death.
In conclusion, the current study represents the first findings of SOD1 aggregate mediated
activation of macropinocytosis pathways, similar to those utilized by virions, in neuronal
cells, in the specific context of ALS. While, this was not demonstrated in vivo, it is likely that
the activation of macropinocytosis occurs potentially alongside other pathways. Indeed,
future studies investigating whether macropinocytosis occurs in vivo is warranted.
Collectively, this suggests that extracellular SOD1 aggregates together with the activation of
macropinocytosis are key components of ALS progression. Thus, future investigations into
the role of SOD1-induced activation of macropinocytosis during disease progression in
SOD1-ALS in vivo are warranted.
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Chapter 3
SOD1 AGGREGATES
PROPAGATE IN A PRION-LIKE
MANNER
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3.1 Background
Amyotrophic lateral sclerosis (ALS) is a fatal and rapidly progressing neurodegenerative
disorder, affecting both upper and lower motor neurons. ALS is characterised by a focal onset
of motor neuron degeneration, followed by outward neurospatial spreading of disease
pathology, to neighbouring neurons and to distant regions via axonal pathways (Braak et al.,
2013). One potential explanation for the progressive spread of pathology is the prion-like
propagation of protein misfolding. Evidence is mounting that ALS associated proteins, such
as SOD1, may play an active role in the systematic spread of disease pathology (Ayers et al.,
2016; Grad et al., 2014; Münch et al., 2011; Zeineddine and Yerbury, 2015).
For propagation of aggregation to occur, the newly formed intracellular aggregates must
initially be released into the extracellular space. The secretion or release of SOD1 by
neuronal cells has been suggested to occur via both active mechanisms such as the secretion
of proteins from cells via exosomes and passive mechanisms such as cell death, as previously
demonstrated in vivo (Gomes et al., 2007; Grad et al., 2014; Urushitani et al., 2006). Both
human wild type (WT) and mutant SOD1 proteins have been observed in association with
vesicles, particularly exosomes (Gomes et al., 2007; Grad et al., 2014; Silverman et al., 2016)
or released as free aggregates as a result of cell death (Grad et al., 2014). SOD1 has also been
detected in the cerebrospinal fluid of ALS patients with and without SOD1 mutations and in
animals, implying its release via non-classical mechanisms (Jacobsson et al., 2001; Winer et
al., 2013; Zetterstrom et al., 2011). Given that SOD1lacks an ER signal peptide, this suggests
that the secretion of pathogenic SOD1 from affected cells may occur via similar mechanisms
in vivo and in vitro; however the exact triggers and mechanisms of secretion in vivo are yet to
be established.
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Soluble and aggregated SOD1 have previously been shown to be taken up by neuroblastoma
cells (mouse NSC-34 and human SHSY5Y) via macropinocytosis (Grad et al., 2014;
Sundaramoorthy et al., 2013) (reviewed in Chapter 1). Once SOD1 internalises into cells, it
accumulates in cytosolic inclusions (Sundaramoorthy et al., 2013). In addition, the uptake of
extracellular misfolded WT or mutant SOD1 inhibits protein transport between the ER-Golgi
apparatus, leading to Golgi fragmentation, induction of ER stress and apoptotic cell death,
(Sundaramoorthy et al., 2013), similar to ER-stress related neurodegenerative pathways
observed in ALS pathology (Atkin et al., 2008; Saxena et al., 2009).
For intracellular spread of pathological proteins to occur, after exogenous misfolded SOD1 is
internalised into neighbouring naïve cells, the SOD1 misfolding competent seeds need to
escape the vesicular lumen and gain access to the cytosol to further nucleate the aggregation
of soluble endogenous SOD1. Examples of protein aggregates escaping membrane vesicles is
that amyloid fibrils have previously been shown to induce membrane damage, thus causing
the rupture of membrane vesicles leading to cellular toxicity (Milanesi et al., 2012). In
addition, particles such as virions, including those of the vaccinia virus, Japanese encephalitis
and adenovirus species (Mercer and Helenius, 2012), have been shown to hijack
macropinocytosis pathways to enter the cytoplasm of cells, including neurons (Kalia et al.,
2013). A lack of physical structure of the macropinosome is thought to leave it vulnerable to
a loss of integrity and may explain why particles (e.g. bacteria and virions) can efficiently
escape macropinosomes and reach the cytosol (Conner and Schmid, 2003).
Previous work has shown that exogenously applied mutant SOD1 aggregates induce a self‐
perpetuating seeding of aggregation of native SOD1 (Grad et al., 2014; Munch et al., 2011).
Importantly, recent work shows that injection of spinal cord homogenates from symptomatic
G93A SOD1 mice into the sciatic nerve of mice expressing G85R SOD1-YFP has been
shown to kindle protein aggregation and subsequently induce an ALS-like phenotype (Ayers
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et al., 2014). In addition, using human embryonic kidney HEK‐293 or human WT SOD1‐
expressing murine primary spinal cord cultures, it has been reported that uptake and selfperpetuating propagation of SOD1 misfolding is dependent upon the passage of misfolded
SOD1 (either WT or mutant) from cell-to-cell, a process that can be neutralised by antibodies
reactive with misfolded SOD1 epitopes (Grad et al., 2014). However, the precise mechanism
by which SOD1 aggregates reached the cytosol to seed endogenous SOD1 was not
determined in these studies. Presumably, the newly formed aggregates must then be secreted
or released into the extracellular space to reinitiate the propagation cycle.

3.1.1 Aims
SOD1 aggregates have been shown to be released, associated with cell death, and internalised
by naïve cells to seed the aggregation of native soluble proteins (Grad et al., 2014; Münch et
al., 2011). Thus, this study aimed to investigate the mechanisms of SOD1 aggregate uptake in
to naïve cells, and more importantly identify and quantify seeding activity between donor and
recipient cells expressing SOD1 using a novel technique for quantifying inclusions; flow
cytometric characterisation of inclusions and trafficking (FloIT).
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3.2 Methods
3.2.1 Reagents and antibodies
DMEM/F-12 medium, DMEM/F-12 without phenol red, 0.05% trypsin-EDTA, GlutaMAX,
SuperSignal West Pico Chemiluminescent Substrate, FM® 1-43FX, fixable analog of FM® 143 membrane stain, LysoTracker Red DND-99, Lipofectamine 2000, Lipofectamine 3000,
SuperSignal West Pico Chemiluminescent Substrate, Subcellular Protein Fractionation Kit
for Cultured Cells, CellTrace CFSE Cell Proliferation Kit, restriction endonucleases BamHI
and HindIII, Ez- link- NHS- Biotin and SYTOX Red dead cell stain were purchased from
ThermoFisher Scientific. Cell culture 8‐chamber μ‐slides were purchased from Ibidi,
(Planegg‐Martinsried, Germany). Any kD Mini-PROTEAN TGX Precast Protein Gels and
Precision Plus Protein dual color protein standard were from Bio-Rad (California, USA).
Foetal Bovine Serum (heat-inactivated prior to addition in media; FBS) was from Bovogen
Biologicals (East Keilor, Australia). Amersham Hyperfilm and cellulose acetate membrane
(0.2 µm) was obtained from GE Healthcare (Little Chalfont, Buckinghamshire, UK). RedDot
2 was from Biotium (Hayward, CA). Sterile cell culture plates were form Greiner Bio-One
(Frickenhausen, Germany). Casein (heat denatured before use; HDC), dimethyl sulfoxide
(DMSO), bovine serum albumin (BSA), β-mercaptoethanol, Brilliant blue R concentrate,
paraformaldehyde (PFA), biotinamidohexanoic acid 3-sulfo-N-hydroxysuccinimide ester
sodium salt, Bicinchoninic Acid Kit, Propidium iodide, Osmium tetroxide solution (4 WT. %
in H2O), ethidium bromide, Deoxyribonuclease I from bovine pancreas and dithiothreitol
(DTT) were from Sigma-Aldrich (St. Louis, MO). Ethylenediaminetetraacetic acid (EDTA)
was from Amresco (Solon, USA). Digitonin, High Purity was from Calbiochem was from
San Diego, CA, USA. Glass coverslips (19 mm) were from ProSciTech (Kirwan, Australia).
Protease inhibitor cocktail tablets (complete, Mini, EDTA-free) was from Roche Diagnostics
(Penzberg, Germany). All other reagents including salts, powders and chemicals were from
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Amresco, Sigma-Aldrich or Astral Scientific (Gymea, Australia). All reagents used were
endotoxin free. Antibodies (Abs) and inhibitor compounds and their respective
manufacturing companies used in this current study are listed in Table 3.1.
Table 3.1 Antibodies used in this study to investigate the effect of SOD1 proteins on TDP-43
pathology
Host species
(clonality)1
Mouse (mAb)
Rabbit (pAb)
Rabbit (pAb)
Mouse (mAb)
Mouse (mAb)

Anti-body target
(Immunogen)2
Beta Actin [AC-15]
Vimentin
EEA1
LAMP1 [H4A3]
beta III Tubulin [2G10]

Rabbit (pAb)

Conjugate
-

Manufacturer
(product number)3
Abcam (ab8226)
Abcam (ab137321)
Abcam (ab2900)
Abcam (25630)
Abcam (78078)

-

Abcam (ab6556)

Mouse (mAb)
Sheep (pAb)

Green fluorescent
protein
BiP/GRP78
SOD1

-

Goat (pAb)

Transferrin

-

Mouse (pAb)

GST

-

Mouse (mAb)
Goat (pAB)

Galectin 3
Mouse IgG

Alexa Fluor 488

Goat (pAb)

Rabbit IgG

Alexa Fluor 488

Donkey (pAb)
Goat (pAb)

Sheep IgG
Mouse IgG

Alexa Fluor 488
Alexa Fluor 633

Donkey (pAb)
Goat (pAb)

Sheep IgG
Mouse IgG

HRP
HRP

BD Biosciences (610978)
ThermoFisher Scientific
(PAI-30817)
Sigma‐Aldrich
(T2027)
Sigma‐Aldrich
(ge27-4577-01)
Abcam (A3A12)
ThermoFisher Scientific
A-(11001)
ThermoFisher Scientific
( A-11008)
Abcam (150177)
ThermoFisher Scientific
( A-21052)
Abcam (97125)
Merck Millipore (12-349)

1

pAb, polyclonal anti-body, mAb, monoclonal anti-body; 3 Abcam, Cambridge, USA; ThermoFisher Scientific
(Waltham,MA, USA); BD Biosciences San Jose, CA, USA; Merck Millipore, Billerica, Massachusetts, USA; Cytoskeleton
(Denver, CO,USA) ; Sigma‐Aldrich (St. Louis, MO)

3.2.2 Cell Lines
The mouse neuroblastoma x spinal cord hybrid cell line (NSC-34 cells) (Cashman et al.,
1992) were routinely cultured in DMEM/F12 supplemented with 10% (v/v) FBS and 2 mM
GlutaMAX. Cells were maintained in an incubator at 37°C under a humidified atmosphere
containing 5% (v/v) CO2.
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3.2.3 Cell Transfections
3.2.3.1 Plasmid purification
pEGFP-N1 expression vectors containing SOD1WT, SOD1G93A and SOD1A4V cDNAs were
provided by Bradley Turner (University of Melbourne, Melbourne, Australia) (Turner et al.,
2005a). pFUW expression vectors containing SOD1G127X cDNAs were kindly provided by
Edward Pokrishevsky (University of British Columbia, Vancouver, Canada) (Grad et al.,
2011). SOD1-tomato red (TdTomato) constructs were created by replacing the EGFP
sequences with tdTomato from pcDNA3.1(+)Luc2tdT by GenScript (Piscataway, NJ).
pCAG-RFP expression vectors containing TDP-43WT cDNA was obtained from Addgene,
provided by Zuoshang Xu (University of Massachusetts Medical School, Worcester,
Massachusetts, USA)(Yang et al., 2010). Chemically competent DH5α Escherichia coli cells
were provided by Jason McArthur (University of Wollongong, Wollongong, Australia). Cells
were transformed with the TDP-43 and SOD1 containing plasmids as per manufacturer’s
instructions, using the heat shock (42 ºC) method. Transformed cells were then transferred
onto lysogeny broth (10% w/v tryptone, 10% w/v NaCl, and 5% w/v yeast; LB) agar plates
with 50 µg/ml kanamycin sulphate and incubated overnight at 37°C. Single-transformed
bacterial colonies were selected and inoculated into sterile LB media containing 50 µg/ml
kanamycin sulphate to prepare starter cultures. Plasmid DNA was then extracted from
bacterial cells using the CompactPrep Plasmic Maxi Kit (Qiageb, Hilden, Germany), as per
manufacturer’s instructions.
The purity (260/280 ratio) and concentration of extracted DNA was measured using the
NanoDrop 2000c dual-mode UV-Vis Spectrophotometer (ThermoFisher Scientific, Waltham,
USA). To further confirm the purity of the extracted DNA samples, a restriction digestion
was carried out at 37ºC for 1 h using enzymes HindIII and BamHI that correspond to specific
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restriction sites in the plasmids. Digested DNA samples were separated on a 1% agarose gel
in tris-acetate-EDTA (TAE) buffer (1 mM ethylenediaminetetraacetic acid (EDTA) disodium
salt, 40 mM Tris and 20 mM acetic acid). The resulting gel was then stained with ethidium
bromide overnight and visualised using the GS-800 Calibrated Densitometer (Bio-Rad).
3.2.3.2 Transfecting cells with Lipofectamine 2000
NSC-34 cells were maintained in DMEM/F12 medium supplemented with 10% FBS and 2
mM GlutaMAX (complete culture medium) at 37°C under a humidified atmosphere
containing 5% (v/v) CO2 unless otherwise stated. To transfect, cells previously seeded at (6 x
105 cells/mL) were incubated in DMEM/F-12, in the absence of serum, containing 2 μg
plasmid DNA and Lipofectamine 2000 for 5 h. Cells were then washed once with serum free
DMEM/F12 media and replenished with complete culture medium for the duration of the
experiment.
3.2.3.3 Transfecting cells with Lipofectamine 3000
NSC-34 cells were seeded in 8-well chamber slides at a density of 3-4 x 105 cells/ 200 µL/
chamber and were incubated overnight. Cells were then incubated in complete DMEM/F-12
culture medium containing 2 μg plasmid DNA, P3000 reagent and Lipofectamine 3000
(diluted in serum free DMEM/F-12 medium) for either 24 h, 48 h, or 72 h. For cotransfection assays, 1 μg of each plasmid was used for a total of 2 μg of DNA.
3.2.3.4 Collection and separation of transfected cells and conditioned media
To confirm transfection and determine sufficient transfection efficiency, cells were visualised
by fluorescence microscopy using an Eclipse TE2000 inverted microscope (Nikon, Tokyo,
Japan). Following transfection (2, 24, 48, or 72 h), conditioned media were collected from
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respective treatments. Cells were harvested using 0.05% trypsin (5 min, 37°C) and
conditioned media were processed and analysed as described below.
3.2.4 Aggregation and biotinylation of WT and mutant G93A SOD1
WT and G93A (mutant SOD1) SOD1 were expressed and purified from E.coli as previously
outlined (Lindberg et al., 2002; Roberts et al., 2013). SOD1 aggregation was performed in
vivo as previously described (Roberts et al., 2013). Briefly, solutions of purified WT or
mutant SOD1 (1 mg/ml) in PBS were incubated with 20 mM dithiothreitol (DTT) and 5 mM
EDTA (Sigma, St. Louis, MO) for 72 h at 37 °C with shaking using a digital shaker
(universal IKA® MS 3, 230 V). The aggregated SOD1 was then labelled with
biotinamidohexanoic acid 3-sulfo-N-hydroxysuccinimide ester sodium salt (40 mg/ml) in
DMSO for 2 h at RT. The unconjugated biotin was then separated from the aggregates by
centrifugation (21 000 x g for 30 min) and washed three times with PBS (300 x g for 5 min).
The purified aggregates free of unconjugated biotin were then resuspended in PBS (1 mg/ml).
A bicinchoninic acid (BCA) protein assay was performed to determine the amount of protein
remaining after labelling.
3.2.5 Aggregated SOD1 association with acidic compartments by confocal microscopy
NSC-34 cells (2–3 x 104 cells/200 µL/chamber) were cultured in chamber slides at 37°C
overnight. Cells were pre-treated with Lysotracker Red (75 nM) for 2 h at 37°C as per the
manufacturer’s instructions. Cells were then washed and incubated with 20 μg/ml of
aggregated WT and mutant SOD1 for either 10 min, 30 min or 60 min at 37°C. Cells were
fixed at respective time points with 4% PFA in PBS for 20 min at RT and washed twice with
PBS over 5 min. Cells were then incubated with Triton X-100 for 30 min at 4°C. Cells were
incubated with blocking solution (5% FCS, 1% BSA and 0.3% Triton X-100) for 20 min at
RT. Cells were incubated with anti- SOD1 IgG (1:500 diluted in 4% BSA and 0.1% Triton X91

100) overnight at 4°C. Cells were subsequently washed again in PBS and incubated with antisheep IgG conjugated to Alexa Fluor 488 (1:500 diluted in 1% BSA and 0.1% Triton X-100)
protected from light for 1 h at RT. An inverted microscope (DM IBRE) and a Leica TCS SP
confocal imaging system were used to visualise and image cells (excitation 488, emission
collected at 520-540). Fluorescence, bright field (differential interference contrast; DIC) and
merged images were captures using Leica confocal software.
3.2.6 Subcellular Fractionation assay of NSC-34 cells
NSC-34 cells were incubated with WT or mutant G93A SOD1 proteins in aggregated form
(20 µg/mL) in PBS for 2 h at 37°C/5% CO2. Post incubation, the cells were washed three
times with PBS (300 x g for 5 min) harvested using 0.5% trypsin and 5 mM EDTA and
washed (500 x g for 5 minutes). The cells were washed three times with ice cold PBS (500 x
g for 3 minutes) for fractionation using a Subcellular Protein Fractionation Kit for Cultured
Cells as per manufacturer’s instructions (Thermo Fisher Scientific). Initially, NSC-34 cells
(10 x 106 cells/mL) were incubated with cytoplasmic extraction buffer (CEB) containing
protease inhibitors for 10 min rotating at 4°C. The supernatant (cytoplasmic fraction) was
collected (500 × g for 5 minutes). The cell pellet was then incubated with membrane
extraction buffer (MEB) containing protease inhibitors for 10 min rotating at 4°C. Post
incubation, the supernatant (extracted membrane fraction) was collected (3000 × g for 5
minutes). Ice cold nuclear extraction buffer (NEB) containing protease inhibitors was added
to the cell pellet for 30 min rotating at 4°C. The supernatant (extracted soluble nuclear
fraction) was collected (5000 × g for 5 minutes). Chromatin-bound extraction buffer (NEB,
100 mM CaCl2 and 300 units of Micrococcal Nuclease) was added to the pellet for 15 mins at
RT. The supernatant (chromatin-bound nuclear extract) was collected (16,000 x g for 5 mins).
Lastly, Pellet Extraction Buffer (PEB) containing protease inhibitors was added to the cell
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pellet for 10 mins at RT. The supernatant (the cytoskeletal extract) was collected (16,000 x g
for 5 mins).
Protein concentration was determined using the BCA method. Fractions (20 μg protein/lane)
were separated under reducing conditions (5% β-mercaptoethanol) using Any kD MiniPROTEAN TGX Stain-Free™ Precast Gels. Proteins were then transferred to nitrocellulose
membranes using a Trans-Blot Turbo Transfer System (Bio-Rad). Total protein per lane was
then imaged and measured with a Bio-Rad Criterion Stain Free Imager and Image Lab
software. Membranes were blocked with heat denatured casein (HDC) in for 1 h at 37°C. To
test the efficiency of the separation, rabbit anti-EEA1 pAb (1:500), rabbit anti-Vimentin pAb
(1:500) and mouse anti-actin mAb (1:5000), diluted in HDC/PBS for 1 h at 37°C were used
to probe the CE, ME, NE and PE fractions. Membranes were visualised using
chemiluminescent substrate and Amersham Hyperfilm ECL (GE Healthcare). Images of films
were collected using a GS-800 Calibrated Densitometer (Bio-Rad). The processing of films
was achieved using GBX Developer and Replenisher and GBX Fixer and Replenisher
(Kodak Australiasia, Collingwood, Victoria Australia). Images of the films were collected
using a GS-800 Calibrated Densitometer (Bio-Rad).
3.2.7 Selective Permeabilisation of NSC-34 cells
NSC-34 cells were incubated in chamber slides with 20 μg/ml of soluble and biotinconjugated aggregated WT and G93A SOD1 protein for either 60 or 120 min at 37°C. Cells
were immediately fixed with 4% PFA in PBS for 20 min at RT and washed twice with PBS
over 5 min. Cells were incubated with either Triton X-100 (0.5%) or digitonin (10 µM) for 30
min and 10 min at 4°C respectively. Cells were then incubated with blocking solution (5%
FCS, 1% BSA and 0.3% Triton X-100) for 20 min at RT. Cells were incubated with antiSOD1 IgG (1:500 diluted in 4% BSA and 0.1% Triton X-100) overnight at 4°C. Cells were
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washed again in PBS and incubated with Alexa Fluor 488 streptavidin (1:1000 diluted in 1%
BSA and 0.1% Triton X-100) for 1 h at RT. Cells were incubated with Sytox Red (5 nM) for
10 min at RT. An inverted microscope (DM IBRE) and a Leica TCS SP confocal imaging
system were used to visualise and image cells (excitation 488, emission collected at 510550). Fluorescence and merged images were captured using Leica confocal software.
3.2.7.1 Controls for selective permeabilisation
NSC-34 cells incubated in chamber slides for 24 h in complete culture media were fixed with
4% PFA in PBS at RT for 20 min at RT, and washed twice with PBS over 5 min. Cells were
incubated with either Triton X-100 (0.5%) or digitonin (10 µM) for 30 min and 10 min at 4°C
respectively. Cells were then incubated with blocking solution (5% FCS, 1% BSA and 0.3%
Triton X-100) for 20 min at RT. Next, cells were incubated with mouse anti-LAMP1 (mAb)
(0.3 µg/ 100µL), mouse anti-BiP/GRP78 (mAb) (0.5 µg/ 100µL), mouse anti-β-tubulin
(mAb) (0.2 µg/ 100µL) and rabbit anti-EEA1 (pAb) (0.5 µg/ 100µL) overnight at 4°C. Cells
were subsequently washed again in PBS and incubated with goat Alexa Fluor 488‐conjugated
goat anti‐rabbit IgG Ab (0.3 μg/ 100 μL) and Alexa Fluor 488‐conjugated goat anti‐mouse
IgG Ab (0.3 μg/ 100 μL) in PBS containing 1% BSA and 0.1% Triton X-100 protected from
light for 1 h at RT. Cells were incubated with RedDot2 (1:200) for 10 min at RT. Imaging
was performed as outlined above.
3.2.8 Membrane damage (haemolytic) assay
Fresh Human venous blood was kindly provided by Wollongong Hospital Pathology Unit;
NSW, Wollongong, Australia (The University of Wollongong Human Ethics Approval
H202/080). Firstly, human blood was incubated with 5 mM EDTA and protease inhibitor
cocktail, pH 7.0 for 1 h at 4ºC. The next day, the blood samples were gently mixed by
inversion and were washed three times in PBS (300 x g for 5 min) and harvested (1 x10 6
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cells/mL/tube) by resuspension in phosphate/sodium acetate buffer (10 mM CH3CO2Na,
10mM Na2HPO4, 137 mM NaCl, 2.7 mM and 2 mM) pH 7.2. Clarified blood cells were
incubated with 20 μg/ml of WT and G93A SOD1 soluble and aggregated protein or 0.1%
Triton-x100 was used for total cell lysis for 2 h at 37°C. Following incubation, blood cells
were washed twice in phosphate/sodium acetate buffer (300 x g for 5 min). Total
Haemoglobin levels of the supernatant were determined via optical density (absorbance)
measurements, a measure of lysed erythrocytes using a SpectraMax Plus 384 Microplate
Reader and SoftMax Pro software (Molecular Devices, Silicon Valley, CA) (540 nm).
3.2.9 Preparation of Giant Unilamellar Vesicles
The rapid evaporation method was used to prepare giant unilamellar vesicles for confocal
microscopy as described in (Milanesi et al., 2012). Briefly, soy L-α-phosphatidylcholine
(Avanti Polar Lipids Inc) was dissolved in CHCl3:MeOH (2:1) to give a phospholipid
concentration of 5 mM. Liposome buffer (50 mM HEPES, 107 mM NaCl, 1 mM EDTA, 0.1
M sucrose, pH 7.4, 2.5 mL) was then added to the lipid/solvent solution in a 50 mL round
bottom flask and the two phases mixed by vigorous pipetting. The organic solvent was
removed by rotary evaporator under reduced pressure (final pressure 44 mbar) for 5 min at
37°C. The resulting liposome suspension was stored overnight at 4°C prior to confocal
microscopy studies. The next day, liposomes were incubated with 20 μg/ml of aggregated
SOD1 proteins for 2 h 37°C.
3.2.10 Galectin -3 as a marker of cell rupture
NSC-34 cells were incubated in chamber slides with 20 μg/ml of soluble and biotinconjugated aggregated WT and G93A SOD1 protein for 2 h at 37°C. Cells were immediately
fixed with 4% PFA in PBS for 20 min at RT and washed twice with PBS over 5 min. Cells
were incubated with either Triton X-100 (0.5%, control) or digitonin (10 µM) for 30 min and
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10 min at 4°C respectively. Cells were then incubated with blocking solution (5% FCS, 1%
BSA and 0.3% Triton X-100) for 20 min at RT. Cells were incubated with anti-Galectin 3
IgG (0.5 µg/100 µL) overnight at 4°C. Cells were subsequently washed again in PBS and
incubated with goat Alexa Fluor 488‐conjugated goat anti‐mouse IgG (0.3 μg/ 100 μL) in
PBS containing 1% BSA and 0.1% Triton X-100 protected from light for 1 h at RT. Cells
were incubated with RedDot2 (1x) for 10 min at RT. Imaging was performed as outlined
above.
3.2.11 Release of SOD1 aggregates and filter trap assay
Following transfection (at 72 h), conditioned media from SOD1 transfected cells were
collected and pre-incubated with 1 unit DNaseI per μg of transfected DNA for 10 min at RT
and centrifuged for 30 min at 21,000 x g at 4°C into soluble and pelletable fractions.
Pelletable fractions were incubated with an equal volume of phosphate‐buffered saline (PBS)
containing 1% SDS at RT for 15 min. Samples were analaysed using using filter trap analysis
and SDS-PAGE. For filter trap analysis, pellatable fractions were added to the microfiltration
apparatus and then SDS resistant protein were collected and separated onto a cellulose acetate
membrane with 0.2 μm pores (GE Healthcare) using a Bio‐Dot SF Microfiltration System
(Bio‐Rad) under vacuum pressure. The membrane was washed with PBS containing 1% SDS
three times over 5 min, followed by PBS. In addition, pelletable fractions were separated
under reducing conditions (5% β-mercaptoethanol) using Any kD Mini-PROTEAN TGX
Stain-Free™ Precast Gels. Proteins were then transferred to nitrocellulose membranes using a
Trans-Blot Turbo Transfer System (all Bio-Rad). The presence of EGFP-SOD1 aggregates
were then detected by immunoblotting. The membranes were blocked with heat denatured
casein (HDC) for 1 h at 37°C. The membranes were then incubated with at 4°C overnight
with an anti‐EGFP pAb (1:1000‐1:10000). The following day, the membrane was washed
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three times over 15 min with PBS containing 0.1% Triton X‐100. The membrane was then
incubated at room temperature for 1 h with peroxidise‐conjugated anti‐rabbit (1:1000) IgG
Ab and then washed as above. Released SOD1 protein aggregates were visualised using
chemiluminescent substrate and Amersham Hyperfilm ECL (GE Healthcare). Images of films
were collected using a GS-800 Calibrated Densitometer (Bio-Rad. Relative EGFP and EGFPSOD1 aggregates were quantified from these images using ImageJ software (Version 1.48)
(National Institutes of Health, Bethesda, MD).
3.2.12 Released protein uptake assay by immunoblotting and confocal microscopy
Conditioned media from transfected cells were collected 72 h post-transfection and preincubated with 1 unit DNaseI per μg of transfected DNA for 10 min at RT and centrifuged for
30 min at 21,000 x g at 4°C into soluble and pelletable fractions. Pelletable fractions were
washed and resuspended in complete culture media (500 μL) and added to adherent naïve
NSC-34 cells plated in 12‐well plates at (1.5 × 106 cells/ 0.4 mL/ well) 24 h prior to treatment
with conditioned media for 2 h at 37°C/5% CO2. Imaging was performed as outlined above
(see section 3.2.5). NSC-34 cells were washed in three times in PBS and harvested using
trypsin (0.5%) and washed (500 x g for 5 minutes). Cells were then lysed over 15 min at 4°C
in ice-cold lysis buffer (10 mM Tris, 150 mM NaCl, 5 mM EDTA, 1% Triton X-100 and
protease inhibitor cocktail, pH 7.0). Cell debris was then cleared (21,000 × g at 4°C for 30
min) and large SDS resistant protein aggregates in the supernatants (100 μg protein/slot) were
trapped onto a cellulose acetate membrane with 0.2 μm pores (GE Healthcare) using a Bio‐
Dot SF Microfiltration System (Bio‐Rad) under vacuum pressure. The membrane was
washed with PBS containing 1% SDS three times over 5 min, followed by PBS. The presence
of EGFP-SOD1 aggregates were then detected by immunoblotting as above. Internalised
SOD1 protein aggregates in the supernatants were visualised using chemiluminescent
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substrate and Amersham Hyperfilm ECL (GE Healthcare). Images of films were collected
using a GS-800 Calibrated Densitometer (Bio-Rad).
3.2.13 Cell death assay
Following transfection (24 , 48 , and 72 h in total), NSC-34 cells expressing EGFP(control),
SOD1WT and SOD1G93A -EGFP were washed twice in incomplete culture media (lacking
FCS) and then harvested using 5 mM EDTA (5 min, 37°C) and then washed again using
centrifugation (300 x g for 5 min). Cells (1 x105 cells/mL/tube) were resuspended in PBS and
incubated with SYTOX Red dead cell stain (5 µM) immediately before analysis by flow
cytometry. Cellular events were collected using a LSR II flow cytometer (excitation 488 nm,
emission collected at 515/20 nm band pass filter; excitation 488nm, emission collected at
575/20 nm band pass filter) for EGFP and PI respectively. The percentage of dead cells was
expressed as cells positive for PI as a proportion of total EGFP-positive cells and was
determined FlowJo software. Results are the average of at least three independent
experiments.
3.2.14 UV ablation assay by confocal microscopy
Adherent NSC‐34 cells in 8‐chamber well slides were transiently transfected with TDP-43WT
and TDPG294A‐EGFP using Lipofectamine 3000 (see above). Following transient transfection
of NSC-34 cells (48 h), a fluorescent cell with aggregates was identified and assessed as
suitable for ablation. UV laser mediated cell selective destruction was performed on the
nucleus of the cell for 20s using Leica Confocal Software. Live cell imaging was performed
at 15 min time intervals and then fluorescent and bright‐field images were captured for 24 h
using a DM IBRE inverted microscope and TCS SP confocal imaging system (Leica,
Germany) (excitation 488 nm, emission collected at 510‐540 nm).
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3.2.15 FloIT assay by flow cytometry
Adherent NSC‐34 cells in 24‐well plates (6 × 105 cells/ 0.5 mL/well) were transiently
transfected separately (co-culture) or co-transfected with SOD1WT and SOD1G93A fused to
either EGFP or tdTomato using Lipofectamine 3000 (see section 3.2.3.3). For the co-culture
assay, following transient transfection (24 h), cells expressing SOD1WT-tdTomato were
washed three times in incomplete culture media, and cells expressing SOD1G93A-EGFP were
harvested using 0.5% trypsin and 5 mM EDTA and washed (500 x g for 5 minutes). The cells
were then resuspended in complete culture media (500 µl) and were co-plated with adherent
cells (at a ratio 1:1) expressing SOD1WT-tdTomato for a total of 72 h (post co-culture). As an
additional control, cells expressing SOD1WT-tdTomato and SOD1G93A-EGFP were cultured
separately, and then mixed immediately before flow analysis (corresponding to the respective
timepoint). For the co-transfection assay, NSC-34 cells were co-transfected with SOD1WTtdTomato and SOD1G93A-EGFP (6 h prior to co-culturing) for a total of 72 h (corresponding
to the time point of the co-culture experiment). For the seeding assays, cells expressing
SOD1WT-tdTomato were cultured in the presence of 20 μg/ml of with human recombinant
mutant SOD1 (G93A) aggregates at the indicated time points. Following co-transfection, coculturing or addition of recombinant SOD1 aggregates (at 24h, 48 h and 72h in total), cells
were harvested using 5 mM EDTA (5 min, 37°C) and then washed again using centrifugation
(300 x g for 5 min). Cells were then washed twice in PBS (300 x g for 5 min) and
resuspended in PBS (0.5 mL/tube). An aliquot of cells were (2 x 10 5cells/0.15mL) collected
then analysed for transfection efficiency (excitation 488 nm, emission collected with 525/50
nm band pass filters; excitation 561 nm and emission collected with 586/15 nm band pass
filters for EGFP and tdTomato respectively) determined by flow cytometry. The remaining
cells (2 x 105cells/0.35mL) were washed as above and lysed prior to analysis in lysis buffer
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(0.5% Triton X-100 and Complete protease inhibitor in PBS). Cell lysates were then
incubated with RedDot2 (1:1000) at RT for 2 min.
All events were collected using a LSRFortessa X‐20 Cell Analyzer (BD Biosciences)
(excitation 488 nm, emission collected with 525/50 band-pass filter and excitation 561,
emission collected with 586/15 nm band-pass filter for EGFP and RedDot2, respectively;
excitation 561 nm and emission collected with 586/15 nm band pass filters for tdTomato). All
parameters were set to log10 during acquisition from cell lysates. The forward scatter
threshold was set to the minimum value (200 AU) to minimize the exclusion of small protein
inclusions. Nuclei were identified and enumerated based on RedDot2 fluorescence and
forward scatter and then excluded from further analysis. The percentage of EGFP +/tdTomato+
particles was determined using quadrant markers in FlowJo software. The remaining particles
were analysed for the presence of inclusions based on GFP/ tdTomato fluorescence, forward
scatter and comparison lysates prepared from cells expressing only the corresponding
fluorescent protein.
The number of inclusions in the population can be normalised to the number of nuclei, and
reported as inclusions/1000 transfected cells (iFloIT) according to the equation:
𝑛𝑖
𝑖𝐹𝑙𝑜𝐼𝑇 = 100 (
)
𝛾. 𝑛𝑛𝑢𝑐
where ni represents the number of inclusions acquired, nnuc is the number of nuclei acquired,
and γ is the transfection efficiency.
Analysis of all events were performed using FlowJo software (Tree Star, Ashland, OR). A
summary of the methods carried out for analysis of SOD1 propagation in NSC-34 cells is
summarised (Figure 3.1) and described below.
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Figure 3.1 Summary of methods to investigate the prion-like propagation of SOD1 in
NSC‐34 motor neurons Following transfection (72 h), conditioned media from NSC‐34 cells were
collected and centrifuged (21,000 x g for 30 min) to remove cell debris, and analysed using filter trap. Naïve
NSC- 34 cells were incubated with fractionated conditioned media for 2 h and then lysates were analysed by
filter trap analysis. In other experiments, SOD1 aggregate formation (in the absence or presence of recombinant
human mutant SOD1 aggregates) was visualised by confocal microscopy. Transiently transfected NSC-34 cells
were either co-cultured or co-transfected with SOD1-EGFP or SOD1 tdTomato for 72 h and assessed by flow
cytometry to identify transfer events.
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3.3 Results
3.3.1 Transient expression of mutant SOD1 can induce cell death in NSC-34 motor
neurons over time
SOD1 proteins have been shown to have spontaneous fibrilisation activity in vivo (Chia et al.,
2010; Furukawa et al., 2008). Therefore, the presence of inclusion bodies containing SOD1
aggregates indicative of spontaneous aggregation was investigated. To investigate the number
of SOD1 positive inclusions in NSC-34 motor neurons, cells were transfected with SOD1WT
tdTomato and SOD1G93A GFP for 48 and 72 h and the number of inclusions were quantified
using flow cytometric characterisation of inclusions and trafficking (FloIT) technique (Figure
3.2A). Initially, the lysates of NSC-34 cells containing large particles were gated (nuclei and
inclusions). After nucleus removal, particles were analysed for green or red fluorescence to
identify inclusions positive for EGFP or tdTomato (Figure 3.2B). A significantly greater
number of inclusion bodies were identified in cells expressing mutant SOD1 G93A and
SOD1WT compared to cells expressing EGFP or tdTomato alone (Figure 3.2C). Furthermore,
a significantly greater number of inclusions were measured between cells expressing mutant
SOD1G93A and SOD1WT. However, there was no statistical difference in the number of
inclusions between tdTomato and EGFP controls.
Next, the relationship between timing of SOD1 aggregate formation and cell death was
investigated. NSC-34 motor neurons were transfected with SOD1WT and SOD1G93A-EGFP for
48 and 72h, treated with SYTOX red dead cell stain and assessed by flow cytometry (Figure
3.2D). Cell death is expressed as the total of dying and dead cells (red dot exclusion) that are
positive for EGFP. A significantly greater amount of cell death was observed for the cells
expressing SOD1WT-EGFP at 48 h relative to cells expressing EGFP alone although this
increase was only ~1% of GFP positive cells. At 72 h however, the percentage of cell death
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between these treatments was similar. A significantly higher percentage of total cell death
was however observed for cells expressing SOD1G93A-EGFP relative to cells transiently
expressing EGFP alone, and this increased two-fold at 72 h. Furthermore, cell death was
significantly higher from 48-72 h in cells expressing SOD1G93A-EGFP compared to cells
transfected with SOD1WT-EGFP, consistent with reports of mutant SOD1 induced toxicity to
cells (Brotherton et al., 2013). These findings suggest a relationship between SOD1-inclusion
body formation and cell death in NSC-34 cells.

Figure 3.2 Spontaneous aggregation of SOD1 and cell death of EGFP -positive cells after
72 h post transfection was exa mined by flow cytometry. Following transfection, using
Lipofectamine 3000, NSC‐34 transiently transfected with SOD1WT tdTomato, SOD1G93A‐EGFP, tdTomato or
EGFP were cultured separately for 48 and 72 h. (A) Cell lysates were firstly gated on forward scatter (FSC) and
RedDot2 fluorescence to identify nuclei and then (B) the number of EGFP and tdTomato positive- inclusions
were identified from the non-nuclei gated population determined by flow cytometry. (C) Results shown as mean
number of inclusions per 100 transfected cells ± SEM, n = 3; ***P < 0.001 and *P < 0.05 compared to controls
(fluorescent tags); †††P < 0.001 compared to corresponding SOD1WT tdTomato. (D) Following transfection at 48
h, and 72 h, using lipofectamine 2000 adherent NSC-34 cells in complete DMEM medium expressing EGFP
(control), SOD1WT and SOD1G93A EGFP were harvested and incubated with propidium iodide (1 mg/mL). Cells
were gated on forward and side scatter to exclude doublets and cell debris and then the percentage of cells
positive for EGFP and SYTOX Red dead cell stain were determined by flow cytometry. Results shown as total
percentage of cell death in EGFP expressing cells ± SD, n = 3; ***P < 0.001 or *P <0.05 compared to
corresponding EGFP control; †††P < 0.001 and †P < 0.05 compared to corresponding SOD1WT-EGFP.
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3.3.2 Intracellular SOD1 aggregates are released from NSC-34 motor neurons
Intracellular SOD1 protein aggregates have been previously been reported to be secreted via
active mechanisms and released by passive means (Gomes et al., 2007; Grad et al., 2014).
Filter trap analysis and immunoblotting is a conventional method to study protein aggregates
(Juenemann et al., 2015), including SOD1 aggregate detection in conditioned media (Grad et
al., 2014), thus this technique was used to observe and quantify the profile of secreted WT
and a series of mutant SOD1 proteins in conditioned media (Figure 3.3). To determine
whether a range of SOD1 aggregates can be released from NSC-34 motor neurons, cells were
transfected with EGFP or WT and mutant SOD1- EGFP variants including SOD1WT and
mutant SOD1 variants including SOD1G93A, SOD1A4V and SOD1G127X for 72 h. Total
conditioned media was then collected from these cells and separated by centrifugation.
Pelletable fractions were examined by immunoblotting, and the relative amount of SOD1EGFP quantified (Figure 3.3A). Little to no EGFP was detected in the fraction derived from
conditioned medium of cells transfected with EGFP. In comparison, filter trap analysis
identified small but significant amounts of SDS‐resistant material that was anti‐EGFP
reactive and larger than the 0.2 μm pore size of the membrane in conditioned media from
cells expressing SOD1WT. A significantly greater amount of SDS‐resistant material positive
for EGFP was identified in conditioned medium from NSC‐34 cells expressing SOD1G93A,
SOD1A4V and SOD1G127X –EGFP (Figure 3.3A).
To further characterise these SOD1 aggregates released from NSC‐34 cells, the conditioned
medium was analysed by SDS PAGE separation and immunoblotting (Figure 3.3B). Again,
no EGFP was identified in the fraction obtained from conditioned medium of cells
transfected with EGFP. In comparison, anti-EGFP bands with an approximate molecular size
of 35 kDa and 50 kDa consistent with the molecular weight of SOD1-EGFP monomer and
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dimer respectively (Turner et al., 2005), were identified in conditioned media from cells
expressing SOD1WT, expressing SOD1G93A, SOD1A4V and SOD1G127X –EGFP. In addition,
high molecular weight, SDS-resistant oligomeric species were detected in these respective
fractions, ranging in molecular size from 150 kDa to above 250 kDa. This is consistent with
above filter trap analysis data.

Figure 3.3 Wild type and mutant SOD1 proteins can be detected in conditioned media of
NSC-34 motor neurons (A) Following transfection (at 72 h) using lipofectamine 2000, conditioned media
were collected and incubated 250 units of DNase for 10 min at RT, fractionated into pelletable fractions by
centrifugation and incubated with 1% SDS in PBS. SDS resistant proteins were separated onto cellulose acetate
membrane (0.2µM) in a filter trap apparatus, and then incubated with anti‐EGFP Ab. Results shown as mean
band density relative to EGFP ± SD, n = 6; ***P < 0.001, **P < 0.01 or *P <0.05 compared to corresponding
EGFP control. (B) Conditioned media were fractionated into pelletable and soluble fractions by centrifugation.
Pelletable fractions were then separated by SDS‐PAGE under reducing conditions and transferred to a
nitrocellulose membrane. The membrane was then incubated with anti‐EGFP Ab. The black arrow indicates
SOD1–EGFP monomer whereas the red arrow indicates SOD1–EGFP dimer. The area indicated by an asterisk
represents SDS-resistant oligomeric SOD1 species. The slot-blot presented is representative of bands cut
horizontally, and displaying n = 1.

3.3.3 Released SOD1 aggregates are capable of entering into Naïve NSC-34 motor
neurons
Next, to investigate whether released SOD1 aggregates are capable of entering into naïve
NSC-34 motor neurons, naïve cells were incubated with pelleted fractions derived from
conditioned medium of NSC-34 cells transfected with SOD1WT and mutant SOD1 variants
including SOD1G93A, SOD1A4V and SOD1G127X for 2 h (Figure 3.4). Following incubation,
conditioned media was then collected from these cells and separated by centrifugation
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(Figure 3.4A). Cells were incubated in conditioned media and visualised by microscopy to
identify SOD1-EGFP inclusions inside the cells (Figure 3.4B), and then whole lysates were
probed with anti-EGFP pAb. SOD1 or EGFP in pelletable fractions derived from conditioned
media was then examined by immunoblotting with an anti‐EGFP pAb (Figure 3.4C).
Similar to above data, no SDS-resistant material was identified in the fraction derived from
conditioned medium of cells transfected with EGFP. However, a substantial amount of SDS‐
resistant material, larger than the 0.2 μm pore size that was anti‐EGFP reactive in conditioned
media from cells expressing SOD1WTand SOD1G93A, SOD1A4V and SOD1G127X –EGFP.
Similarly, large SDS resistant material was present in the respective fractions obtained from
whole lysates of cells expressing WT and mutant variants of SOD1, however these were
present at a much lower intensity. Prior to lysis, cells were assessed by microscopy, cells
incubated with conditioned media from cells expressing SOD1-EGFP displayed discrete and
diffuse fluorescence, characteristic of SOD1 inclusions.

Figure 3.4 Wild type and mutant SOD1 proteins can be detected in conditioned media of
NSC-34 motor neurons transiently transfected with SOD1 and these can transmit to naïve
NSC-34 cells (A) After identifying the presence of aggregates using filter trap analysis (72 h) (B) conditioned
media was collected and treated with 250 units of Dnase for 10 min at RT, centrifuged and pelletable fraction
added onto adherent naïve NSC-34 cells for 2 h and were visualised by confocal microscopy to observe for
internalised extracellular SOD1 protein aggregates. Bars represent 10 μm and results are representative of n=2
(C) Cells were lysed and a pelletable fractions were obtained by centrifugation. Pelletable fractions were then
separated onto cellulose acetate membrane (0.2µM) in a filter trap apparatus, and then incubated with anti‐
EGFP Ab.
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3.3.4 SOD1 aggregates can transfer from cell to cell
Given the ability for naïve cells to take up aggregates from conditioned media, the ability of
aggregate transfer from cell-to-cell was next examined. Prior to analysis, fluorescence
compensation was performed to account for spectral overlap into the GFP channel (Figure
3.5A). Cells were either transfected with GFP or tdTomato separately and then cell
populations mixed, any acceptor cells with both red and green after the incubation period was
deemed a SOD1 transfer event. Next, transfer events were quantified as the percentage of
transfected acceptor cells positive for both EGFP/tdTomato using the gating strategy outlined
in Figure 3.5B. Two cell populations transiently expressing SOD1WT tdTomato or SOD1G93A‐
EGFP proteins were co-cultured at a ratio of 1:1 and analysed using flow cytometry (Figure
3.5C). Control cells were also transfected separately, however they were mixed immediately
prior to flow cytometry analysis. Similar to previous cell to cell in culture findings (Grad et
al., 2014), approximately 2.7 ± 1% at 24 h, 1.2 ± 0.1% at 48 h and 5.2 ± 0.6% at 72 h
acceptor NSC-34 cells were found to contain significantly greater amount of both SOD1WT
tdTomato and SOD1G93A‐EGFP from donor cells, and were scored as EGFP/tdTomato red
double-positive, compared to the controls. These results therefore indicate that that either or
both SOD1WT tdTomato and SOD1G93A‐EGFP can release from NSC-34 donor cells into the
conditioned media, into which they are then taken up by other neighbouring transiently
transfected NSC-34 acceptor cells. This therefore demonstrated cell to cell transfer of SOD1
between donor and acceptor cells.
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Figure 3.5 SOD1WT tdTomato and SOD1G93A ‐EGFP proteins can transfer between co cultured NSC-34 motor neurons. Following transfection, using Lipofectamine 3000, NSC‐34 transiently
transfected with SOD1WT tdTomato, SOD1G93A‐EGFP, tdTomato or EGFP were either co-cultured or cultured
separately for 24, 48 and 72 h. NSC-34 cells cultured separately were mixed prior to analysis (control) (A)
SOD1WT tdTomato compensation to account for spectral overlap into the GFP channel (B) Results shown as dot
plots of one representative set of data demonstrating the quadrant markers (C) mean percentage of cells ± SEM,
n = 3; ∗∗∗P < 0.001 or *P < 0.05 compared to control (mixed population of cells).
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3.3.5 SOD1 aggregates escape the endocytic pathway by damaging or rupturing the
membrane of vesicles to gain access to the cytosol in NSC-34 motor neurons.
3.3.5.1SOD1 aggregates escape the endolysosomal system and enter into cytosol
The data presented in Chapter 2 demonstrated that SOD1 aggregates are indeed able to enter
NSC-34 cells via stimulated macropinocytosis. However, the mechanism by which
exogenously applied SOD1 aggregates induce the formation of cytoplasmic inclusions
containing intracellular SOD1 has not yet been established. Given that this likely involves the
escape of SOD1 from membrane bound endolysosomes, the ability of SOD1 aggregates to
escape from endolysosomal compartments following its uptake was first investigated (Figure
3.6). NSC-34 cells were incubated with SOD1 aggregates at 37°C and imaged following
incubation at incremental time intervals as indicated. Cells were then probed for SOD1
aggregates (using biotin-SA), and for lysosomes using Lysotracker red and images were
captured with confocal microscopy. Exogenously added WT SOD1 aggregates entirely colocalised with Lysotracker dye, until 30 minutes, after which low levels of SOD1 could be
observed outside the acidic endo-lysosomal system (Figure 3.6A) as indicated by the arrows.
Similarly, G93A SOD1 aggregates were predominately observed in association with the
lysotracker at 10 min and 30 min, however at 60 min aggregates were detected outside the
acidic vesicles (Figure 3.6B) as indicated by the arrows.
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Figure 3.6 Internalised SOD1 aggregates entering via the endocytic pathway escape fro m
the endoso mes to the cytosol. Representative confocal images of NSC-34 cells pre-treated with
Lysotracker Red for 2 h followed by treatment with 20 μg/ml of aggregated (A) WT SOD1 or (B) G93A SOD1
for either 10 min, 30 min or 60 min at 37°C, fixed with 4% PFA, permeabilised and labelled with an anti-human
SOD1 pAB and anti-sheep IgG conjugated to Alexa Fluor 488. Slides were analysed by confocal microscopy.
Representative confocal images are shown. Outline of cells are indicated with white dashed lines. Bars represent
10 µm. Results are representative of at least n = 3.

These data suggest that SOD1 aggregates can escape the endolysosomal system (Figure 3.6).
However, to confirm whether SOD1 aggregates had entered the cytosol, NSC-34 cells were
incubated with WT and G93A SOD1 aggregates and their location within the cell was then
investigated by immunoblotting of cytosolic, membrane (ER/Golgi), nuclear and cytoskeletal
supernatant fractions (Figure 3.7). In the WT SOD1 treated fractions (Figure 3.7A), WT
SOD1 aggregates predominantly fractionated with the cytoskeleton (PE) fraction presenting
as a high molecular weight smear ranging from 50 to over 160 kDa in size. An additional
band in the cytoplasmic (CE) fraction was detected, with an approximate size of 16 kDa,
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corresponding to human SOD1 monomer likely separated from larger aggregates. Similarly,
treatment with G93A SOD1 aggregates (Figure 3.7B) resulted in the detection of high
molecular weight smear ranging from approximately 60 to over 150 kDa in size in the
cytoskeleton (PE) fraction. In addition, minor smearing of high molecular weight bands was
observed in the cytoplasmic (CE) fraction ranging from approximately 50-160 kDa in size
and a band at 16 kDa; the predicted size of human SOD1 monomer. Non-specific Ab binding
was also observed, predominantly in the G93A blot. To further confirm the efficiency of the
fractionation, the fractions were immunoblotted using an anti-actin, anti-EEA1 and antivimentin Ab (Figure 3.7C). Confirming the success of the fractionation vimentin (54 kDa)
was predominantly found in the PE fraction and EEA1 (180 kDa) was primarily detected in
the ME fraction. Actin was found in all fractions. Furthermore, proteins remaining in the
endolysosomal system would be present in the membrane extract (ME) fraction, and
therefore absence of these proteins in the ME fraction support above findings.

Figure 3.7 Internalised aggregates are detected in the cytoplasm of NSC-34 cells.
Cytoplasmic extract (CE), membrane extract (ER/Golgi) (ME), nuclear extract (NE) and pellet extract
(cytoskeleton) (PE) fractions by centrifugation from NSC-34 cells treated with either (A) WT or (B) G93A
SOD1 aggregates (20 μg/mL) or (C) PBS alone and were separated by SDS PAGE under reducing conditions,
transferred to nitrocellulose membrane and incubated with streptavidin-HRP, anti-actin, anti-EEA1 or antivimentin Abs (as indicated). Results show one experiment and are representative of two experiments.
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To further investigate the presence of SOD1 aggregate uptake into membrane bound vesicles
and their subsequent escape to the cytosol, a selective permeabilisation assay was performed
(Figure 3.8). Selective permeabilisation involves the use of Triton X-100 detergent, which
disrupts all cellular membranes, or the glycoside digitonin which selectively permeabilises
the plasma membrane leaving only intracellular, nuclear, ER and Golgi membranes intact
(Figure 3.8A) (Nizard et al., 2007). Firstly, the assay conditions were optimised to confirm
adequate and selective permeabilisation of NSC-34 cells. Cells were incubated with either
Triton X-100 (0.5%) or digitonin (10 µM) for 30 min and 10 min at 4°C respectively, and
immunolabelled with Abs specific for lysosomal associated membrane protein 1, LAMP1;
Binding immunoglobulin protein, BiP; Early endosome antigen 1, EEA1; and cytosolic
protein, β-Tubulin and analysed by confocal microscopy (Figure 3.8B). LAMP1, BIP and
EEA1 were detected upon treatment with Triton-X 100 only, and no protein signal was
observed upon treatment with digitonin, consistent with their location in membrane enclosed
vesicles. However, β-Tubulin was detected after treatment with both Triton-X100 and
digitonin consistent with its presence in the cytoplasm. This indicated that the TritonX100/digitonin method under these conditions, and in NSC-34 cells, provides satisfactory
selective permeabilisation.
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Figure 3.8 Digitonin selectively permeabilises the plasma membrane of NSC-34 cells.
Adherent NSC-34 cells were incubated in complete culture media for 24 h. min at 37°C, fixed with 4%
paraformaldehyde, permeabilised with either triton-x 100 or digitonin. Cells were labelled with anti-LAMP1
mAb, anti-BiP/GRP78 mAb, anti-β-tubulin mAb and anti-EEA1 pAb followed by Alexa Fluor 488‐conjugated
anti- rabbit and mouse Ab and analysed by confocal microscopy. RedDot2 (1X) was used as a counter stain (10
min at RT). Representative confocal images are shown. Outline of cells are indicated with white dashed lines.
Bars represent 10 µm. Results are representative of at least n = 2.

Next, to confirm that aggregates were present outside any membrane enclosed compartments,
cells were incubated with aggregated or soluble SOD1 and treated either with Triton X-100
or digitonin, immunolabelled with a specific Ab and analysed by confocal microscopy
(Figure 3.9). At the 60 min time-point, SOD1 aggregates were detected only after Triton X100 permeabilisation in NSC-34 cells treated with WT (Figure 3.9A) and mutant G93A
SOD1 aggregates (Figure 3.9B), with no detectable fluorescence signal in cells treated with
digitonin.
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Figure 3.9 Internalised SOD1 aggregates are n ot detected in the cytoplasm of NSC-34 cells
at 60 min Adherent NSC-34 cells were incubated with 20 μg/ml of aggregated (A) WT or (B)
G93A SOD1 for 60 min at 37°C, fixed with 4% paraformaldehyde, permeabilised with either triton-x 100 or
digitonin and labelled with Alexa Fluor 488 streptavidin for biotinylated aggregates. Sytox Red (5 µM) was
used as a counter stain (10 min at RT). Slides were analysed by confocal microscopy. Representative confocal
images are shown. Outline of cells are indicated with white dashed lines. Bars represent 10 µm. Results are
representative of at least n = 3.

While it had been observed that SOD1 aggregates appear to escape the endolysosomal system
after 60 min incubation, the above data suggest that aggregates remain within membrane
bounded compartments at 60 min of incubation (Figure 3.9). Thus, the release of SOD1
aggregates from membrane bound vesicles was further investigated after the 60 min timepoint in NSC-34 cells (Figure 3.10). Cells were incubated with SOD1 aggregates for an
extended period of 120 min and then treated with either Triton-X 100 or digitonin as above.
Interestingly, both WT (Figure 3.10A) and G93A (Figure 3.10B) SOD1 aggregates were now
detected after permeabilization by digitonin, suggesting that SOD1 aggregates are present in
the cytosol at 120 min. To demonstrate the specificity of the assay, NSC-34 cells were
incubated with the control protein RAP-GST for 120 min (Figure 3.10C). After 120 min
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RAP-GST was detected after Triton-X 100 permeabilisation but not after digitonin
permeablisation, consistent with its maintenance in a membrane bound vesicle.

Figure 3.10 Internalised SOD1 aggregates are detected in the cytoplasm of NSC-34 cells at
120 min Adherent NSC-34 cells were incubated with 20 μg/ml of aggregated SOD1 for 120 min at 37°C, fixed
with 4% paraformaldehyde, permeabilised with either triton-x 100 or digitonin. Biotinylated aggregates were
detected with Alexa Fluor 488 streptavidin or anti-RAP Ab. Sytox Red (5 µM) was used as a counter stain (10
min at RT). Representative confocal images are shown. Outline of cells are indicated with white dashed lines.
Bars represent 10 µm. Results are representative of at least n = 3.
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3.3.5.2 SOD1 aggregates induce the rupture of endocytic vesicles in NSC-34 motor neurons
Exogenous human SOD1 aggregates have been shown to enter into NSC-34 cells via
stimulated macropinocytosis, thus are transported intracellularly in macropinosomes (Chapter
1) which are thought to be ‘leaky’ due to their lack of a physical or rigid structure (Conner
and Schmid, 2003). Since the redistribution of Galectin-3 has been used as a tool to identify
and measure vesicle rupture in studies of bacteria and viruses (Maier et al., 2012; Ray et al.,
2010), here the redistribution of galectin-3 was used to examine if extracellularly applied
SOD1 aggregates could rupture vesicles (Figure 3.11). Galectin-3 is a cytosolic protein that
binds strongly to structures on the luminal side of the endosome, thus upon rupture a
redistribution of galectin-3 occurs. To examine whether SOD1 aggregates lead to the
accumulation of galectin-3, cells were incubated with SOD1 aggregates for 2 h and
specifically permeabilised with digitonin, stained for galectin-3 and then examined by
confocal microscopy (Figure 3.11A). Galectin-3 staining was quantified from these images
(Figure 3.11B). Cells permeabilised by digitonin and treated with PBS alone (negative
control) presented with very little accumulated galectin-3 staining compared to cells
permeabilised with triton x-100 which presented with significantly higher galectin-3 staining.
This is consistent with a large fraction of galectin-3 being bound on the inside of endosomal
compartments (Schneider et al., 2010). Similarly, incubation with WT and G93A SOD1
aggregates and mutant SOD1 soluble protein induced a significant increase galectin-3
staining and pronounced intracellular and punctate structures. This is consistent with
endosome rupture and accumulation of galectin-3.
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Figure 3.11 SOD1 aggregates and mutant SOD1 soluble proteins induce discrete Galectin 3 puncta immunofluorescence (A) Adherent NSC-34 cells were incubated with 20 μg/ml of soluble and
aggregated WT and G93A SOD1 for 2 h at 37°C, fixed with 4% paraformaldehyde, permeabilised with either
triton-x 100 (control only) or digitonin (all samples). Cells were labelled with anti-Galectin 3 mAb followed by
Alexa Fluor 488‐conjugated anti- mouse Ab and analysed by confocal microscopy. RedDot2 (1X) was used as a
counter stain (10 min at RT). Representative confocal images are shown. Outline of cells are indicated with
white dashed lines. Bars represent 10 µm. (B) Mean fluorescence intensities (MFI) of Galectin-3 per cell were
quantified from these images using ImageJ software (Version 1.48) (National Institutes of health, Bethesda,
MD). A minimum of 200 cells were scored per treatment. Results shown as mean cellular fluorescence intensity
means ± SD, n = 3, *** P <0.001, **P < 0.01 or *P < 0.05 compared to corresponding control (no protein
treatment).

3.3.5.3 SOD1 aggregates induce significant changes in biological membrane structures
To further characterise the ability of exogenous human SOD1 aggregates to rupture
membranes, human red blood cells and liposomes were obtained and examined for
interactions with SOD1 aggregates (Figure 3.12). First, purified human red blood cells were
incubated for 2 h in the presence of SOD1 aggregates and then the amount of membrane
disruption was measured by total amount of free hemoglobin in the supernatants (Figure
3.12A). Very little hemoglobin was detected in the supernatants of cells treated with PBS
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only; however, a significantly higher amount of hemoglobin was measured in the
supernatants of red blood cells treated with Triton-X100. Incubation with soluble mutant
G93A SOD1 and aggregated SOD1 proteins significantly increased the amount of free
hemoglobin consistent with an ability to damage biological membranes. Similar to red blood
cells, SOD1 aggregates altered the morphology liposomes, deforming their structures (Figure
3.12B). Collectively, this suggests that SOD1 aggregates are capable of inducing damage to
biological membranes and thus allowing their escape in to the cytosol.

Figure 3.12 Mutant SOD1 and SOD1 protein aggregates damage biological membranes. (A)
Clarified human blood cells were incubated with 20 μg/ml of WT and G93A SOD1 soluble and aggregated
proteins or 0.1% Triton-x100 for 2 h at 37°C. Absorbance of haemoglobin (A540nm) was determined by
spectrometry and results shown as means A540 nm ± SD, n = 6; ***P < 0.001, **P < 0.01 or *P < 0.05 compared
to corresponding control (PBS). (B) Unilamellar vesicles were formed from L-α-phosphatidylcholine and
incubated with 20 μg/ml of SOD1 aggregates for 2 h at 37°C as indicated. Slides were analysed by confocal
microscopy. Bars represent 10µM. Results are representative of one experiment.
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3.3.6 SOD1G93A –EGFP can induce aggregation of SOD1WT tdTomato protein in cocultured NSC-34 motor neurons
The above data indicates that SOD1 proteins can transfer between co-cultured NSC-34 motor
neurons and that SOD1 aggregates can escape membrane bound vesicles. Thus, the ability of
mutant SOD1 aggregates to induce aggregation of WT SOD1 was next characterised in NSC34 cells. Given that SOD1WT tdTomato produces cells with very few aggregates it was used
as a marker for seeding by SOD1G93A‐EGFP (Figure 3.13). Initially, the lysates of NSC-34
cells containing large particles were gated (nuclei and inclusions) and after nucleus removal,
particles were analysed for green or red fluorescence to identify inclusions made by EGFP or
tdTomato (see Figure 3.2). Using FloIT, the number of SOD1WT inclusions was then
investigated to identify and measure seeding activity induced by mutant SOD1 G93A‐EGFP. To
calculate the average number of inclusions per 100 transfected cells in the populations
analysed, the number of inclusions acquired is simply divided by the transfection efficiency
(separately determined by flow cytometry) of the sample, which is then multiplied by the
corresponding number of cell nuclei enumerated. An increase in the amount of SOD1WT
tdTomato inclusion formation in the co-cultured treatment was observed from 24 to 72 h.
However, a statistical significance was only measured at 72 h compared to the corresponding
control, indicative of mutant SOD1G93A‐EGFP induced seeding of SOD1WT. However, the
control treatment which is transfected NSC-34 cells cultured separately and mixed prior to
analysis; presented with significantly high amounts of inclusions overtime, potentially due to
differences in toxicity or an effect of seeding reactions.
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Figure 3.13 Co-culture with SOD1G93A increases WT SOD1 aggregation. Following
transfection, NSC‐34 cells expressing SOD1WT tdTomato or SOD1G93A‐EGFP were subsequently co-cultured,
co-transfected or cultured separately together for 24, 48 and 72 h. The number of WT SOD1 inclusions obtained
were enumerated by the FloIT method; means ± SEM, n = 3; ***P < 0.001 compared to corresponding treatment
at 24 h.

3.3.7 Recombinant mutant SOD1 can seed aggregation and induce inclusion formation
in NSC-34 cells expressing SOD1WT tdTomato protein
It has previously been observed that mutant SOD1 aggregates in conditioned media can
induce the aggregation of soluble intracellular mutant SOD1 (Münch et al., 2011).
Furthermore, other studies have shown that mutant SOD1 induces the misfolding of human
SOD1WT when transfected in human mesenchymal and neural cell lines (Grad et al., 2011). In
addition, the above data indicates that there is a significant increase in the number of
inclusions identified in transfected NSC-34 motor neurons from co-cultured with cells
expressing SOD1G93A at 72 h. Thus, the seeding behaviour of protein only aggregates of
SOD1 was further investigated at 72 h. To assess whether non-vesicular mutant SOD1
aggregates induce the aggregation of endogenous SOD1 proteins in NSC-34 motor neurons,
cells were transiently transfected with SOD1WT tdTomato protein and incubated with human
recombinant G93A mutant SOD1 aggregates for 72 h (Figure 3.14). As previously described
above, the number of inclusions per transfected cell was determined by flow cytometry using
the FLoIT technique. Incubation with mutant SOD1 aggregates at 72 h, induced a
significantly higher number of inclusions (75 ± 3) in comparison to cells incubated in the
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absence of mutant SOD1 aggregates (32 ± 3). This suggests that mutant SOD1 aggregates
can induce aggregation of SOD1WT tdTomato in NSC-34 cells.

Figure 3.14 Recombinant human mutant SOD1 aggregates induce the aggregation of
SOD1WT tdTomato in NSC-34 motor neurons. Following transfection, using Lipofectamine 3000,
NSC‐34 cells expressing SOD1WT tdTomato, were incubated with 20 µg/mL of human recombinant protein
only; G93A mutant SOD1 for 72 h. The number of inclusions obtained were enumerated by FloIT method
means ± SEM, n = 3; ***P < 0.001 compared to corresponding control (absence of mutant SOD1 aggregates). (+)
refers to the presence of recombinant mutant SOD1 aggregates, (-) refers to the absence of recombinant mutant
SOD1 aggregates.
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3.4 Discussion
The current study demonstrated that WT and mutant G93A SOD1 proteins can form
spontaneous aggregates in cells and their appearance coincides with an increase in cell death.
The current study also demonstrated and confirmed that SOD1 aggregates can be released
from transiently transfected NSC‐34 motor neurons potentially from dying or dead cells.
Furthermore, extracellular released SOD1 aggregates derived from conditioned media were
shown associated with naïve cells and their internalisation was confirmed. The transfer of
SOD1 between NSC-34 cells was also confirmed in this study. Upon endocytosis by NSC-34
motor neurons, soluble and aggregated SOD1 escapes the endolysosome system to be
deposited in the cytosol. Lastly, using the novel FLoIT method which is a tool to accurately
measure and quantify inclusions, demonstrated increased inclusion formation of WT SOD1
induced by co culture with cells expressing mutant SOD1. Seeding by protein only human
recombinant exogenous aggregates was also demonstrated, supporting these results. The
results presented here suggest that SOD1 aggregates rupture macropinosomes and escape into
the cytosol where they can induce aggregation of SOD1, consistent with reports of exogenous
mutant SOD1 aggregates identified in the cytosolic compartment of mammalian cells (Münch
et al., 2011). Collectively, this supports a role for SOD1 in the infectious prion-like spread of
protein aggregation in neuronal cells.
Previous studies have suggested that WT and mutant forms of SOD1 can spontaneously form
aggregates and fibrils given the right conditions in vivo (Chia et al., 2010) and in vivo where
human WT SOD1 has been shown to spontaneously aggregate in G93A Gurney strains of
mice (Prudencio et al., 2010). Similar to these observations, spontaneous SOD1 aggregate
formation in NSC-34 cells was confirmed in the current study. In addition, NSC-34 cells
expressing mutant SOD1G93A formed significantly greater numbers of inclusions compared to
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the SOD1WT expressing cells. Inclusion formation has been reported to inversely correlate to
the number of motor neurons found in ALS spinal cord tissue, suggesting that inclusion
formation is toxic and leads to cell death (Giordana et al., 2010). Similarly, a previous study
has reported that cytoplasmic mislocalisation and aggregation of mutant SOD1 induces cell
death in WT and mutant G93A SOD1 mouse primary neurons and astrocytes (Lee et al.,
2015). Supporting this notion, a significant increase in cell death was observed over the 72 h
transfection period in NSC-34 cells expressing SOD1G93AEGFP. Cell death was also apparent
for NSC-34 cells expressing SOD1WT-EGFP to a lesser extent. Although misfolded wild-type
and mutant SOD1 have been reported to activate the same neurotoxic mechanism and share
an aberrant conformation (Bosco et al., 2010), mutants possess a higher inherent propensity
to aggregate, thus may be more toxic to cells (Prudencio et al., 2009b; Valentine and Hart,
2003). Recently, a study was able to show that different mutant SOD1 variants have
differential aggregation propensities in NSC-34 cells (McAlary et al., 2016). This study also
reported that cellular aggregation correlates with cell loss and that the major predictor for
cellular aggregation of SOD1 variants is the abundance of destabilized SOD1 states which differs
between different mutants. However, although a strong correlation exists between cellular

aggregation and cell loss, translating this to severity of human disease is limited, given that
one of the variants (SOD1G37R) reported in this study is toxic in cells and has a high
propensity to aggregate, however has a mean disease duration of 17 years (McAlary et al.,
2016).
While there is now good evidence that both soluble and aggregated SOD1 can be taken up by
neurons and neuron like cells, there is little work describing the release of SOD1 aggregates.
Soluble SOD1 secretion into the culture medium has previously been shown using human
hepatocyte, fibroblast, neuroblastoma, and thymic-derived cell lines (Cimini et al., 2002;
Mondola et al., 1996). In the current study, the release of WT and mutant SOD1 variants
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including G93A, A4V and G127X from NSC-34 motor neurons was initially observed 72 h
following transfection. The release of SOD1 from transiently transfected cells has previously
been attributed to cell death (Grad et al., 2014). While other studies have reported SOD1
release is mediated via constitutive mechanisms such as calcium dependant release and
chromaginin mediated secretion of SOD1 (Santillo et al., 2007; Urushitani et al., 2006), the
current study suggests that SOD1 release coincides with toxicity, under the conditions used
for the filter trap assay.
The work presented here cannot rule out that SOD1G93A-EGFP released from cells was
secreted either via exosomes, microvesicles or neurosecretory vesicles or a combination of
these. In support of this idea, the active release of SOD1 as part of exosomes and
microvesicles from NSC-34 and neuroblastoma cells respectively, has been previously
reported (Gomes et al., 2007; Grad et al., 2014; Mondola et al., 2003). Further supporting this
notion, ALS pathology spreads from region to region in a spatiotemporal manner (Ravits and
Spada, 2009) prior to obvious cell death, suggesting an active release process in the early
stages of the disease. In addition, mutant SOD1 can interact with chromogranins which
promote their secretion from neurosecretory vesicles (Urushitani et al., 2006). Consistent
with this, mutant SOD1 has shown to translocate from the cytosol to the ER-Golgi pathway
(Urushitani et al., 2008), and the secretion of mutant SOD1 from NSC-34 can be reduced
upon incubation with a secretion inhibitor (Turner et al., 2005). In addition, it is suggested
that less mutant SOD1 is secreted when compared to WT SOD1, and this impaired secretion
coincides with intracellular formation of inclusions thus toxicity (Gomes et al., 2007; Turner
et al., 2005).
Recent lines of evidence implicate the transmission of extracellular SOD1 in the progression
of disease in ALS via a prion-like mechanism, involving pathological interactions with the
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cell surface and internalisation into neuronal and non-neuronal neighbouring cells. A toxic
role for SOD1 was suggested by a previous study, which found secreted SOD1 from
astrocytes derived from post-mortem spinal cord tissues from sALS and SOD1-related fALS
induced motor neurons cell death (Haidet-Phillips et al., 2011). The uptake of SOD1 has
previously been thought to be mediated by non-specific endocytosis, specifically
macropinocytosis (see Chapter 1) (Münch et al., 2011; Sundaramoorthy et al., 2013).
Furthermore, both WT and mutant SOD1 can be detected in the cerebrospinal fluid of fALS
patients and healthy controls (Zetterstrom et al., 2011). In the current study, both WT and
mutant SOD1 variants released into conditioned media were found to internalise into naïve
NSC-34 cells. This transmission was unaffected by DNase digestion of conditioned media,
ruling out a role for residual plasmid in recipient culture media. The uptake of secreted SOD1
from conditioned media was also reported in other studies (Grad et al., 2014; Münch et al.,
2011; Sundaramoorthy et al., 2013). While experiments in chapter 2 showed that uptake of
SOD1 was relatively specific (i.e. GST was not taken up), here we could not rule out a nonspecific uptake of GFP given no measurable amount of EGFP was detected in the conditioned
media. Moreover, consistent with observations presented here, media-to-cell transfer of
protein aggregates has been previously reported for α-synuclein (Desplats et al., 2009),
polyglutamine peptides and Huntingtin protein aggregates associated with Huntington’s
disease (Ren et al., 2009; Yang et al., 2002).
Cell-to-cell transmission is a characteristic of mammalian prions. The spreading of pathology
through neuronal pathways has previously been suggested to involve the cell-to-cell
transmission of toxic protein species in ALS. Recent work has identified transmission of
protein misfolding in the case of both WT and mutant SOD1 (Grad et al., 2014; Münch et al.,
2011). However, the exact mechanisms involved in this transfer are not yet understood. In the
current study, SOD1 released into co-culture conditioned medium from cells expressing
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SOD1WT-EGFP and SOD1G93A-EGFP were found to be taken up into acceptor cells. This
suggests that these proteins were able to transfer from cell-to-cell, consistent with reports
from others (Grad et al., 2014; Münch et al., 2011). The percentage of co-cultured cells
containing dual fluorescence, that is containing both WT SOD1-tdTomato and G93A SOD1EGFP was around 1-2% for the first 48 h after which the numbers of dual coloured cells
increased to around 5 % at 72 h. This suggests that at a time point when both aggregation and
toxicity is increased so too is transfer of protein. This further supports the idea that motor
neurons may be dying, releasing their content and transferring from cell to cell during disease
propagation.
The autophagic-lysosomal pathway has been shown to play major roles in the removal of
intracellular protein aggregates, however, previous reports suggest that certain infectious
protein aggregates can escape these intracellular vesicles to enter into the cytosol (Freeman et
al., 2013; Frost et al., 2009; Ren et al., 2009). Furthermore, propagation of aggregation in
SOD1-ALS has been suggested to involve the escape of SOD1 aggregates from membrane
bound endolysosomes (Münch et al., 2011). In the current study, recombinant WT and G93A
SOD1 aggregates co-localised with acidic compartments until 30 min after which SOD1
aggregates were detected in the cytosol at 60 min. Thus, this suggests that SOD1 aggregates
are initially compartmentalised to acidic compartments but rapidly escape these.
It has been identified previously that aggregates that enter cells somehow escape endocytic
vesicles to interact with cytosolic protein. As described in Chapter 2 and other studies suggest
that SOD1 aggregates are entering via macropinocytosis, thus these SOD1 aggregates are
likely trafficked through large macropinosomes once internalised and the subsequent fate of
macropinosomes varies depending on the cell type (Meier and Greber, 2003; Swanson and
Watts, 1995). Macropinosomes are known to be leaky due to their lack of physical structure
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and the resulting relatively easy loss of integrity of the macropinosome membrane (Conner
and Schmid, 2003). This fact is often exploited by certain viruses to reach the cytosol (Kalia
et al., 2013; Mercer and Helenius, 2009; 2012). Thus, it is suggested that the rigid structure of
the SOD1 aggregates promote their escape from membrane bound vesicles, as a result of the
destabilisation of the lipid bilayer (Holmes et al., 2013).
Consistent with the current study, protein aggregates made from other proteins, including α‐
synuclein associated with Parkinson's disease, enters cells via macropinocytosis and then the
newly formed macropinosomes undergo traditional maturation and fuse with the lysosome
(Nara et al., 2012). However, α‐synuclein aggregates were then shown to induce the rupture
of lysosomes following endocytosis into SH-SY5Y cells (Freeman et al., 2013). In addition,
amyloid plaques, which are associated with Alzheimer’s disease, are shown to contain active
lysosomal hydrolases, which implies that plaques may originate from lysosomal rupture
(Nixon et al., 2000). Moreover, protein aggregates are not the only infectious particle that
enter the cytosol via rupture of endosomes, other infectious particles such as the Adenovirus
protein type 5 enter the cytosol via this mechanism (McGuire et al., 2011). In the current
study, SOD1 aggregates and mutant SOD1 G93A soluble protein induced membrane damage
and rupture in human red blood cells, further supporting the notion that aggregated or
misfolded SOD1 can interact with and destabilize membranes through exposed hydrophobic
surfaces, therefore this suggests that the G93A soluble protein may have been in its unfolded
state. Consistent with this idea, fibrillar β2-microglobulin amyloid fibrils caused pronounced
distortions to the membrane of liposomes (Milanesi et al., 2012). Further evidence of protein
aggregate rupture of vesicles is the fact that non-monomeric forms α‐synuclein induced the
relocalisation of galectin-3 and the rupture of vesicles in the neuronal cell lines N27 and SHSY5Y (Freeman et al., 2013). Similarly, in the current study, SOD1 aggregates and mutant
SOD1 soluble proteins were shown to be able to disrupt the integrity of vesicular membranes
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resulting in the relocation of galectin-3. Previous studies have shown that ROS generation is
induced upon vesicular rupture (Freeman et al., 2013; Halle et al., 2008; McGuire et al.,
2011), therefore making cells more susceptible to cell death. While it was not a line of
investigation in the current study, it will be an interesting future direction to determine
whether SOD1 induced rupture of lysosomes corresponds with an increase in cellular reactive
oxygen species (ROS) and cell dysfunction and death in neurons, possibly contributing to
disease progression.
Work presented here shows that both WT and G93A SOD1 aggregates were localised to the
cytoplasmic and cytoskeleton fractions 2 h post-incubation. These results are consistent with
SOD1 aggregates having a density comparable to cytoskeleton elements and, in addition, is
consistent with cytosolic exposure of SOD1 aggregates. There was also a very small amount
of high molecular weight WT SOD1 detected associated with the nuclear fraction, again
consistent with cytosolic exposure (outside of the endo-lysosome system). However, in
confocal microscopy experiments, aggregates were not observed within the nucleus
suggesting aggregated material either bound the external portion of the nuclear membrane or
pelleted at a similar density to the nuclear fraction. Nevertheless, this is consistent with other
reports (Münch et al., 2011).
Selective permeabilisation using digitonin and Triton-X 100 (Nizard et al., 2007) confirmed
that SOD1 aggregates were present outside any membrane-enclosed compartments.
Specifically, imaging after plasma membrane permeabilisation with digitonin suggested that
SOD1 aggregates could only be detected in cells after 120 min incubation with aggregates.
This work suggests that SOD1 aggregates were within membrane bound organelles at 60 min,
after which time the membrane of vesicles were ruptured by recombinant SOD1 aggregates.
In comparison, RAP-GST, which is well-established to be internalised by receptor mediated
endocytosis because of the recognition of RAP by LRP (Caetano-Pinto et al., 2016), was not
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detected after digitonin permeabilsation at 120 min, indicating the maintenance of RAP-GST
in endosomal-lysosomal compartment and suggesting that rupture of intracellular vesicles
and/or escape of SOD1 is specific to SOD1.
A role for misfolded or aggregated SOD1 in seeding the aggregation of intracellular native
SOD1 in a fashion similar to that of prions has been suggested by a number of recent studies
(Chia et al., 2010; Grad et al., 2014; Münch et al., 2011; Pokrishevsky et al., 2012). It is well
established that misfolded protein alone is sufficient to induce further misfolding in native
proteins (Prusiner, 1982), and that newly formed misfolded protein may propagate misfolding
pathology either through template-directed misfolding or nucleated polymerisation (Horwich
and Weissman, 1997). In the current study, mutant SOD1 expressed in one population of
cells was shown to induce the aggregation of intracellular WT SOD1 in another population of
cells in a mechanism that must involve cell-to-cell transfer. Given that the methods used
identified both dual coloured NSC-34 cell populations and also measured increases in
intracellular WT SOD1 associated aggregates, this indicates that the transfer of mutant SOD1
seeded the aggregation of intracellular WT SOD1 proteins. Furthermore, the addition of
human recombinant mutant SOD1 G39A protein aggregates to cells expressing SOD1WTEGFP enhanced the average number of WT SOD1 inclusions measured following incubation
at 72 h, suggesting that mutant SOD1 aggregates are capable of inducing the misfolding and
aggregation of human WT SOD1 in NSC-34 cells in a manner similar to prion template
misfolding. Furthermore, this observation is consistent with another study that observed the
conversion of native WT SOD1 to misfolded SOD1 in both a cellular context and in a cellfree system by mutant conformers (Grad et al., 2011). Although the exact mechanisms were
not investigated in this current study, previous studies suggest that inducing the misfolding of
human WT SOD1 is limited by the exposure of a single amino acid residue, a tryptophan
(Trp) at position 32 (Grad et al., 2011). The seeding behaviour observed in the current study
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is therefore similar to that of prion-activity, and consistent with the hypothesis that the
propagation of protein aggregates between cells is responsible for the orderly progression of
disease pathology observed in some neurological disorders (Clavaguera et al., 2009; Desplats
et al., 2009; Jucker and Walker, 2013; Li et al., 2008; Ren et al., 2009; Volpicelli-Daley et al.,
2011).
In conclusion, expression of WT and mutant SOD1 induced spontaneous aggregation of these
proteins and cell death in NSC-34 cells. The release of SOD1 aggregates and their subsequent
uptake in to naïve cells occurred at a time point that corresponded to a significant increase in
cell death. It is therefore likely that aggregates are released via cell death however active
release via exosomes cannot be ruled out. Furthermore, there are likely other pathways
mediating the secretion of SOD1 in vivo and a range of mechanisms of SOD1 release, maybe
potentially working in conjunction in vivo. The internalisation of both WT and mutant SOD1
protein aggregates induced the rupture of endocytic vesicles to gain access to the cytosol. The
ability of these aggregates to induce damage and rupture in vesicles and biological
membranes was confirmed and thus may play a role in cellular dysfunction. The underlying
mechanisms by which misfolding propagation exerts toxic effects, whether it be inducing the
misfolding of endogenous proteins through template directed misfolding or through
secondary nucleation in the recipient cell is yet to be determined. The similarities observed
between both WT and mutant SOD1 may explain the clinically indistinguishable nature of
sALS and fALS.
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Chapter 4
THE MISLOCALISATION AND
AGGREGATION OF THE
PRION-LIKE PROTEIN TDP-43
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4.1 Background
Amyotrophic lateral sclerosis (ALS) is an incurable neurodegenerative disorder characterized
by the loss of both the upper and lower motor neurons in the brain and spinal cord
respectively, resulting in the progressive paralysis of the muscles of speech, limbs,
swallowing and respiration, due to the progressive degeneration of innervating motor neurons
(Cleveland and Rothstein, 2001).
The neuropathology of all cases of ALS are characterised by disease-specific proteins, mutant
and wild type alike; mislocalised and abnormally accumulated as misfolded, insoluble
aggregates in the cytoplasm of afflicted motor neurons (Bosco et al., 2010; Leigh et al., 1991;
Ross and Poirier, 2004). Proteinaceous inclusions, containing misfolded aggregated proteins,
peptides and fragments, also occur in many other neurodegenerative disorders including
Alzheimer’s disease (AD), Parkinson’s disease (PD), frontotemporal dementia (FTLD),
Huntington’s disease (HD) (Forman et al., 2004); and prion diseases, such as CreutzfeldtJakob disease, Kuru and fatal familial insomnia diseases (Prusiner, 1982; Prusiner, 1984).
Mutations in several genes cause familial ALS (fALS) which account for 5-10% of total ALS
cases and contribute to the development of sporadic ALS (sALS, 90% of ALS cases)
(Andersen and Al-Chalabi, 2011). In fALS, mutations in the gene encoding the Cu/Zn
superoxide dismutase (SOD1), a ubiquitously-expressed homodimeric enzyme, results in the
misfolding and aggregation of this normally stable protein (Banci et al., 2009) found in
patients carrying SOD1 mutations and in mutant SOD1 rodent disease models (Bruijn et al.,
1997; Wang et al., 2002). However, recently misfolded SOD1 species have been increasingly
identified in non-SOD1 fALS and sALS cases (Bosco et al., 2010; Forsberg et al., 2010),
suggesting that misfolded SOD1 may play a pathological role in all types of ALS
(Pokrishevsky et al., 2012).
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In addition to SOD1, TAR DNA binding protein (TDP-43) has been identified as a major
component of cytoplasmic inclusions in sALS, SOD1-negative fALS and ALS with
dementia; as well as most common pathological subtype of frontotemporal lobar dementia
(FTLD) with ubiquitinated inclusions (Arai et al., 2006; Cairns et al., 2007; Davidson et al.,
2007; Mackenzie et al., 2010; Neumann et al., 2007; Neumann et al., 2006). Clinical and
pathological overlap of these diseases has suggested a pathogenic mechanistic-link between
these disorders and has prompted their reclassification as TDP-43-proteinopathies. These
diseases exhibit the same pathological features in cells containing neuronal cytoplasmic
inclusions (NCIs) including; loss of the normal nuclear TDP-43, co-localisation of TDP-43
and ubiquitin, ubiquitinated and hyperphosphorylated TDP-43 proteins and lastly formation
of abnormal fragments of TDP-43 in post-mortem tissue (Neumann et al., 2007; Nonaka et
al., 2009a; Zhang et al., 2009). Of interest, AD associated Aβ has been implicated in
triggering the phosphorylation and cytosolic accumulation of pathogenic TDP-43 in rodent
models and in brain autopsies from AD patients, similar to other observations in ALS-FTLD
(Herman et al., 2011). This may explain the presence of TDP-43 pathology in a proportion of
AD cases (Wilson et al., 2011).
TDP-43 is a conserved heterogeneous ribonucleoprotein that is ubiquitously expressed. TDP43 has two RNA recognition motifs and a glycine rich C-terminal domain (Ayala et al., 2008;
Buratti and Baralle, 2001) and functions as a regulator of transcription (Ou et al., 1995) and
alternative splicing (Buratti et al., 2001; Mercado et al., 2005), respectively. TDP-43 is also
involved in nucleocytoplasmic shuttling of messenger RNA (Ayala et al., 2008) and
participates in nuclear body formation (Buratti and Baralle, 2008; Ou et al., 1995). Of
interest, the C-terminal region of TDP-43 contains a prion-like domain which is predicted to
be prone to misfolding and aggregation (Mousavi and Hotta, 2005). In addition, the C-
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terminal fragments can bind with full-length TDP-43 to possibly facilitate the aggregation of
full length TDP-43 (Nonaka et al., 2009b; Zhang et al., 2009).
Furthermore, a number of dominant mutations in the gene encoding TDP-43 have been
associated with fALS and FTLD, confirming the importance of the role TDP-43 in disease
pathogenesis (Daoud et al., 2009; Gitcho et al., 2008; Kabashi et al., 2008; Sreedharan et al.,
2008; Van Deerlin et al., 2008; Yokoseki et al., 2008). Of note, TDP-43 pathology is not
present in cases with SOD1 mutations, thus demonstrating TDP-43 inclusions are not
required to initiate ALS (Lagier-Tourenne et al., 2010; Mackenzie et al., 2007).
TDP-43 is largely restricted to the nucleus in healthy cells (Ayala et al., 2008). However, in
afflicted cells in ALS, abnormal cellular distribution and post-translational modification(s) of
TDP-43, result in the mislocalisation and subsequent deposition in the cytoplasm as insoluble
misfolded aggregates (Arai et al., 2006; Gregory et al., 2012; Li et al., 2015; Neumann et al.,
2006). In TDP-43-positive cytoplasmic inclusions, TDP-43 is abnormally phosphorylated,
unbiquitinated and truncated, resulting in the accumulation of both full-length TDP-43 and
toxic TDP-43 fragments (Li et al., 2015). These fragments have been identified as a 25-kDa
C-terminal fragment (CTF25) and a 35-kDa (CTF35) C-terminal fragment, in addition to
other minor CTFs, in cytoplasmic aggregates (Li et al., 2015). Overexpression of full length
TDP-43 in cultured cells and animals has been found to result in the production of CTF25,
with current understanding suggesting that TDP-43 is capable of inducing the misfolding of
SOD1 upon accumulation in the cytosol (Li et al., 2015).
It is well established that TDP-43 redistributes and deposits as insoluble TDP-43 aggregates
in the cytoplasm of affected motor neurons in the majority of cases of ALS. It has also been
shown that TDP-43 pathology causes misfolding of WT SOD1 (Pokrishevsky et al., 2012),
and separately shown that WT SOD1 misfolding can be propagated cell to cell (Grad et al.,
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2014). While previous work has shown that uptake of wild type SOD1 aggregates can cause
endoplasmic reticulum (ER) stress (Sundaramoorthy et al., 2013), whether uptake of SOD1
aggregates influence TDP-43 pathology is yet to be established.
The presence of aberrant protein aggregates in affected neurons are characteristic of most
neurodegenerative diseases, however, the mechanisms that underlie pathology are not yet
completely understood. An increasing number of recent studies now support the prion-like
propagation of a range of aggregated proteins associated with various neurodegenerative
diseases (reviewed in Marciniuk et al., 2013). In addition to SOD1, the propagation of TDP43 aggregation has been likened to a prion-like seeding mechanism, with evidence of regional
spreading of pathology occurring in a sequential pattern through the neuroaxis
(Brettschneider et al., 2013). Recent evidence suggests that phosphorylated and ubiquitinated
TDP-43 aggregates may propagate from cell to cell in cultured neuroblastoma cells and
induce TDP-43 aggregation in the cells expressing human TDP-43 in a self-templating
fashion (Nonaka et al., 2013). An additional study presented evidence to suggest that TDP-43
can transfer between cells and induce the seeding of endogenous TDP-43 in a prion like
manner (Feiler et al., 2015). More recently, it was observed that TDP-43 fibrils triggered the
seed-dependant aggregation of WT TDP-43 or TDP-43 lacking a nuclear localisation signal
and similar to prions, different peptides sequences of TDP-43 produce fibrils that induces
different TDP-43 associated pathologies (Shimonaka et al., 2016).
In the current study, we aimed to investigate whether exogenous recombinant SOD1 protein
aggregates can induce and/or contribute to TDP-43 pathology, specifically its mislocalisation
and aggregation. Upon incubation with large recombinantly formed SOD1 aggregates with
cells we detected mislocalised WT TDP-43 in the cytoplasm of both mouse neuronal-like
cells and human embryonic kidney cells. We also demonstrate that, upon addition of the
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SOD1 aggregates, fragments of TDP-43 can be observed in the cytoplasm of NSC-34 cells.
Thus, we conclude that addition of recombinant SOD1 aggregates to the extracellular
environment of neuron like cells results in TDP-43 mislocalisation, aggregation and
fragmentation.
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4.2 Methods
4.2.1 Reagents and Antibodies
DMEM/F-12 medium, DMEM/F-12 without phenol red, 0.05% trypsin-EDTA, GlutaMAX,
Lipofectamine 2000, Lipofectamine 3000, SuperSignal West Pico Chemiluminescent
Substrate, Subcellular Protein Fractionation Kit for Cultured Cells, restriction endonucleases
BamHI and HindIII, Ez- link- NHS- Biotin, SYTOX Red dead cell stain and Lab-Tek
chambered coverglass 8 well with cover were purchased from ThermoFisher Scientific
(Waltham, USA). Any kD Mini-PROTEAN TGX Precast Protein Gels and Precision Plus
Protein dual color protein standard were from Bio-Rad (California, USA). Foetal Bovine
Serum (heat-inactivated prior to addition in media; FBS) was from Bovogen Biologicals
(East Keilor, Australia). Amersham Hyperfilm was obtained from GE Healthcare (Little
Chalfont, Buckinghamshire, UK). Agar, Mg132, Ethidium Bromide, Casein (heat denatured
before use; HDC), dimethyl sulfoxide (DMSO), bovine serum albumin (BSA), βmercaptoethanol, Brilliant blue R concentrate, paraformaldehyde (PFA) and dithiothreitol
(DTT) were from Sigma-Aldrich (St. Louis, MO). Ethylenediaminetetraacetic acid (EDTA)
was from Amresco (Solon, USA). All other reagents including salts, powders and chemicals
were from Amresco, Sigma-Aldrich or Astral Scientific (Gymea, Australia). All reagents
used were endotoxin free. Antibodies (Abs) and their respective manufacturing companies
used in this current study are listed in Table 4.1.
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Table 4.1 Antibodies used in this study to investigate the effect of SOD1 proteins on TDP-43 pathology

Host species
(clonality)1
Mouse (mAb)

Antibody target
(Immunogen)2
Beta Actin [AC-15]

Rabbit (pAb)

Conjugate
-

Manufacturer
(product number)3
Abcam (ab6276)

Vimentin

-

Abcam (ab137321)

Rabbit (pAb)

EEA1

-

Abcam (ab2900)

Mouse (mAb)

TARDBP

-

Saphire Bioscience
(K1B8)

Goat (pAb)

Rabbit IgG

HRP

Bio-Rad (1706515)

Goat (pAb)

Mouse
(IgM, IgG, IgA)
SOD1

HRP

Merck Millipore (AP501P)

Sheep (pAb)

-

Pierce (PAI-30817)

1

pAb, polyclonal antibody, mAb, monoclonal antibody; 2Ig, immunoglobulin; 3 Abcam, Cambridge, USA;
Saphire Biosciences (Redfern, Australia), Bio-Rad (California, USA); Merck Millipore, Billerica,
Massachusetts, USA.

4.2.2 Cell Lines
The mouse neuroblastoma x spinal cord hybrid cell line ( NSC-34 cells (Cashman et al.,
1992a) were routinely cultured in DMEM/F-12 supplemented with 10% (v/v) FBS and 2 mM
GlutaMAX. Cells were maintained in an incubator at 37°C under a humidified atmosphere
containing 5% (v/v) CO2. Human embryonic kidney (HEK)-293 cells were from the
American Type Culture Collection (Manassas, VA). HEK-293 cells were cultured in
DMEM/F-12 medium supplemented with 10% FBS and 2 mM GlutaMAX, in an incubator at
37°C under a humidified atmosphere containing 5% (v/v) CO2.
4.2.3 Aggregation and biotinylation of WT and mutant G93A SOD1 proteins
WT and G93A SOD1 were expressed and purified from E.coli as previously outlined
(Lindberg et al., 2002; Roberts et al., 2013). SOD1 aggregation was performed in vivo as
previously described (Roberts et al., 2013). Briefly, solutions of purified WT or G93A mutant
SOD1 protein (1 mg/mL) in PBS was co-incubated with 20 mM DTT and 5 mM EDTA for
72 h at 37°C with shaking using a digital shaker (universal IKA® MS 3, 230 V) (Sigma, St.
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Louis, MO). The aggregated SOD1 was then labelled with biotinamidohexanoic acid 3-sulfoN-hydroxysuccinimide ester sodium salt (40 mg/mL) in DMSO for 2 h at RT. The
unconjugated biotin was then separated from the aggregates by centrifugation (21 000 x g for
30 min) and washed three times with PBS (300 x g for 5 min). The purified aggregates free of
unconjugated biotin were then resuspended in PBS (1 mg/ml). A bicinchoninic acid (BCA)
protein assay was performed to determine the amount of protein in solution.
4.2.4 Cell Transfections
4.2.4.1 Plasmid purification
pCAG-RFP expression vectors containing WT TDP-43 cDNA was obtained from Addgene,
provided by Zuoshang Xu (University of Massachusetts Medical School, Worcester,
Massachusetts, USA)(Yang et al., 2010). pCMV6-AC-GFP expression vector containing WT
TDP-43 cDNA was obtained from Origene. pCMV6-AC-EGFP expression vector containing
TDP-43WT cDNA was obtained from Origene. TDP-tomato red (TdTomato) constructs were
created by replacing the EGFP sequences in the SOD1-EGFP plasmids with tdTomato (by
Genscript, USA) and site directed mutagenesis was also performed by Genscript (Piscataway,
NJ) to create the G124A mutant. Chemically competent DH5α Escherichia coli cells were
provided by Jason McArthur (University of Wollongong, Wollongong, Australia). Cells were
transformed with the TDP-43 containing plasmids as per manufacturer’s instructions, using
the heat shock (42 ºC) method. Transformed cells were then transferred onto lysogeny broth
(10% w/v tryptone, 10% w/v NaCl, and 5% w/v yeast; LB) agar plates with 50 µg/ml
kanamycin sulphate and incubated overnight at 37°C under a humidified atmosphere
containing 5% (v/v) CO2. Single-transformed bacterial colonies were selected and inoculated
into sterile LB media containing 50 µg/ml kanamycin sulphate to prepare starter cultures.
Plasmid DNA was then extracted from bacterial cells using the CompactPrep Plasmic Maxi
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Kit (Qiageb, Hilden, Germany), as per manufacturer’s instructions. The purity (260/280 ratio)
and concentration of extracted DNA was measured using the NanoDrop 2000c dual-mode
UV-Vis Spectrophotometer (ThermoFisher Scientific, Waltham, USA). To further confirm
the purity of the extracted DNA samples, a restriction digestion was carried out at 37ºC for 1
h using enzymes HindIII and BamHI that correspond to specific restriction sites in the
plasmids. Digested DNA samples were separated on a 1% agarose gel in tris-acetate-EDTA
(TAE) buffer (1 mM ethylenediaminetetraacetic acid disodium salt, 40 mM Tris and 20 mM
acetic acid). The resulting gel was them stained with ethidium bromide overnight and
visualised using the GS-800 Calibrated Densitometer (Bio-Rad).
4.2.4.2 Transfecting cells with Lipofectamine 2000
NSC-34 cells (2 – 3 x 104 cells/ 0.2 mL/ chamber) were cultured in 8-well chamber slides in
complete culture medium and were incubated overnight at 37°C under a humidified
atmosphere containing 5% (v/v) CO2. Cells were then incubated in DMEM-F-12 serum-free
culture medium containing 2 μg WT TDP tomato red (TR) plasmid DNA and Lipofectamine
2000 for 5 h at 37°C under a humidified atmosphere containing 5% (v/v) CO2. Cells were
then washed once with serum free media and replenished with complete culture medium.
Cells were then incubated for a longer period of time either for 19 h, 43 h or 67 h (24 h, 48 h,
and 72 h in total, respectively).
4.2.4.3 Transfecting cells with Lipofectamine 3000
Hek-293 cells (3 – 4 x cells/ 0.2 mL/ chamber) were cultured in 8-well chamber slides and
were incubated overnight at 37°C/5% CO2. Cells were then incubated in complete DMEM/F12 culture medium containing 2 μg WT TDP GFP plasmid DNA, P3000 reagent and
Lipofectamine 3000 (diluted in serum free DMEM/F-12 medium) for 24 h at 37°C/CO2.
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Cells were then incubated for a longer period of time for either 19 h, 43 h or 67 h (24 h, 48 h,
and 72 h in total, respectively).
4.2.5 Treatment of transfected NSC-34 cells with SOD1
Cells were visualised prior to experimentation using an Eclipse TE2000 inverted microscope
(Nikon, Tokyo, Japan) to confirm transfection and determine transfection efficiency. NSC-34
cells were incubated with labelled biotinylated aggregates, or soluble (non-aggregated) WT
and mutant G93A SOD1 proteins (20 µg/mL) or no protein as a control at 37°C/CO2, for
either 2 h or 72 h. Post incubation, cells were immediately fixed with 4% PFA in PBS for 20
min at RT and washed twice with PBS over 5 min. Cells were incubated with Triton-X 100
for 30 min at 4°C. Cells were incubated with blocking solution (5% FCS, 1% BSA and 0.3%
triton-x100) for 20 min at RT. The cells were then probed with Alexa Fluor 488 streptavidin
(1:1000 diluted in 1% BSA and 0.1% triton-x100) for the aggregates or sheep anti-SOD1
(1:500 diluted in 4% BSA and 0.1% Triton-x100) for for 1 h at RT or overnight at 4°C
respectively. Cells were then incubated with anti-sheep IgG conjugated to Alexa Fluor 488
(1:500 diluted in 1% BSA and 0.1% Triton-x100) for 1 hr at RT for soluble proteins.
4.2.6 Treatment of transfected HEK-293 cells with SOD1 proteins
The medium was then replaced, and the transfected HEK-293 cells were incubated with
labelled biotinylated aggregates of WT and mutant G93A SOD1 proteins (20 µg/mL) at
37°C/CO2, or no protein as a control or MG132 (10 µM) for 24 h and imaged under live cell
condition. Imaging was repeated at 48 h and 72 h. Post 72 h incubation, the cells were fixed
with 4% PFA in PBS for 20 min at RT and washed twice with PBS over 5 min. Cells were
incubated with Triton-X 100 for 30 min at 4°C. Cells were incubated with blocking solution
(5% FCS, 1% BSA and 0.3% triton-x100) for 20 min at RT. The cells were then probed with
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Alexa Fluor 488 streptavidin (1:1000 diluted in 1% BSA and 0.1% triton-x100) for the
aggregates for 1 h at RT.
4.2.7 TDP-43 Pathology by Confocal microscopy
An inverted microscope (DM IBRE) and a Leica TCS SP confocal imaging system were used
to visualise and image transfected dual colour NSC-34 cells (excitation 488, emission
collected at 495-515 and 561 nm, emission collected at 590-630 nm) and HEK-293 cells
(excitation 488, emission collected at 475-515). Fluorescence, bright field (differential
interference contrast; DIC) and merged images were captures using Leica confocal software.
4.2.8 Subcellular Fractionation assay of NSC-34 cells
NSC-34 cells were incubated with WT SOD1 in soluble and aggregated form (20 µg/mL) in
PBS for 2 h at 37°C/5% CO2. Post incubation, the cells were washed three times with PBS
(300 x g for 5 min) harvested using 0.5% trypsin and 5 mM EDTA and washed (500 x g for 5
minutes). The cells were washed three times with ice cold PBS (500 x g for 3 minutes) for
fractionation using a Subcellular Protein Fractionation Kit for Cultured Cells as per
manufacturer’s instructions (Thermo Fisher Scientific). Initially, NSC-34 cells (10 x 106
cells/mL) were incubated with cytoplasmic extraction buffer (CEB) containing protease
inhibitors for 10 min rotating at 4°C. The supernatant (cytoplasmic fraction) was collected
(500 × g for 5 minutes). The cell pellet was then incubated with membrane extraction buffer
(MEB) containing protease inhibitors for 10 min rotating at 4°C. Post incubation, the
supernatant (extracted membrane fraction) was collected (3000 × g for 5 minutes). Ice cold
nuclear extraction buffer (NEB) containing protease inhibitors was added to the cell pellet for
30 min rotating at 4°C. The supernatant (extracted soluble nuclear fraction) was collected
(5000 × g for 5 minutes). Chromatin-bound extraction buffer (NEB, 100mM CaCl2 and 300
units of Micrococcal Nuclease) was added to the pellet for 15 mins at RT. The supernatant
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(chromatin-bound nuclear extract) was collected (16,000 x g for 5 mins). Lastly, Pellet
Extraction Buffer (PEB) containing protease inhibitors was added to the cell pellet for 10
mins at RT. The supernatant (the cytoskeletal extract) was collected (16,000 x g for 5 mins).
Protein concentration was determined using the BCA method. Supernatants (20 μg
protein/lane) were separated under reducing conditions (5% β-mercaptoethanol) using Any
kD Mini-PROTEAN TGX Stain-Free™ Precast Gels. Proteins were then transferred to
nitrocellulose membranes using a Trans-Blot Turbo Transfer System (Bio-Rad,). Total
protein per lane was then imaged and measured with a Bio-Rad Criterion Stain Free Imager
and Image Lab software. Membranes were blocked with heat denatured casein (HDC) in for
1 h at 37°C. To test the purity of the separation, mouse anti-TDP-43 mAb (1:200); rabbit
anti-EEA1 pAb (1:500), rabbit anti-Vimentin pAb (1:500) and mouse anti-actin mAb
(1:5000), diluted in HDC/PBS for 1 h at 37°C were used to probe the CE, ME, NE and PE
fractions. Membranes were visualised using chemiluminescent substrate and Amersham
Hyperfilm ECL (GE Healthcare). Images of films were collected using a GS-800 Calibrated
Densitometer (Bio-Rad). The processing of films was achieved using GBX Developer and
Replenisher and GBX Fixer and Replenisher (Kodak Australiasia, Collingwood, Victoria
Australia). Images of the films were collected using a GS-800 Calibrated Densitometer (BioRad).
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4.2.9 Presentation of data and statistical analyses
Data is presented as the mean ± SD. ANOVA paired with Tukey’s HSD multiple comparison
post-test tests were used to analyse and compare differences between multiple treatments.
Unpaired student’s t-tests were performed for single treatment comparisons. Prism 5 for
Windows (Version 5.01) (GraphPad Software, San Diego, CA) was used to generate these
statistical analyses. Differences were defined as significant for P < 0.05.
4.2.10 FloIT assay by flow cytometry
The FloIT assay was performed as outlined in section 3.2.15. Briefly, NSC‐34 cells were
transiently transfected with TDP-43 (TDP-43WT tdtomato and TDP-43G124A‐EGFP) using
Lipofectamine 3000 (see above). Following transient transfection at 24h, 48 h and 72h in
total, cells were harvested and then washed again using centrifugation. Cells were then
washed twice and resuspended in PBS (0.5 mL/tube). An aliquot of cells (2 x
105cells/0.15mL) were collected then analysed for transfection efficiency. The remaining
cells (4 x 105cells/0.35mL) were washed as above and lysed prior to analysis in lysis buffer.
Cell lysates were then incubated with RedDot2 (1:1000) at RT for 2 min. Events were
collected using a LSRFortessa X‐20 Cell Analyzer (BD Biosciences) (excitation 488 nm,
emission collected with 525/50 band-pass filter and excitation 561, emission collected with
586/15 nm band-pass filter for EGFP and RedDot2, respectively). Lysates were firstly gated
on forward and side scatter and then the fluorescence from RedDot2 were determined by flow
cytometry. All parameters were set to log10 during acquisition from cell lysates. The forward
scatter threshold was set to the minimum value (200 AU) to minimise the exclusion of small
protein inclusions. Nuclei were identified and enumerated based on RedDot2 fluorescence
and forward scatter and then excluded from further analysis. The remaining particles were
analysed for the presence of inclusions based on GFP/ tdTomato fluorescence, forward
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scatter and comparison lysates prepared from cells expressing only the corresponding
fluorescent protein. The number of inclusions in the population can be normalised to the
number of nuclei, and reported as inclusions/100 transfected cells (iFloIT) according to the
equation outlined in section 0. Analysis of all events was determined using FlowJo software
(Tree Star, Ashland, OR).
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4.3 Results
4.3.1 Transient expression of TDP-43 proteins induces endogenous TDP-43 aggregation
and inclusion formation in NSC-34 motor neurons over time.
TDP-43 is localised mostly in the nucleus where it can perform its normal functions including
RNA processing (Buratti and Baralle, 2001; Lee et al., 2012). Under non-physiological and
disease conditions however, TDP-43 is known to mislocalise to the cytosol and form
insoluble aggregates (Neumann et al., 2006), although the mechanisms underlying TDP-43
mislocalisation and aggregation are not completely understood. However, a previous study
has reported that TDP-43 is intrinsically aggregation-prone and thus can spontaneously form
aggregates; a property attributed to the C-terminal domain (Johnson et al., 2009). Here, the
presence of inclusion bodies containing TDP-43 aggregates was initially investigated over
time. To investigate the number of TDP-43 positive inclusions in murine NSC-34 cells, cells
were transfected with TDP-43WT and TDP-43G124A for 24, 48 and 72 h and the number of
inclusions were quantified using flow cytometric characterisation of inclusions and
trafficking (FloIT) (Figure 4.1) as outlined in section 3.2.15. A significant amount of
inclusions of both TDP-43WT and TDP-43G124A were observed in cells expressing EGFP
fusion proteins. Consistent with mutant TDP-43 being aggregation prone a significantly
greater number of inclusion bodies were identified in cells expressing mutant TDP-43G124A
compared to cells expressing TDP-43WT. However, there was a significant decrease in the
number of cells containing TDP-43G124A inclusions measured at 72 h, possibly due to cell
toxicity and death in cells containing inclusions. This is consistent with previous reports
which demonstrate that ALS-linked TDP-43 mutations in the TDP-43 gene increase the
number of TDP-43 aggregates and promote toxicity in vivo (Johnson et al., 2009).
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Figure 4.1 Spontaneous aggregation of TDP -43 was exa mined by flow cytometry. Following
transfection, using Lipofectamine 3000, NSC‐34 transiently transfected with either TDP-43WT or TDP-43G124A
for 24, 48 and 72 h and analysed using flow cytometry. Results shown as mean number of inclusions per 100
transfected cells ± SEM, n = 3; ***P < 0.001, **P < 0.01 and *P < 0.05 compared to TDP-43WT.

4.3.2 TDP-43 aggregates can transfer from cell to cell
Next, the ability of TDP-43 to transfer from cell-to-cell in culture was examined. Transfer
events were quantified as the percentage of transfected cells positive for both
EGFP/tdTomato using the gating strategy outlined in Figure 3.5. Two cell populations
transiently expressing either TDP-43WT tdTomato or TDP-43G124A EGFP proteins were cocultured at a ratio of 1:1 and analysed using flow cytometry (Figure 4.2). Control cells were
also transfected separately, however, they were mixed immediately prior to flow cytometry
analysis. Similar to previous findings for SOD1 (Figure 3.5), approximately 3.4 ± 0.3% at 24
h and 3.1 ± 0.3% at 48 h acceptor NSC-34 cells were found to contain significant amounts of
both TDP-43WT tdTomato and TDP-43G124A EGFP presumably from donor cells, and were
scored as EGFP/tdTomato red double-positive (dual fluorescence). These results suggest that
TDP-43 is capable of transferring between cells in culture. However at 72 h, the percentage
of dual fluorescent cells significantly decreased, compared to 24 h and 48 h time points. This
is likely due to cellular toxicity associated with the presence of aggregates.
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Figure 4.2 TDP-43WT or TDP-43G124A proteins can transfer fro m don or to recipient
NSC-34 motor neurons. Following transfection, using Lipofectamine 3000, NSC‐34 transiently transfected
with TDP-43WT tdTomato or TDP-43G124A EGFP were either co-cultured or cultured separately for 24, 48 and 72
h. NSC-34 cells cultured separately were mixed prior to analysis (control). Results shown as mean percentage of
cells ± SEM, n = 3; **P < 0.01 compared to control (mixed population of cells).

4.3.2.1 TDP-43G124A GFP can induce aggregation of TDP-43WT tdTomato protein in cocultured NSC-34 motor neurons
The above data implies that TDP-43 or more likely TDP-43 protein aggregates can transfer
between co-cultured NSC-34 motor neurons. Thus, whether mutant TDP-43 aggregates can
induce the aggregation of TDP-43WT in a manner that could be described as seeding
behaviour was next investigated (Figure 4.3). To test this, cells were either co-transfected
with TDP-43WT tdTomato and TDP-43G124A EGFP or transfected separately and populations
mixed or not (control), cells were lysed and aggregates counted by FLoIT. In particular, the
number of TDP-43WT inclusions were counted to identify and measure seeding activity
induced by mutant TDP-43G124A EGFP. To calculate the average number of inclusions per
100 transfected cells in the populations analysed, the number of inclusions acquired is simply
divided by the transfection efficiency (separately determined by flow cytometry) of the
sample, which is then multiplied by the corresponding number of cell nuclei enumerated. An
almost two-fold significant increase in the amount of TDP-43WT tdTomato inclusions detected
in the co-transfected treatment compared to the corresponding control was observed from 48
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to 72 h. This suggests that within individual cells mutant TDP-43G124A induced the
aggregation of TDP-43WT. Interestingly, the control treatment (in which separately
transfected populations are mixed just prior to analysis) showed an increase in inclusions
through time likely indicative of cellular stress. Importantly, co-culture of cells expressing
TDP-43G124A induced cells with TDP-43WT to significantly increase the number of inclusions
formed compared to controls consistent with a cell-to-cell propagation of misfolding and
aggregation.

Figure 4.3 FloIT detects inclusions containing dual fluorescence from NSC -34 cells
Following transfection, using Lipofectamine 3000, NSC‐34 cells expressing TDP-43WT tdTomato or TDP43G124A EGFP were subsequently co-cultured, co-transfected or cultured separately together for 24, 48 and 72.
The number of inclusions obtained were enumerated by FloIT method means ± SEM, n = 3; **P < 0.01 or*P <
0.05 compared to corresponding treatment.

4.3.3 Transiently expressed TDP-43WT is observed deposited in the cytosol of NSC-34
cells upon treatment with recombinant SOD1 protein aggregates
TDP-43 redistribution and aggregation is observed in the cytoplasm of affected cells in a
diverse set of neurodegenerative diseases. However, the contributing factors responsible for
TDP-43 mislocalisation and aggregation remain ambiguous. Both SOD1 and TDP-43 have
been implicated in fALS and sALS pathogenesis, although whether SOD1 aggregates
contribute to TDP-43 pathology is yet to be established. Thus the presence of SOD1
aggregates and deposition of TDP-43 proteins in the cytosol of NSC-34 cells was thus
investigated. (Figure 4.5). To confirm whether exogenously added SOD1 aggregates have an
effect on TDP-43 cytosolic mislocalisation and aggregation, purified human WT TDP-43-
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tomato red (TDP-43WT tdTomato) plasmid DNA was used to transiently transfect NSC-34
cells (Figure 4.4A). Post transfection, cells were incubated with either WT or mutant G93A
SOD1 in both their aggregated and soluble state (Figure 4.4B). The percentage of cells
containing mislocalised TDP-43 into foci that measured >1µm per treatment was determined
by confocal microscopy (Figure 4.5A and B). Mislocalised TDP-43 by this definition
included both TDP-43WT cleared from the nucleus and TDP-43 that had accumulated in the
cytosol even though some nuclear TDP-43WT remained. A summary of the methods is
outlined in Figure 4.4.

Figure 4.4 Treat ment of NSC-34 cells with large SOD1 protein aggregates induces TDP-43
mislocalisation and aggregation. Immunofluorescence labelling of SOD1 (green) and TDP-43WT (red)
neuronal cytoplasmic inclusions (NCIs) in NSC-34 cells. Confocal microscopy of transfected NSC-34 cells
expressing TDP-43WT TR were incubated in complete DMEM medium in the (A) absence (control) or (B)
presence of WT or G93A SOD1 proteins in their aggregated or soluble form (20 μg/mL) for 72 h. Bars represent
10 µm. Outline of cells are indicated with white dashed lines. TEM bar represents 50 nm.

Confocal microscopy and quantitative analysis was performed (Figure 4.5). The addition of
SOD1 protein aggregates to NSC-34 cells resulted in a rapid and significant increase in
percentage of cells that contained mislocalised TDP-43WT (Figure 4.5A) when treated with
either WT (23±5%) or G93A SOD1 (25±4%) aggregates compared to the control cells
(absence of protein treatment; % cells with aggregates). In contrast, while there was a
significant increase in cells displaying mislocalised TDP-43WT when incubated with soluble
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G93A SOD1 (16±3%) there was no significant difference between control cells and those
treated with soluble WT SOD1 (10±2%) of transfected cells with mislocalised TDP-43WT.
Furthermore, little to no cells were observed to contain TDP-43WT positive cytoplasmic
inclusions without protein treatment at 2h. While cells incubated with aggregated G93A
SOD1 aggregates had more TDP-43WT inclusions than those incubated with soluble G93A,
no significant differences were detected between them. In contrast, cells treated with WT
SOD1 aggregates had significantly more TDP-43WT aggregates when compared to soluble
SOD1 protein (Figure 4. 5B).

Figure 4.5 Cytosolic mislocalisation and aggregation of TDP-43 W T in NSC-34 cells is
observed upon addition of the recombinant SOD1 protein aggregates at 2h.
Immunofluorescence labelling of SOD1 (green) and TDP-43WT (red) neuronal cytoplasmic inclusions (NCIs) in
NSC-34 cells. (A) Confocal microscopy of transfected NSC-34 cells expressing TDP-43WT tdTomato were
incubated in complete DMEM medium in presence of WT or G93A SOD1 proteins in their aggregated or
soluble form (20 μg/mL) for 2h. Bars represent 20 µm. Outline of cells are indicated with white dashed lines.
(B) The percentage of NSC-34 cells containing TDP-43WT positive aggregates was assessed by the number of
cells containing mislocalised TDP-43WT into foci that measured >1µm per treatment including both TDP-43WT
cleared from the nucleus and TDP-43WT that had accumulated in the cytosol even though some nuclear TDP43WT remained, as determined by Image J. Results shown as means ± SD, n = 3; ***P < 0.001 and **P < 0.01
compared to corresponding control (TDP-43WT tdTomato), †††P < 0.001 compared to corresponding soluble
protein form.

151

Given TDP-43 translocation can be a rapid response to stress (Zhang et al., 2014) that can be
reversible (Liu-Yesucevitz et al., 2010), we next tested whether the TDP-43WT
mislocalisation associated with SOD1 aggregate treatment persisted for 72 h (Figure 4.6).
After the extended incubation with SOD1 aggregates, a large number of cells still exhibited
mislocalised TDP-43WT, which appeared as larger clusters of aggregates or inclusion bodies,
when assessed by confocal microscopy (Figure 4.6A).
Incubation of aggregated SOD1, both WT and G93A, resulted in a significantly higher
percentage of transfected cells with miscolcalised TDP-43WT compared to the control cells
(Figure 4.6B). Although, no significant difference was detected in the percentage of
transfected cells with mislocalised TDP-43WT when treated with the WT (24±7%) and G93A
(27±7%) soluble proteins compared to the control cells, some cells were observed to contain
large TDP-43WT positive inclusions in the cytosol of the soluble G93A treated cells (as shown
in Figure 4.5).
In contrast to the 2 h experiment, a significant difference was found to exist between the cells
that were treated with the soluble and the aggregated form of the mutant G93A protein. Thus,
incubating the cells with the aggregated form of SOD1 had a significant effect on TDP-43WT
extranuclear accumulation in NSC-34 cells. However, it is important to note that complete
loss of normal nuclear staining was still not observed. Addition of SOD1 aggregates leads to
a variety of aggregation states outlined in Figure 4.7.
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Figure 4.6 Cytosolic mislocalisation and aggregation of TDP-43 in NSC-34 cells is
observed upon treatment with recombinant SOD1 protein aggregates at 72 hr.
Immunofluorescence labelling of SOD1 (green) and TDP-43WT (red) NCIs in NSC-34 cells. (A) Confocal
microscopy of transfected NSC-34 cells expressing TDP-43WT TR were incubated in complete DMEM medium
in the absence (control) or presence of WT or G93A SOD1 proteins in their aggregated or soluble form (20
μg/mL) for 72 h. Bars represent 20 µm. Outline of cells are indicated with white dashed lines. (B) The
percentage of NSC-34 cells containing TDP-43WT positive aggregates was assessed by the number of cells
containing mislocalised TDP-43WT into foci that measured >1µm per treatment including both TDP-43WT
cleared from the nucleus and TDP-43WT that had accumulated in the cytosol even though some nuclear TDP43WT remained, as determined by Image J. Results shown as means ± SD, n = 3; ***P < 0.001 or **P < 0.01
compared to corresponding control (TDP-43WT TR), compared to corresponding soluble protein form.
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Figure 4.7 TDP-43 redistribution and aggregation in various states in NSC-34 cells. (A)
Under normal conditions, TDP-43 localisation is limited to the nucleus. (B) Under temporary cellular stress
conditions, TDP-43 can be mislocalised from the nucleus, however some TDP-43 may remain in the nucleus.
(C-D) Under abnormal conditions, complete loss of nuclear TDP-43 is observed, and large inclusions bodies
positive for TDP-43 are observed in the cytoplasm. (E-F) Inclusion bodies, containing TDP-43 can also be
present diffusely throughout the cell under pathological conditions. (G-I) Distinct inclusions bodies can also be
found diffusely surrounding the nucleus. (J-L) Large distinct clusters of TDP-43 positive inclusions can
accumulate in the cytoplasm (foci > 20µm). These images are examples of the scoring system for mislocalisaed
and aggregated TDP-43. Bars represent 10 µm

4.3.4 Recombinant mutant SOD1 can seed aggregation and induce inclusion formation
in NSC-34 cells expressing TDP-43WT tdTomato protein
Given that the above data demonstrates that the addition of SOD1 protein aggregates to NSC34 cells resulted in a rapid and significant increase in percentage of cells that contained
mislocalised TDP-43WT, FloIT was next employed to confirm seeding behaviour and quantify
these findings. To investigate whether mutant SOD1 aggregates can induce the aggregation
of TDP-43WT in NSC-34 motor neurons, cells were transiently transfected with TDP-43WT
tdTomato protein and incubated with human recombinant G93A mutant SOD1 aggregates for
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either 24, 48 or 72 h (Figure 4.8). As outlined above, the number of inclusions per transfected
cell was determined by flow cytometry using the FLoIT technique. A significant increase in
the number of TDP-43WT inclusions were identified from 24 to 72 h in cells incubated in the
presence of mutant SOD1 aggregates compared to the corresponding cells in the absence of
mutant SOD1 aggregates. This increase in inclusion formation was almost five fold from 24
to 72 h. This is therefore indicative of significant seeding events associated with mutant TDP43 induced aggregation of SOD1WT tdTomato in NSC-34 cells.

Figure 4.8 SOD1 aggregates are capable of inducing significant aggregation in TDP -43WT
expressing NSC-34 cells using the Flo -it method. Following transfection (24 , 48 and 72 h) using
lipofectamine 3000, adherent NSC-34 cells transiently transfected with TDP-43WT were co-cultured with 20
μg/ml and aggregated G93A SOD1 at indicated time intervals at 37°C. Cells were harvested for supernatant
analysis and then lysed. Cell lysates were incubated with RedDot2 for 2 min at RT. Transfection efficiencies,
the number of inclusions and nuclei were determined by flow cytometry and results means ± SD, n = 3, *P <
0.05 compared to corresponding control (no protein treatment).

4.3.5 TDP-43WT cytosolic mislocalisation and aggregation induced by exogenous SOD1
recombinant proteins is not limited to the NSC-34 cell line
The work presented above suggests that exogenously added SOD1 proteins induce the
mislocalisation of TDP-43WT in the NSC-34 cell line. It was therefore of interest to examine
if these effects are limited to the mouse motor neuron like cell line (NSC-34). Thus, human
embryonic kidney (HEK-293) cells were used to further investigate the effect of exogenous
SOD1 on cell produced TDP-43 (Figure 4.10). In this experiment, a plasmid encoding a
human TDP-43WT GFP fusion was used to transiently transfect HEK-293 cells and SOD1
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aggregates were used unlabelled. Post transfection, cells were incubated with either
aggregated WT or mutant G93A SOD1 for either 24, 48 and 72 h, or the same time frames in
the absence of protein as a control. In addition, MG132, an inhibitor of proteasome activity,
which has been shown to induce TDP-43 aggregation (van Eersel et al., 2011) was used as a
positive control. A summary of the methods is outlined in (Figure 4.9).

Figure 4.9 Recombinant SOD1 aggregates induce aggregation in HEK293 cells.
Immunofluorescence labelling of TDP-43WT (green) neuronal cytoplasmic inclusions (NCIs) in HEK293 cells.
Transfected HEK-293 cells in culture medium expressing TDP-43WT eGFP were incubated in (A) the absence
(control) or (B) presence of protein aggregates (20 μg/mL) for 72 h or (C) mg132 (10 µM). Arrows represent
area of TDP-43 aggregates. Bars represent 10 µm. Outline of cells are indicated with white dashed lines. TEM
bar represents 50 nm.

As shown in Figure 4.10, incubation with either the WT (34±4%) or G93A (32±3%) SOD1
protein aggregates resulted in a significantly higher percentage of cells containing
mislocalised TDP-43WT at 24 h, compared to the control (19±2%). Similarly, after 48 h SOD1
aggregate treatment resulted in an increase in the percentage of cells with mislocalised TDP43WT (G93A 38 ±3 %, WT 35± 3%) relative to the control (20±3%). However, at 72 h,
although there was a significant difference in the percentage of cells containing mislocalised
156

TDP-43WT when treated with G93A (38 ±2 %) SOD1 aggregates compared to the control,
there was no difference in the percentage of cells when compared to the 48 h period.
Interestingly, in cells incubated with aggregated WT SOD1 there was a 5% decrease between
the 48 and 72 h time points suggesting cells were recovering or that cells with inclusions had
died. The positive control, MG132, induced TDP-43WT cytoplasmic inclusions in a time
dependant manner with an almost two-fold increase in the percentage of cells containing
mislocalised TDP-43WT between the 24 and 72 h time points (from 23±2% to 59.08±5%).

Figure 4.10 Aggregate formation is also induced in human HE K-293 cells expressing TDP43WT GFP in the presence of reco mbinant SOD1 aggregates . (A) Transfected HEK-293 cells in
DMEM/F12 expressing TDP-43WT GFP were incubated in the absence (control) or presence of WT or mutant
G93A SOD1 protein aggregates (20 μg/mL) for 24-72 h (as indicated). Bars represent 20 µm. Outline of cells
are indicated with white dashed lines, arrows indicate TDP-43WT positive inclusions. (B) The percentage of
HEK-293 cells containing TDP-43-positive inclusions was assessed by the number of cells containing
mislocalised TDP-43WT into foci that measured >1µm per treatment including both TDP-43WT cleared from the
nucleus and TDP-43WT that had accumulated in the cytosol, as determined by Image J. Results shown as means
± SD, n = 3; ***P < 0.001 or **P < 0.01 or *P < 0.05 compared to corresponding control (TDP-43WT TR).
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4.3.6 Exogenous recombinant SOD1 aggregates induce the cytosolic mislocalisation and
fragmentation of endogenous TDP-43 in naive NSC-34 cells.
Current understanding suggests that the accumulation of the truncated TDP-43 fragment;
CTF25 is a pathological feature detected in proteinopathies. Since this fragment has been
suggested to play a critical role in ALS pathogenesis, we investigated whether adding
aggregated SOD1 to NSC-34 cells had any effect on the formation of CTF25. We have
previously shown that exogenously-added recombinant SOD1 proteins are capable of
entering into NSC-34 cells and escaping into the cytosol (Zeineddine et al., 2015). To begin
to investigate the effect of SOD1 aggregates on TDP-43 location and truncation, a subcellular
fractionation assay and western blot was carried out on NSC-34 cell lysates (Figure 4.11).
Given that the response of NSC-34 cells to WT and mutant G93A SOD1 proteins were
similar, in the following experiment NSC-34 cells were treated with exogenous soluble and
aggregated WT SOD1 for 2 h.
The presence of endogenous TDP-43 protein was then investigated by immunoblotting of the
cytosolic, membrane (ER/Golgi), nuclear and cytoskeletal supernatant fractions. In the SOD1
aggregate-treated fractions (Figure 4. 11A), TDP-43 was detected as a range of bands but
predominantly as distinct bands at 43 kDa and ~25 kDa. In contrast to the untreated controls
where TDP-43 is found in the nuclear fraction (Figure 4.11C), after treatment with SOD1
aggregates TDP-43 is found in all the fractions. In the ME fraction additional bands were
present at approximately 40 kDa and 18 kDa. The additional 40 kDa band was also present in
the NE and PE supernatant fractions. Interestingly, the full length TDP-43 was predominantly
cytosolic suggesting a rapid movement from the nucleus after SOD1 aggregate addition. In
comparison, treatment with the WT SOD1 soluble protein (Figure 4.11B), resulted in the
detection of only one band immunoreactive for endogenous TDP-43 in the NE fraction at

158

approximately 43 kDa similar to the untreated control with no evidence of bands at 25 kDa.
To further confirm the purity of the supernatants, fractions were immunoblotted using an
anti-actin, anti-EEA1 and anti-vimentin Ab (Figure 4.12D). These bands were detected in the
ME fraction for EEA1 (180 kDa), vimentin (54 kDa) in the PE fraction and actin (42 kDa) as
a loading control.

Figure
4.11 Exogenous recombinant SOD1 proteins induce
TDP-43cytosolic
mislocalisation in NSC-34 cells. Cytoplasmic extract (CE), membrane extract (ER/Golgi) (ME), nuclear
extract (NE) and pellet extract (cytoskeleton) (PE) fractions by centrifugation from NSC-34 cells treated with
either (A) WT SOD1 aggregates or (B) WT SOD1 soluble (20 μg/mL) or (C) no added protein were separated
by SDS PAGE under reducing conditions, transferred to nitrocellulose membrane and incubated with anti-TDP43 and (D) control Ab anti-actin, anti-EEA1 or anti-vimentin Abs (as indicated). Results are representative of at
least 6 experiments.
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4.4 Discussion
Mutations in the TDP-43 gene are found in sporadic and non-SOD1 familial ALS,
implicating TDP-43 as a contributing factor to disease (Kabashi et al., 2008; Sreedharan et
al., 2008). TDP-43 has previously been reported to spontaneously form aggregates that
resemble TDP-43 deposits in degenerating neurons in ALS FTLD-U patients (Johnson et al.,
2009). Furthermore, previous studies have reported that in the TDP-43 protein sequence, the
C-terminal domain is critical for spontaneous aggregation and therefore TDP-43 is
intrinsically aggregation prone (Ivanova et al., 2014; Johnson et al., 2009). In addition,
previous work indicates that ALS associated mutations in TDP-43 can increase the number of
discrete aggregates in the cytoplasm of yeast (Johnson et al., 2009) suggesting that ALS
mutations increase the aggregation propensity of TDP-43. The work presented here is
consistent with this; inclusions were detected in cells expressing WT and mutant TDP-43,
with mutation increasing inclusion formation.
The in vivo cell-to-cell transmission of TDP-43 and induction of TDP-43 aggregation in
recipient cells was observed in the current study. Similarly, the ability of TDP-43 to transfer
between cultured SH-SY5Y (human neuroblastoma) cells in co-cultured experiments was
demonstrated in another study, which found that phosphorylated TDP-43 aggregates could be
released from donor cells and taken up into recipient cells (Nonaka et al., 2013). In addition,
mutant TDP-43G124A was shown to induce the aggregation of TDP-43WT in NSC-34 motor
neurons when co-cultured together. Similarly, conditioned media containing TDP-43–from
cultured cells or lysates from ALS patient brain lysate have been shown to induce
oligomerisation in recipient cells (Feiler et al., 2015). Furthermore, another study
demonstrated that pathological TDP-43 aggregates from diseased brains exhibit prion-like
properties when added to cultured cells containing plasmid-derived TDP-43 (Nonaka et al.,
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2013). In the latter study, detergent-insoluble TDP-43 prepared from cells containing TDP-43
aggregates as well as seeds from brains were shown to induce the formation of selftemplating intracellular TDP-43 aggregation in cultured cells (Nonaka et al., 2013). These
findings together therefore support a role for the prion-like seeding of mutant TDP-43
induced aggregation of TDP-43WT.
Consistent with misfolded SOD1 detected in sALS, previous work has demonstrated that WT
SOD1 misfolding can be propagated cell to cell (Grad et al., 2014). Here we have shown that
exogenously added large-SOD1 protein aggregates are capable of inducing the cytoplasmic
mislocalisation and accumulation of cytosolic TDP-43 in both the motor neuron-like cell line
(NSC-34 ) and in human embryonic kidney cells (HEK-293). Furthermore, the present study
demonstrates that the addition of large SOD1 aggregates induces rapid fragmentation of
TDP-43 in the cytoplasmic fraction of NSC-34 cells. Collectively, this suggests that
exogenous SOD1 protein aggregates are capable of stimulating TDP-43 pathology through an
unknown mechanism(s), resulting in their redistribution, fragmentation and aggregation,
similar to what has been observed in most cases of ALS (Arai et al., 2010; Correia et al.,
2015; Nonaka et al., 2009a; Pokrishevsky et al., 2012).
An association between misfolded and/or aggregated SOD1 and TDP-43 mislocalisation has
been previously suggested. For example, a study has reported that TDP-43 cytoplasmic
mislocalisation and deposition into ubiquitin immunoreactive inclusions were observed in
lower motor neurons of end stage mutant SOD1 transgenic mice (Shan et al., 2009). In
addition to this, misfolded human WT SOD1 has been observed in association with cytosolic
accumulation of mutant TDP-43 in TDP-43-fALS and WT TDP-43 in sALS (Pokrishevsky et
al., 2012). It has been suggested that mutant TDP-43 may indirectly induce the propagation
of WT SOD1 misfolding in fALS and sALS (Pokrishevsky et al., 2012). Given that the
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aggregation of TDP-43 and SOD1 appear to be distinct processes with structurally and
morphologically discrete aggregates (Farrawell et al., 2015), it is unlikely that one will seed
aggregation of the other in a conventional manner and therefore must be explained by an
alternate mechanism, possibly through exerting stress.
The deposition of TDP-43 into the cytoplasm of NSC-34 cells was dependant on the length of
time exposed to the SOD1 aggregates. The 2 h incubation with SOD1 aggregates was
sufficient to induce aberrant TDP-43 mislocalisation in a proportion NSC-34 cells. Further,
we have shown using a subcellular fractionation assay on NSC-34 cells at 2 h treated with
SOD1 aggregates, that a distinct truncation product at ~25 kDa, was present in the
cytoplasmic fraction as previously reported in sALS and SOD1-negative fALS (Kwong et al.,
2008; Mackenzie et al., 2010; Neumann et al., 2006).
In contrast, after 72 h incubation with SOD1 aggregates TDP-43 mislocalisation was
observed in a significantly higher percentage of cells; equating to an almost two fold increase
for the WT SOD1 and the G93A aggregate treated cells from 2 to 72 h. This effect may be
due to the stress imposed on cells by the uptake of SOD1 aggregates (Stieber et al., 2000),
consistent with a direct relationship between SOD1 aggregates and cellular toxicity that has
been previously reported (Bruijn et al., 2004; Cleveland and Rothstein, 2001). Similarly,
incubation with SOD1 aggregates induced similar pathological features in HEK-293 cells.
However, the effect was apparent at 24 h and changed little in over 72 h incubation period.
The cell type specific differences may reflect differences in proteostasis capacity between
different cell types; neurons have a relatively high threshold for inducing the heat shock
response (Yerbury et al., 2016). Regardless, while there is a clear effect of SOD1 aggregate
uptake on TDP-43 distribution the precise mechanism underlying this remains unclear.
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Cytoplasmic accumulation of WT TDP-43 as a local response to injury or cell stress has been
previously described in sporadic ALS (Liu-Yesucevitz et al., 2010). In addition to this,
misfolded and aggregated WT and mutant SOD1 are well known to induce ER stress and
dysfunction and stress granule formation in cell culture (Nishitoh et al., 2008), rodent ALS
models at symptom onset and disease end stage and human ALS patients (Atkin et al., 2006;
Atkin et al., 2008; Ilieva et al., 2007; Kaus and Sareen, 2015; Saxena et al., 2009).
There is evidence that the uptake of extracellular misfolded WT and mutant G93A SOD1 into
human and mouse neuronal cells causes disruptions to protein transport between the ER and
Golgi apparatus, resulting in ER stress, Golgi fragmentation, and subsequent apoptotic cell
death (Sundaramoorthy et al., 2013). ER stress is activated when proteins accumulate within
the ER lumen, thus triggering the unfolded protein response (UPR), which in turn may lead to
cellular apoptosis if unresolved (Atkin et al., 2014). There is a strong link between ALS
pathology and ER stress (Walker and Atkin, 2011) and it has been proposed that prolonged
ER stress leads to motor neuron death in ALS (Walker and Atkin, 2011). While generally the
unfolded protein response activated by ER stress is a protective response able to rescue cells
from proteotoxicity, in the ALS context this can lead to further aggregation of ALS
associated proteins such as TDP-43 (Suzuki et al., 2011). Taken together, these data are
consistent with the idea that ER stress caused by uptake and maintenance of SOD1
aggregates may trigger TDP-43 mislocalisation and accumulation.
In fact, TDP-43 mislocalisation is a common response to a variety of stressors including
oxidative stress (Colombrita et al., 2009), heat shock stress (Chang et al., 2013), and
proteosomal stress (Scotter et al., 2014). Indeed extranuclear accumulation of WT TDP-43
has been shown to be a common pathology in sALS, FTLD and Alzheimer’s disease, and
therefore may be a general consequence of cellular stress (Wilson et al., 2011). Interestingly,
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exogenously applied Aβ amyloid aggregates associated with Alzheimer’s disease have also
been shown to induce TDP-43 mislocalisation (Herman et al., 2011) suggesting that uptake of
any aggregate regardless of which protein they are made from might be enough to trigger
TDP-43 mislocalisation.
In conclusion, the work presented here demonstrates that TDP-43 can form aggregates
spontaneously, transfer between cells in culture and induce the misfolding of their WT
counterpart, similar to that reported for SOD1 and prions. In addition, the work presents
findings to support the notion that aggregates made from SOD1 are able to induce TDP-43
mislocalisation and rapid fragmentation consistent with TDP pathology observed in sporadic
disease. However, the exact mechanism(s) for this observation were not determined. It is
likely that the stress induced by aggregate uptake was enough to trigger the mislocalisation of
TDP-43. However, it should be noted that a high concentration (20 µg/ml) of large SOD1
protein aggregates were used in the current study to induce TDP-43 pathology, as
demonstrated above. This concentration is higher than that used in a number of similar
studies (Münch et al., 2011; Nonaka et al., 2013) and in vivo. Future investigations into the
mechanism(s)/role of SOD1 aggregates on the formation of pathological TDP-43 are
therefore warranted.
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Chapter 5
THE ABILITY OF PROTEIN
AGGREGATES TO TRIGGER
MACROPINOCYTOSIS IS
GENERIC
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5.1 Background
Amyotrophic Lateral Sclerosis (ALS) is characterised by the selective death and degeneration
of upper and lower motor neurons (Cleveland and Rothstein, 2001). There is now significant
evidence that protein aggregation is linked closely to motor neuron death in ALS
(Abdolvahabi et al., 2016; Sundaramoorthy et al., 2013; Walker et al., 2013). In addition,
other common neurodegenerative diseases, including Alzheimer’s, Tauopathies such as
Frontotemporal Dementia, Parkinson’s, Huntington’s diseases, and transmissible spongiform
encephalopathies (TSEs), have common pathological changes such as loss of neurons and the
presence of pathological protein aggregates into either intracellular inclusions bodies or
extracellular plaques. Although the peptides and proteins that aggregate are unrelated in
terms of their native structure, often the resulting deposits are very similar, sharing a ropelike fibrillar morphology, a common cross-β core structure, and the ability to bind specific
dyes such as thioflavin T and Congo red (Dobson, 2003). In addition, these common
neurodegenerative diseases, including ALS, exhibit distinctive anatomical patterns of disease
progression which are consistent with a spreading of pathology between nearby cells and
remotely connected regions of the brain along axonal pathways (Brettschneider et al., 2015;
Brundin et al., 2010). These patterns are consistent with the propagation of the protein
misfolding, aggregation and spread reminiscent of those underpinning prion disease.
(reviewed in Zeineddine and Yerbury, 2015). Furthermore, proteins known to aggregate in
these disorders including 𝛽-amyloid, tau, α-synuclein and proteins with polyQ expansions are
suggested to propagate the misfolding of their native soluble counterparts (see Aguzzi and
Calella, 2009; Brundin et al., 2010). In addition, it has been shown that these protein
aggregates can enter into cells, cross cellular membranes to transmit pathogenic proteins in a
‘prion-like’ manner through the triggering the misfolding of their normally structured
counterparts in cells, tissues, and animal models (Brettschneider et al., 2015).
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In order to facilitate the propagation of intracellular aggregation in neurodegenerative
diseases, such as ALS, Parkinson’s, Alzheimer’s and Huntington’s diseases, active aggregate
nuclei or seeds must gain access to the cytosol of naïve cells. Active nuclei could be large
aggregates such as those macroscopically visible accumulating in neurons (> 2 microns in
size) or small soluble oligomeric aggregates that might diffuse between cells. Fibrillar
aggregates are generally 1-20 nanometre across and can be hundreds of nm long and large
aggregates that accumulate many fibrils in cells can be several micrometres in diameter.
Thus, given that neurons are not professional phagocytes it would be reasonable to assume
that endocytosis of protein aggregates by neurons would be almost impossible.
A role for macropinocytosis in the uptake of protein aggregates associated with various
neurodegenerative diseases has been highlighted in several studies and the work presented in
earlier chapters (Grad et al., 2014; Holmes et al., 2013; Münch et al., 2011; Sundaramoorthy
et al., 2013). The study on the propagation of SOD1 aggregation by Münch et. al (2011) was
the first to demonstrate that mutant SOD1 ALS protein aggregates enter into N2A cells via
endocytic vesicles mediated by ATP and lipid raft dependent macropinocytosis (Münch et al.,
2011). The study utilised a wide panel of inhibitors of a range of cellular functions to identify
potential pathways of endocytosis specific for SOD1 (Münch et al., 2011). Subsequently,
these results were confirmed by an additional study which showed that uptake of both
extracellular wildtype and mutant SOD1 soluble forms into NSC-34 cells can be inhibited by
small molecule inhibitors of macropinocytosis EIPA and rottlerin (Sundaramoorthy et al.,
2013). Similarly, EIPA was shown to inhibit the uptake of human WT SOD1 aggregates into
NSC-34

cells

(Grad

et

al.,

2014)

consistent

with

macropinocytosis.

EIPA

(ethylisopropylamiloride) is an analogue of amiloride that is an inhibitor of Na+/H+
exchangers. EIPA is well-recognised as specific to macropinocytosis (compared to other
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forms of endocytosis) as a result of the susceptibility of GTPases such as RAC1 to pH
changes (Koivusalo et al., 2010).
More broadly, uptake and cell-to-cell transmission of α-synuclein into neurons has been
shown to be mediated via an unconventional endocytosis (Desplats et al., 2009; Lee et al.,
2008). Also, while initially synthetic polyQ fibrils were proposed to enter cells via direct
penetration of the lipid bilayer (Ren et al., 2009) recently cell surfaces structures have been
implicated in the binding and internalisation of both synthetic polyQ (K2Q44K2) and
huntingtin exon 1 Q44 (Htt exon1Q44) fibrils suggesting a role for endocytosis mediated
uptake (Trevino et al., 2012). Further, exogenously added AD associated-recombinant Tau
fibrils have also been shown to be taken up by cultured cells in a process consistent with
pinocytosis suggested by the co-localisation of Tau aggregates with Dextran, a marker of
fluid phase endocytosis (Frost et al., 2009). In support of these findings, a recent study was
able to show that small misfolded Tau species are also internalised through the process of
bulk endocytosis (Wu et al., 2013). Further to this, uptake of fibrillar Tau into C17.2 cells
(mouse neural stem cells) could be inhibited by both amiloride and rottlerin consistent with
macropinocytosis (Holmes et al., 2013). The same study demonstrates that Tau fibrils could
be observed in vacuoles and invaginations with diameters of approximately 5 μm also
consistent

with

macropinocytosis.

Lastly,

in

a

result

that

suggests

stimulated

macropinocytosis has been activated, the uptake of the fluid phase marker dextran was
increased with increased doses of Tau fibrils (Holmes et al., 2013). This uptake could be
inhibited by suppressing cell binding of Tau fibrils by blocking binding to heparan sulfate
proteoglycans, indeed this also blocked uptake when aggregates were injected in to the brains
of mice (Holmes et al., 2013). However, how the binding to heparan sulfate proteoglycans on
the cell surface relate to activation of macropinocytosis remains unclear.
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The fact that neurons can engulf large particles such as protein aggregates seems
counterintuitive. Macropinocytosis of large particles is usually thought of as restricted to
professional phagocytes such as macrophages and microglia. This endocytic pathway is
useful for engulfment of viral particles, bacteria, and fragments of dying cells in order to
degrade and remove them from the cell. Without extensive degradation machinery, such as in
macrophages, neurons are seemingly left vulnerable with the ability to take up large particles
whilst not built to remove them. Irrespective of the ability of neurons to perform such a
function, it is unlikely that neurons have evolved to specifically endocytose pathogens and
large protein aggregates. Although, several viruses are known to enter neurons via
macropinocytosis (Hollidge et al., 2012; Kalia et al., 2013; Talekar et al., 2011), this is likely
due to the hijacking of machinery involved in macropinocytosis evolved for other purposes.
Macropinocytosis, or closely related processes, are thought to regulate growth cone
membrane recycling and is an integral part of growth cone collapse and axon retraction and
turning during development and injury (Jurney et al., 2002; Kabayama et al., 2011; Kolpak et
al., 2009; Tom et al., 2004). The membrane recycling process in growth cones is associated
with actin-dependent membrane ruffles that fuse back on the plasma membrane creating large
pinosomes dependent on PI3K and RAC1; all characteristic of macropinocytosis. Upon
synaptogenesis this process is supressed, consistent with the idea that mature neurons do not
undergo bulk changes in the membrane via macropinocytosis. However, axonal injury in in
vivo and in vitro models triggers axonal remodelling in adult neurons that is associated with
large amounts of fluid uptake (Tom et al., 2004) consistent with macropinocytosis.
Interestingly, some disease associated mutations such as those in ALS2 (Amyotrophic lateral
sclerosis) and γPKC (Spinocerebellar ataxia 14) result in dysregulation of macropinocytosis
(Otomo et al., 2008; Yamamoto et al., 2014) suggesting dysfunction of these processes are
detrimental to large neurons. In addition, a cell culture model of methamphetamine toxicity
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suggested that meth induced over stimulation of macropinocytosis could lead to lysosomal
exhaustion and cell death (Nara et al., 2012).
Most protein aggregation studies associated with these neurodegenerative disorders to date
have been performed in vivo or in vivo using rodent models of ALS. However, given the
unnatural (induced) nature of the ALS-like disease in rodents and differences between
rodents and humans, there is a need for more applicable human models. Humanised models
of ALS have been generated in the last few years, through the use of reprogramming biology
and development of humanised models of ALS has been established. The generation of
patient specific induced pluripotent stem cells (iPSCs) derived from reprogrammed somatic
cells from a range familial and sporadic ALS patients now represent a more effective disease
model of ALS (Hedges et al., 2016; Lee and Huang, 2015). A range of disease-relevant cell
types including neurons and motor neurons can be differentiated from human induced
pluripotent stem cells which can be used to study pathogenic mechanisms and elucidate
specific drug targets.
4.1.1 Aims
Results presented in Chapter 2 indicate that SOD1 aggregates enter NSC-34 cells via
macropinocytosis. Here, this work aimed to determine if activation of macropinocytosis by
protein aggregates was a generic phenomenon. To test this, aggregates found to trigger
macropinocytosis in cell lines were tested on human neurons, both iPSC derived motor
neurons and primary neurons. In addition, given the generic role of protein aggregates
associated with other neurodegenerative diseases in mediating disease progression, such as
TDP-43, huntingtin and α-synuclein, this work aimed to further investigate the mechanisms
of uptake and further characterise the activation of macropinocytosis by these protein
aggregates into NSC-34 motor neurons. Lastly, this study aimed to confirm that activation of
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macropinocytosis was not limited to specific disease associated protein species by using the
non-disease protein α-lactalbumin in its amorphous and fibrillar aggregation state.

171

5.2 Methods
5.2.1 Reagents and Antibodies
DMEM/F-12 medium, DMEM/F-12 without phenol red, Neurobasal Medium, B-27
supplement, Glucose powder, 0.05% trypsin-EDTA, GlutaMAX, SuperSignal West Pico
Chemiluminescent Substrate, SYTOX Red dead cell stain, FM® 1-43FX, fixable analog of
FM® 1-43 membrane stain, 10 kDa 647-dextran, Image-iT ™ LIVE Red caspase detection kit
Laminin, fibronectin and Lab-Tek chambered coverglass 8 well with cover were purchased
from ThermoFisher Scientific (Waltham, USA). Any kD Mini-PROTEAN TGX Precast
Protein Gels and Precision Plus Protein dual color protein standard were from Bio-Rad
(California, USA). Foetal Bovine Serum (heat-inactivated prior to addition in media; FBS)
was from Bovogen Biologicals (East Keilor, Australia). Amersham Hyperfilm was obtained
from GE Healthcare (Buckinghamshire, UK)). RedDot 2 was from Biotium (Hayward, CA).
Sterile cell culture plates were from Greiner Bio-One (Frickenhausen, Germany). Casein
(heat denatured before use; HDC), dimethyl sulfoxide (DMSO), bovine serum albumin
(BSA), β-mercaptoethanol, Brilliant blue R concentrate, paraformaldehyde (PFA),
biotinamidohexanoic acid 3-sulfo-N-hydroxysuccinimide ester sodium salt, Bicinchoninic
Acid Kit, Glutaraldehyde solution (50% in H2O), Propidium iodide, Osmium tetroxide
solution (4 WT. % in H2O) and dithiothreitol (DTT) were from Sigma-Aldrich (St. Louis,
MO). Ethylenediaminetetraacetic acid (EDTA) was from Amresco (Solon, USA). Digitonin,
High Purity was from Calbiochem was from San Diego, CA, USA. Uranyl acetate and 19
mm glass coverslips were from ProSciTech (Kirwan, Australia). mRNA was purchased from
Miltenyi Biotec Australia (Macquarie Park, Australia) (Protease inhibitor cocktail tablets
(complete, Mini, EDTA-free) was from Roche Diagnostics (Penzberg, Germany). RAC1 GLISA Activation Assay Kit (Colorimetric Based) was purchased from Cytoskeleton (Denver,
CO). ISOLATE II RNA Mini Kit was purchased from Bioline (Alexandria, Australia).
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Reagents for cDNA preparation were obtained from Promega (USA). All other reagents
including salts, powders and chemicals were from Amresco, Sigma-Aldrich or Astral
Scientific (Gymea, Australia). All reagents used were endotoxin free. Antibodies (Abs) and
inhibitor compounds and their respective manufacturing companies used in this current study
are listed in Table 5.1 and Table 5.2 respectively.
Table 5.1 Antibodies used in this study to investigate the effect of SOD1 proteins on TDP-43
pathology
Host species
Anti-body target
Conjugate
Manufacturer
(clonality)1
(Immunogen)2
(product number)3
Sheep (pAB)
SOD1
ThermoFisher
Scientific
(PAI-30817)
Mouse (mAb)
RAC1
Cytoskeleton
(ARC03)
Rabbit (mAb)
Islet 1
Abcam
[EP4182]
(ab109517)
Mouse (mAb)
SMI32
Abcam (ab73273)
Mouse (mAb)

Human OCT4

Alexa Fluor 488

STEMCELL Technologies
Australia (3A2A20)
ThermoFisher Scientific A(11001)
ThermoFisher Scientific
( A-11008)
Abcam (150177)

Goat (pAB)

Mouse IgG

Alexa Fluor 488

Goat (pAB)

Rabbit IgG

Alexa Fluor 488

Donkey (pAb)

Sheep IgG

Alexa Fluor 488

Goat (pAb)

Mouse IgG

Alexa Fluor 633

Donkey (pAb)

Sheep IgG

HRP

ThermoFisher Scientific
( A-21052)
Abcam (97125)

Goat (pAb)

Mouse IgG

HRP

Merck Millipore (12-349)

1

pAb, polyclonal anti-body, mAb, monoclonal anti-body; 3 Abcam, Cambridge, USA; ThermoFisher Scientific
(Waltham,MA, USA); BD Biosciences San Jose, CA, USA; Merck Millipore, Billerica, Massachusetts, USA; Cytoskeleton
(Denver, CO,USA), STEMCELL Technologies Australia, Tullamarine, VIC, Australia.

Table 5.2 Pharmacological inhibitors used in this study to investigate the mechanisms of SOD1
uptake
Compound
Manufacturer
(product number)1
5-N-ethyl-N-isopropyl-amiloride (EIPA)
Sigma (A3085)
Chlorpromazine hydrochloride (Chlorp HCL)

Sigma (C8138)

Genistein (Gen)

Sigma (G6649)

Rottlerin (Rot)

Sigma (R5648)

RAC1 inhibitor W56

Tocris Bioscience (2221)

1

Sigma, (St. Louis, MO, USA), Tocris Bioscience (Avonmouth, Bristol,UK)
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5.2.2 Cell Lines
The mouse neuroblastoma x spinal cord hybrid cell line (NSC-34 cells) (Cashman et al.,
1992) were routinely cultured in DMEM/F12 supplemented with 10% (v/v) FBS and 2 mM
GlutaMAX. Cells were maintained in an incubator at 37°C under a humidified atmosphere
containing 5% (v/v) CO2. Human primary neurons were cultured from 14 to 18 week foetal
brains collected after therapeutic termination with informed consent and were prepared with
the approval from Human Ethics Committees at the Universities of Sydney and New South
Wales (Sydney, Australia), as previously described (Guillemin et al., 2005). Briefly, neurons
were isolated from mixed foetal brain cells using a neuron isolation kit (Miltenyi Biotec,
Australia). Human primary neurons were plated in culture flasks coated with Matrigel (BD
Biosciences, CA) (1/20 in Neurobasal medium) for an hour at 37°C prior to seeding. Cells
were maintained in neurobasal medium supplemented with 2% B-27 supplement, 2 mM
Glutamax, and 5 mM glucose (complete medium) at 37oC at 5% CO2. Cells were cultured in
complete medium for up to 10 weeks. The medium was changed once a week.
Human fibroblasts were sourced from non-ALS individuals (female aged 62 and male aged 59
at the time of collection) and reprogrammed into induced pluripotent stem cells using mRNA
(Miltenyi Biotec, Australia). Pluripotency was confirmed by PluriTest Bioline RNA
purification kit Genea and differentiation of the cells (Muller et al., 2011). Karyotyping was
carried out in iPSCs, to ensure chromosomal abnormalities were not introduced during
reprogramming and culture. Immunocytochemistry confirmed the expression of the
pluripotency marker Oct4 (STEMCELL Tech). Differentiation of pluripotent stem cells into
motor neurons was carried out as in (Bilican et al., 2014) and one clone from each line was
used in experiments. Motor neurons (1.5 x 104 cells/ well) were plated onto laminin (20
µg/mL) and fibronectin (10 µg/mL) coated 13 mm coverslips. The timeline (Figure 5.1B)
summarizes the differentiation stages and the growth factor conditions used during
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differentiation. The morphological changes of each cell line were examined at each stage of
the differentiation process.
Confirmation of motor neuron phenotype was carried out, including expression analysis by
quantitative reverse transcription PCR and immunocytochemistry. The differentiated neurons
expressed the motor neuron specific markers neurofilament heavy and islet 1.
Immunocytochemistry identified the presence of extended dendrites ~100 µm in length.
Quantitative reverse transcription PCR analysis identified the expression of the motor neuron
specific gene MNX1 (that encodes the transcription factor homeobox 9, HB9) (Arber et al.,
1999). MNX1 was specifically expressed in motor neurons and MNX1 was silent in
pluripotent stem cells. The cholinergic specific marker acetylcholine esterase (ACHE that
encodes the enzyme responsible for the degradation of the neurotransmitter acetylcholine)
was expressed in cholinergic motor neurons. The expression levels for both MNX1 and
ACHE, were normalized to the housekeeper gene GAPDH.
5.2.3 Fixed cell antibody staining of iPSCs.
The iPSCs were plated on matrigel-coated 8 mm coverslips at a density of 2.5x 104 cells/cm2
and cultured for 3 days prior to staining. Cells were fixed with 4% PFA in PBS for 20 min at
RT and washed twice with PBS over 5 min. Cells were washed once with ice-cold PBS and
then incubated with 0.5% Triton-X 100 for 30 min at 4°C. Cells incubated with blocking
solution (5% BSA) for 20 min at RT. The iPSC colonies were incubated with anti- Oct3/4
IgG Ab (1:500 diluted in 4% BSA and 0.1% Triton X-100) overnight at 4°C. Cells were
washed again in ice cold PBS and incubated with anti-mouse IgG conjugated to Alexa Fluor
488 (1:1000 diluted in 1% BSA and 0.1% Triton X-100) for 1 h at RT protected from light.
An inverted microscope (DM IBRE) and a Leica TCS SP confocal imaging system were used
to visualise and image cells (excitation 488, emission collected at 520-545 nm).
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Fluorescence, bright field (differential interference contrast; DIC) and merged images were
captured using Leica confocal software.
5.2.4 Fixed cell antibody staining of motor neurons.
Cells were plated on coverslips coated with laminin (20 µg/mL) and fibronectin (10 µg/mL)
at a density of 4.2 x 104 cells/cm2. Cells were fixed with 4% PFA in PBS for 20 min at RT
and washed twice with PBS over 5 min. Cells were washed once with ice-cold PBS and then
incubated with 0.5% Triton-X 100 for 30 min at 4°C. Cells incubated with blocking solution
(5% BSA) for 20 min at RT. Cells were incubated with anti- NFH (SMI32) IgG Ab (1:800
diluted in 4% BSA and 0.1% Triton X-100) overnight at 4°C. Cells were washed again in ice
cold PBS and incubated with anti-mouse IgG conjugated to Alexa Fluor 488 (1:1000 diluted
in 1% BSA and 0.1% Triton X-100) for 1 h at RT protected from light. An inverted
microscope (DM IBRE) and a Leica TCS SP confocal imaging system were used to visualise
and image cells (excitation 488, emission collected at 520-545). Fluorescence, bright field
(differential interference contrast; DIC) and merged images were captured using Leica
confocal software.
5.2.5 Quantitative RT-PCR
RNA was extracted and purified from differentiated cell using the ISOLATE II RNA Mini
Kit (Bioline, USA), as per manufacturer’s instructions. The purified RNA was quantified
using NanoDrop 2000c dual‐mode UV‐Vis Spectrophotometer (ThermoFisher Scientific).
RNA was reverse transcribed into complementary DNA (cDNA) for subsequent analysis. 5
µg of purified RNA was annealed to random primers (0.75 µg) and oligo dT primers (0.75
µg) by incubating at 65°C for 4 min, followed by 1 min incubation on ice. For reverse
transcription, Moloney-murine leukaemia virus reverse transcriptase (M-MLV RTase) (150
U), 96 nmol dNTPs, RNasin (60 U) and 1x MMLV RTase Buffer were added to the reaction
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mixture and then incubated at 37 ºC for 100 min. Primers used in Chapter 5 for qRT-PCR
were obtained from Sigma Aldrich (USA) (unless stated otherwise) and sequences are
outlined in Table 5.3.
Table 5.3 Primers used in Chapter 5 for qRT-PCR had the following sequences:
Gene
Forward
Reverse

Acetylcholinest
erase (AChE)

Homeobox 9
(MNX1)

5’-

5’-

GGAACCGCTTCCTCCCCAAAT

TGCTGTAGTGGTCGAACTGGTTCTTC-

TG-3’

3’

5’-

5’-GGTTCTGGAACCAAATCTTC-3’

GTTCAAGCTCAACAAGTACC3’

GFAP

glyceraldehyde
3-phosphate
dehydrogenase

5’-

5’-

CTGGATCTGGAGAGGAAGATT

CTCATACTGCGTGCGGATCTCTTTCA-

GAGTCG-3’

3’

5’-

5’

GAGCACAAGAGGAAGAGAGA

GTTGAGCACAGGGTACTTTATTGATG

GACCC-3’

GTACATG-3’

GAPDH

The final qRT-PCR reaction consisted of 10 µL of SYBR Select Master Mix, 800 nM of each
forward and reverse primer, 2 µL of cDNA in a final reaction volume of 20 µL. Each reaction
was run in duplicate and a negative control (water) and no reverse transcription (RNA)
control was included as well as a positive control using cDNA of human putamen. The
amplification consisted of 40 cycles, of 95ºC for 15 s (activation step), 58ºC for 15 s
(annealing step) and 72ºC for 1 min. A melting curve analysis was conducted to confirm the
presence of the appropriate amplified target. The acquired data was normalized against
quantitative expression levels of the housekeeping gene GAPDH and analyzed using the
comparative threshold cycle method.
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5.2.6 Aggregation and biotinylation of SOD1, Httex146Q, α-synuclein, TDP-43, and αlactalbumin aggregates
WT and G93A SOD1 were purified and labelled as outlined in section 2.3.3. Proteins αsynuclein and α-lactalbumin protein aggregates were kindly provided by Dr Heath Ecroyd
(University of Wollongong, Wollongong, Australia). TDP-43 was produced by Melbourne
Protein Production Unit (Monash University) and kindly provided by Natalie Farrawell.
Monomeric Httex146Q-Cerulean-MBP fusion protein was kindly provided by Danny M.
Hatters (The University of Melbourne, Melbourne, Australia). Monomeric Httex146QCerulean-MBP fusion protein aggregation of Httex146Q was performed as previously
described (Ramdzan et al., 2010). Briefly, Httex146Q-Cerulean-MBP was thawed from frozen
stocks, diluted to 9 μM, and rapidly mixed with a 1/20 stock of TEV protease. After 15 min
incubation at RT, the resulting cleaved fusion protein (Httex146Q-Cerulean) was diluted to 2
µM and divided into single use aliquots, snap frozen in liquid nitrogen and stored at -80°C
for later use in experiments.
5.2.7 Transmission electron microscopy of Httex146Q, α-synuclein, TDP-43, and αlactalbumin RCM and amorphous protein aggregates
Negative staining transmission electron microscopy (TEM) was performed as outlined in
section 2.2.5. Briefly, 2 µl aliquots of Httex146Q, α-synuclein, TDP-43, and α-lactalbumin
RCM and amorphous proteins (1 mg/ml) were loaded onto carbon-coated nickel grids for 1
min at RT, washed 3 times with filtered Milli-Q water and negatively stained using 2% (w/v)
uranyl acetate diluted in Milli-Q water for 2 min at RT. Grids were then dried and stored until
processing. Protein structure and morphology was then analysed using a JEOL 2011 TEM
(Tokyo, Japan) operated at 200kV. Images were taken using Gatan Microscopy Suite
(Version 2.30.542.0) (California, USA).
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5.2.8 Httex146Q, α-synuclein, TDP-43, and α-lactalbumin RCM and amorphous
aggregated protein detection in NSC-34 cells by confocal microscopy
NSC-34 cells (2–3 x 104 cells/0.2 ml/chamber) were cultured in chamber slides at
37°C/5%CO2 overnight. Briefly, cells were incubated with 20 μg/ml of biotin-conjugated
aggregates of Httex146Q, α-synuclein, TDP-43, α-lactalbumin RCM and amorphous proteins
or PBS (no protein, control) for 2 h at 37°C. Cells were fixed with 4% PFA, incubated with
Triton X-100 and blocked for detection with 1 µg/ml Alexa Fluor 488 streptavidin (diluted in
1% BSA and 0.1% Triton X-100) for 1 h at RT protected from light. An inverted microscope
(DM IBRE) and a Leica TCS SP confocal imaging system were used to visualise and image
cells (excitation 488, emission collected at 520-545 nm). Fluorescence, bright field
(differential interference contrast; DIC) and merged images were captured using Leica
confocal software.
5.2.9 Fluid phase uptake assays
Fluid phase uptake assay was performed as outlined in section 2.2.17. Briefly, NSC-34 cells
(2–3 x 104 cells/0.2 ml/chamber) were incubated with 20 µg/ml of Httex146Q, α-synuclein,
TDP-43, α-lactalbumin RCM and amorphous aggregates in PBS alone or a positive control,
200 nM PMA, for 30 min. Prior to harvesting or fixation, cells were then co-incubated for 15
min with 0.5 mg/ml 10 kDa dextran conjugated to Alexa Fluor 647 (10 kDa 647-dextran) at
37°C/5% CO2. The cells were then placed on ice, washed three times with ice cold PBS and
once with low pH buffer (0.1 M sodium acetate, 0.05 M NaCl, pH 5.5) for 10 min. The cells
were then fixed with 4% PFA and permeabilised with 0.5% Triton-X 100. Cells were then
incubated with anti-SOD1 IgG Ab overnight at 4°C. Cells were washed again in PBS and
incubated with Alexa Fluor 488 streptavidin for 1 h at RT. This same assay was performed on
human iPSC-derived and primary motor neurons incubated with 20 µg/ml of SOD1
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aggregates. An inverted microscope (DM IBRE) and a Leica TCS SP confocal imaging
system were used to visualise and image cells (excitation 488, emission collected at 495-515
and 650-668 nm). Fluorescence, bright field (differential interference contrast; DIC) and
merged images were captured using Leica confocal software. In addition, cellular events were
collected in a separate study using a LSR II flow cytometer as outlined in section 0.
5.2.10 Quantifying Inhibition of Httex146Q, α-synuclein, TDP-43, α-lactalbumin RCM
and amorphous aggregated protein uptake
Inhibitor assays were performed as outlined in section 2.2.13. Briefly, NSC-34 cells were
pre-treated with 100 µM 5-N-ethyl-N-isopropyl-amiloride (EIPA), 5 µM chlorpromazine
hydrochloride (Chlorp HCl), 10 µM genistein (Gen) or 3 µM rottlerin (Rot) diluted in 1%
BSA/PBS for 30 min. Cells were then co-incubated with by 20 μg/ml Httex146Q, α-synuclein,
TDP-43, α-lactalbumin RCM and amorphous aggregated proteins for an additional 30 min.
Aggregates were only incubated for 30 mins (shorter time) as uptake of aggregates is
proposed to occur within this timeframe. Cells were immediately fixed with 4% PFA, washed
twice with PBS and incubated with Triton X-100 for 30 min at 4°C. Cells were then
incubated with blocking solution (5% FCS, 1% BSA and 0.3% Triton X-100) for 20 min.
Cells were incubated with with Alexa Fluor 488 streptavidin for 1 h. Sytox Red (5 nM) was
used as a counter stain, and incubated with cells for 10 min at RT. This same assay was
performed on human iPSC-derived and primary motor neurons incubated with 20 µg/ml of
SOD1 aggregates. An inverted microscope (DM IBRE) and a Leica TCS SP confocal
imaging system were used to visualise and image cells (excitation 488, emission collected at
520-545). Fluorescence, bright field (differential interference contrast; DIC) and merged
images were captured using Leica confocal software. In addition, cellular events were
collected in a separate study using a LSR II flow cytometer as outlined in section 5.2.9.
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5.2.11 Membrane activity quantification
Membrane dye uptake assay was performed as outlined in section 2.2.16. Briefly, human
iPSC-derived motor neurons and human primary neurons were cultured as described above
(see section 5.2.2). Cells were incubated with 20 µg/ml of SOD1, PBS alone, or PMA (200
nM) in PBS for 2 h at 37°C/5% CO2. Cells were then washed, incubated with 10 µM of FM
1-43FX membrane stain diluted in PBS for 7 min and excess dye was removed by several
washes in PBS and incubated in ice-cold PBS. Cells were then fixed in 4% PFA for 20 min at
4°C. Post fixation, cells were washed twice in PBS and incubated with 1x Red Dot 2 for 10
min at RT.
5.2.12 Field emission scanning electron microscopy (FESEM)
FESEM assay was performed as outlined in section 2.2.15. Briefly, NSC-34 cells were serum
starved in phenol red free culture medium for 24 h and incubated with 20 µg/ml Httex146Q, αsynuclein, TDP-43, α-lactalbumin RCM and amorphous aggregated proteins in PBS or PBS
containing 200 nM PMA for 2 h. Post incubation, cells were fixed in 2.5%
glutaraldehyde/4% PFA in 0.1 M phosphate buffer for 3 h at 4°C. Cells were then washed
and postfixed in 2% OsO4/water at RT for 1 h. After washing with water, the cells were
dehydrated using a gradient of ethanol, critical point dried for 2 h using a LEICA CPD030
and coated with graphite-gold in a sputter coater. This same assay was performed on human
iPSC-derived and primary motor neurons incubated with 20 µg/ml of SOD1 aggregates
Cellular structures were visualised with a JEOL 6490LV SEM (Tokyo, Japan) microscope
operated at 10 kV at a 10 mm working distance and a spot size setting of 35.
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5.2.13 RAC1 activation Elisa assays
RAC1 activation assay was performed as outlined in section 2.2.20. Briefly, NSC-34 cells
serum starved in phenol red free culture medium for 24 h and incubated with 20 µg/ml of
Httex146Q, α-synuclein, TDP-43, α-lactalbumin RCM and amorphous aggregated proteins for
30 min at 37°C/5% CO2. Cells were washed, harvested by treatment with 0.05% trypsin for
10 min and washed again (300 x g for 5 min) in PBS. RAC1 activation was measured using a
G-LISA activation kit (Kit #BK128 Cytoskeleton, Inc. Denver, USA) as per the
manufacturer’s recommendations. Absorbance values of wells were recorded with a
SpectraMax Plus 384 Microplate Reader and SoftMax Pro software (Molecular Devices,
Silicon Valley, CA) (490nm).
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5.3 Results
5.3.1 SOD1 aggregates are internalised via macropinocytosis pathways in iPSC-derived
and primary human motor neurons
5.3.1.1 Characterisation of a motor neuron phenotype in iPSC-derived motor neurons
The results of investigations presented in detail in Chapter 2, demonstrate that SOD1
aggregates enter NSC-34 cells via macropinocytosis. To determine whether or not these
findings extend to human neurons, SOD1 uptake pathways were next investigated in human
cultured iPSC-derived motor neurons and human primary neurons. Prior to investigating the
uptake pathways of SOD1 in human iPSC-derived motor neurons, the pluripotency and
differentiation of the cells was characterised (Figure 5.1). Initially, karyotyping (StemCore,
Australian Institute for Bioengineering and Nanotechnology, Australia) demonstrated that
chromosomal abnormalities were not introduced during reprogramming and culture (data not
shown). Immunocytochemistry confirmed the expression of the pluripotency marker Oct4 in
iPSCs (Figure 5.1A). Differentiation of pluripotent stem cells into motor neurons was carried
out as in (Bilican et al., 2014) and outlined in Figure 5.1B. The differentiated neurons
expressed the motor neuron specific marker SMI32 (Figure 5.1C). Immunocytochemistry
identified the presence of extended dendrites ~100 μm in length. Quantitative reverse
transcription PCR analysis identified the expression of the motor neuron specific gene MNX1
(that encodes the transcription factor homeobox 9, HB9) (Arber et al., 1999). MNX1 was
specifically expressed in motor neurons and MNX1 was silent in pluripotent stem cells. The
cholinergic specific marker acetylcholine esterase (ACHE that encodes the enzyme
responsible for the degradation of the neurotransmitter acetylcholine) was specifically
expressed in cholinergic motor neurons. The expression levels for both MNX1 and ACHE,
were normalized to the housekeeper gene GAPDH (Figure 5.1D).
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Figure 5.1 Characterisation of iPSC derived motor neurons. (A) Immunocytochemistry
confirmed the expression of the pluripotency marker Oct4. Human induced pluripotent stem cells were cultured
in TeSR-E8 on glass coverslips coated with Matrigel, fixed and stained with Alexa Fluor 488-conjugated Oct4
antibody. Confocal and brightfield images were taken on a Leica SP5 confocal microscope. Scale bar is 60 mm.
(B) The timeline summarises the differentiation stages and the growth factor conditions used during
differentiation (Billican et al.). Example images of cellular morphological changes during differentiation are
shown. Scale bars are 100 mm, 50 mm, 50 mm respectively. (C) Motor neurons were cultured on glass
coverslips coated with laminin, collagen and fibronectin. Immunocytochemistry confirmed the expression of the
motor neuron marker SMI-32. Scale bars are 30 mm. (D) Expression of neuronal and cholinergic markers were
quantified using quantitative RT-PCR. Data plotted as mean relative gene expression in motor neurons
normalised to GAPDH (± SEM, n=3). MNX1 and ACHE expression was silent in pluripotent cells. This work
was performed by Dzung Do-Ha, Monique Bax and Lezanne Ooi.

Next, the purity of the resulting motor neuron cultures was assessed by microscopy.
Immunocytochemical analysis confirmed that the majority of the motor neuron cultures were
positive (90.5 ± 1.4 %) for the motor neuronal marker SMI32 and 88.8 ± 1.4 % of cells were
positive for neural stem cell marker Islet 1, with large cell bodies, consistent with a large
proportion of the cells having a motor neuron morphology (Figure 5.2).
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Figure 5.2 Characterisation of iPSC derived motor neu rons. Quantification of Islet 1 (A) and
SMI32 (B) positive cells was performed using immunocytochemistry and analysis using Image J software. Islet
1 and SMI32 positive cells were calculated as a percentage of the total number of cells (determined by nuclear
stain) from motor neuron cultures generated from six donor cell lines, using 6-10 images from each technical
replicate (separate differentiation experiments using 3 technical replicates for Islet 1 and 2 technical replicates
for SMI32). The motor neuron cultures contained 90.5 ± 1.4 % SMI32-positive cells and 88.8 ± 1.4 % Islet 1positive cells. Scale bars are (A) 100 mm and (B) 50 mm respectively. This work was performed by Dzung DoHa, Monique Bax and Lezanne Ooi.

5.3.1.2 Pharmacological inhibitors of Macropinocytosis reduce SOD1 aggregate uptake in
human iPSC-derived and primary motor neurons
To examine the pathway of SOD1 uptake in human neurons, iPSC-derived motor neuron
cultures (Figure 5.3A) and primary motor neurons (Figure 5.3B) were in pre-incubated in the
absence or presence of the Na+/H+ exchange inhibitor; EIPA and the RAC1 inhibitor W56
which specifically inhibits RAC1 activity. Cells were firstly incubated with SOD1 aggregates
in the absence or presence of EIPA and W56 and then the mean fluorescence intensity for the
SOD1 aggregates was examined by confocal microscopy analysis. Relative SOD1 uptake was
quantified from these images using ImageJ software.
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Firstly, the uptake of WT and mutant SOD1 aggregates into human cultured iPSC-derived
motor neurons and primary neurons was assessed. Similar to previous observations reported
in Chapter 1, pre-incubation of human iPSC-derived motor neuron cells with 100 µM EIPA
and 200 nM W56 significantly reduced WT SOD1 aggregate uptake by 17 ± 0.4% and 41 ±
0.5%, respectively. Similarly, incubation with EIPA and W56 significantly inhibited mutant
G93A SOD1 aggregate uptake by 52 ± 0.7% and 58 ± 0.6%, respectively. In addition, human
primary neurons were pre-incubated in the absence or presence of EIPA and W56 before
addition of SOD1 aggregates. Incubation with EIPA and W56 significantly reduced WT
SOD1 aggregate uptake by 56 ± 1% and 13 ± 0.9% and the uptake of mutant G93A SOD1
aggregate by 23 ± 1% and 35 ± 1%, respectively . Thus, given the large size of the aggregates
and the ability of EIPA and W56 to modulate uptake, this suggests that macropinocytosis-like
pathways play a role in the uptake of WT and mutant SOD1 aggregates in human neurons,
similar to observations made in the mouse motor neuron-like (NSC-34) cell line (Chapter 1).
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Figure 5.3 Small molecule inhibitors block macropinocytosis. (A) iPSC-derived and (B) primary
human motor neurons were incubated with 20 μg/ml of aggregated SOD1 proteins (20 µg/ml) for 30 min at
37oC, in the absence (control) or presence of a pre-incubation step with either EIPA (100 µM) or RAC1W56
(200nm) inhibitor, fixed with 4% PFA, permeabilised and labelled with either anti-human SOD1 Ab (nonaggregated/ soluble) or Alexa Fluor 488 streptavidin. Slides were analysed by confocal microscopy. Outline of
cells are indicated with white dashed lines. Bars represent 20 µm. Results are representative of at least n = 3.
Uptake of proteins under the same conditions were determined by flow cytometry and results shown as mean
fluorescence intensity ± SD, n = 6, ***P < 0.001 or *P < 0.05 compared to corresponding control.
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5.3.2 SOD1 aggregates trigger cell surface ruffling in human cultured iPSC-derived
motor neurons and primary neurons
5.3.2.1 SOD1 aggregates induce cell surface ruffles and blebs in the membrane to enter into
human cultured iPSC-derived motor neurons and primary motor neurons
Since membrane ruffling associated with macropinocytosis was implicated in SOD1 uptake
into NSC-34 cells, the role of SOD1 aggregates in triggering actin-mediated membrane
ruffling and blebbing in the plasma membrane of human cultured iPSC-derived motor
neurons and primary neurons was tested. To investigate this, initially the detailed morphology
of the cell surface was examined by field emission scanning electron microscopy (FESEM)
(Figure 5.4). Incubation of human cultured iPSC-derived motor neurons (Figure 5.4A) with
WT and mutant G93A SOD1 aggregates induced significant membrane perturbations in the
form of systemic blebbing and lamellipodia-like membrane protrusions similar to that
observed for cells treated with positive control; PMA. However, no obvious membrane
perturbations were seen in cells incubated in the absence of protein treatment.
Similarly, primary neurons (Figure 5.4B) incubated in the presence of WT and mutant G93A
SOD1 aggregates displayed lamellipodia- like ruffling and blebbing in the cell surface. These
membrane perturbations were more prominent in cells treated with PMA, which present in
the form of systemic blebbing and ruffling in the cell surface relative to the cells treated in
the absence of protein.
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Figure 5.4 Aggregated SOD1-induced macropinocytosis involves ruffles in the plasma
membrane of human iPSC-derived and primary motor neurons. (A) iPSC-derived and (B)
primary human motor neurons were serum starved for 24 h and were incubated with PBS (control, no protein),
PBS containing 200 nm phorbol 12-myristate 13-acetate (PMA) or 20 μg/ml of aggregated SOD1, for 2 h, fixed
with 2.5% glutaraldehyde/4% PFA in 0.1 M phosphate buffer for 3 h, postfixed in 2% OsO 4/ water, dehydrated
using a gradient of ethanol (30-100%, 30 min per treatment), critical point dried for 2 h and coated with
graphite-gold. Increases in membrane perturbations can be observed, such as ruffles and blebs. Slides were
analysed by field emission scanning electron microscopy. Bars represent 1 µm. Results are representative of n =
2.

Next, to quantify the extent of the observed membrane ruffling and blebbing in the plasma
membrane, human cultured iPSC-derived motor neurons and primary neurons were
pretreated with membrane dye FM 1-43FX, which has been used in previously for studies of
membrane perturbation during growth cone ruffling (Kolpak et al., 2009). Cells were then
incubated with SOD1 aggregates or PMA for 2 h (Figure 5.5). Incubation with SOD1
aggregates induced significantly higher membrane perturbations, as measured by an increase
in cellular fluorescence compared to controls, in both human cultured iPSC-derived motor
neurons (Figure 5.5A) and primary neurons Figure 5.5B). This finding reflected the FESEM
data above and is consistent with increased ruffles and blebs at the cell surface.
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Figure 5.5 SOD1 aggregates induce membrane perutbations in the cell surface of iPSC derived and primary human motor neurons (A) iPSC-derived and (B) primary human motor neurons
were incubated with PBS alone, 200 nM PMA or 20 μg/ml of aggregated SOD1for 2 h at 37°C, incubated with
the membrane dye FM1-43FX and fixed with 4% PFA. Outline of cells are indicated with white dashed lines.
Bars represent 20 µm. Mean fluorescence intensities (MFI) of membrane dye per cell were quantified from
these images using ImageJ software (Version 1.48) (National Institutes of health, Bethesda, MD). A minimum
of 200 cells were scored per treatment. Results shown as mean cellular fluorescence intensity means ± SD, n =
3, ***P <0.001 compared to corresponding control (no protein treatment).

5.3.2.2 SOD1 protein aggregates induce fluid uptake in human cultured iPSC-derived motor
neurons and primary neuronal cells
One of the consequences of macropinocytosis is the non-selective internalisation of
significant amounts of fluid and membrane (Swanson and Watts, 1995), thus fluid uptake into
human cultured iPSC-derived motor neurons and primary neurons cells was next investigated
(Figure 5.6). To investigate fluid uptake, internalization of fluorescently labeled dextran (a
fluid-phase marker) into cells was assessed, as previously used in Chapter 2. In both human
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cultured iPSC-derived motor neurons (Figure 5.6A) and primary neuron cells (Figure 5.6B),
WT and mutant SOD1 aggregates induced a significantly higher uptake of 10 kDa 647dextran compared to cells treated in the absence of protein, consistent with the triggering of
macropinocytosis.

Figure 5.6 SOD1 aggregates trigger fluid phase uptake in iPSC -derived and primary
human motor neurons using fluorescently labelled dextran . (A) iPSC-derived and (B) primary
human motor neurons were incubated with PBS alone (mock) or 20 μg/ml of aggregated SOD1 for 30 min at
37°C, co-incubated with dextran Alexa-647 for 15 min, fixed with 4% PFA, permeabilised and labelled with
Alexa Fluor 488 streptavidin. Slides were analysed by confocal microscopy. Outline of cells are indicated with
white dashed lines. Bars represent 10 µm. Results are representative of at least n = 3, ***P <0.001 or **P < 0.01
compared to corresponding mock (no protein treatment);. Mean fluorescence intensities (MFI) per cell of
dextran uptake were quantified from confocal images using ImageJ software (Version 1.48) (National Institutes
of health, Bethesda, MD).
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5.3.3 Activation of membrane ruffling is not restricted to SOD1 aggregates
There is now substantial evidence that SOD1 aggregates can enter into neuronal cells via
macropinocytosis (Grad et al., 2014; Münch et al., 2011; Sundaramoorthy et al., 2013), with
evidence from the study in Chapter 2 demonstrating that this process is not a passive one but
that SOD1 aggregates can trigger the activation of membrane ruffling and entry via
macropinocytosis. The possibility that the triggering of membrane ruffling is a generic
cellular response to protein aggregates was then next investigated.
5.3.3.1 Purified Httex146Q, α-synuclein, TDP-43, and α-lactalbumin RCM and amorphous
aggregates are heterogeneous in morphology
To determine the morphology of the purified recombinant Httex146Q, TDP-43, α-synuclein
and the model proteins RCM induced fibrillar or amorphous α-lactalbumin protein
aggregates, negative staining TEM was performed (Figure 5.7). Representative TEM images
of endpoint aggregates for Httex146Q (Figure 5.7A), TDP-43 (Figure 5.7B), α-synuclein
(Figure 5.7C), and the model protein α-lactalbumin RCM (Figure 5.7D) were found to consist
of long fibril structures, similar to those seen in neurodegenerative diseases (reviewed in
Brettschneider et al., 2015). The amorphous α-lactalbumin (Figure 5.7E) model protein was
observed to have an amorphous structure but clumped together in large aggregates.
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Figure 5.7 Fibrillar and amorphous Morphology of protein aggregates using TEM (A)
Purified Httex146Q , (B) TDP-43, (C) α-synuclein, , and (D) α-lactalbumin RCM and (E) amorphous proteins (1
mg/ml). Representative TEM image of endpoint aggregates. Protein aggregate (1 mg/ml) samples (2 µl) were
loaded onto carbon-coated nickel grids for 1 min at RT and negatively stained using 2% uranyl acetate for 2 min
at RT. Bars represent 20nm.

5.3.3.2 Httex146Q, α-synuclein, TDP-43, and α-lactalbumin RCM and amorphous
aggregates are detected in motor-neuron like NSC-34 cells
Next, the putative uptake of disease-associated fibrillar aggregates formed by Httex146Q
TDP-43, α-synuclein, and also of amorphous and fibrillar aggregates formed from the model
protein α-lactalbumin (Kulig and Ecroyd, 2012) into NSC-34 cells was examined by confocal
microscopy using Alexa Fluor 488 streptavidin (Figure 5.8). Httex146Q (Figure 5.8A), TDP43 (Figure 5.8B), α-synuclein (Figure 5.8C), and also both amorphous (Figure 5.8D) and
RCM α-lactalbumin (Figure 5.8E) aggregates were observed to be internalised by NSC-34
cells after 2 h incubation.
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Figure 5.8 Htt e x1 46Q , α-synuclein, TDP-43, and α-lactalbumin RCM and amorphous
aggregate protein aggregates enter into NSC -34. NSC-34 cells treated with 20 μg/ml of (A-E)
aggregated proteins (20 µg/ml) for 2 h at 37 oC, fixed with 4% PFA, permeabilised and labelled with Alexa Fluor
488 streptavidin. Chamber wells were analysed by confocal microscopy. Outline of cells are indicated with
white dashed lines. Bars represent 20 µm. Results are representative of at least n = 2.

5.3.3.3 Pharmacological inhibitors of macropinocytosis reduce Httex146Q, α-synuclein, TDP43, and α-lactalbumin RCM and amorphous aggregate uptake in to NSC-34 cells
Uptake of SOD1 aggregates into NSC-34 cells (Chapter 2) and in to human neurons (Figure
5.8) has been shown to be reduced in the presence of small molecule inhibitors of pathways
involved in the regulation of macropinocytosis. Given that NSC-34 cells can efficiently take
up of a variety of protein aggregates (Figure 5.8), it was next investigated whether small
molecule inhibitors of macropinocytosis have an effect on the uptake of Httex146Q, TDP-43,
α-synuclein, and amorphous and fibrillar α-lactalbumin aggregates (Figure 5.9). NSC-34 cells
were firstly incubated with aggregates in the absence or presence of EIPA (an inhibitor of the
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Na+/H+ pumps, essential for macropinocytosis) and then mean fluorescence intensity for
uptake of protein aggregates uptake were examined by confocal microscopy (Figure 5.9A).
Relative aggregate uptake was quantified from these images using ImageJ software (Figure
5.9B). Incubation with EIPA resulted in significant reductions in the uptake of Httex146Q (51
± 1.6%), TDP-43 (26 ± 1.3 %), α-lactalbumin amorphous (35 ± 1.3 %) and fibrillar (14 ± 1.9
%) aggregates. However, in contrast incubation with EIPA was not observed to inhibit the
internalisation of α-synuclein

Figure 5.9 Small molecule inhibitors block macropinocytosis and entry of Htt e x1 46Q ,
TDP-43, α-lactalbumin RCM and amorphous aggregated proteins. (A) NSC-34 cells treated
with 20 μg/ml Httex146Q , α-synuclein, TDP-43, α-lactalbumin RCM and amorphous aggregated protein for 30
min at 37oC, in the absence (control) or presence of a pre-incubation step with EIPA (100 µM) a Na+/H+
exchange inhibitor, fixed with 4% PFA, permeabilised and labelled with Alexa Fluor 488 streptavidin. Slides
were analysed by confocal microscopy. Outline of cells are indicated with white dashed lines. Bars represent 20
µm. Results are representative of at least n = 3 (B) Uptake of proteins under the same conditions were
determined by flow cytometry and results shown as mean fluorescence intensity ± SD, n = 6, ***P < 0.001 or *P
< 0.05 compared to corresponding control.
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5.3.3.4 Httex146Q, α-synuclein, TDP-43, and α-lactalbumin fibrillar and amorphous
aggregates trigger cell surface ruffling activation of RAC1 and fluid uptake in NSC-34 cells
Given that above data implicates a role for a more general role of macropinocytosis in the
uptake of protein aggregates, the association of aggregates with induction of plasma
membrane ruffling and/ or blebbing was next examined. To investigate whether there were
any perturbations to the cell surface membrane caused by incubation with a variety of protein
aggregates, cells were treated with either PMA or protein aggregates for 2 h and then the
detailed morphology of cells was examined by FESEM (Figure 5.10). NSC-34 cells
incubated with Httex146Q and TDP-43 aggregates displayed large planar lamellipodia-like
ruffles. Similarly, α-synuclein induced cell-wide systemic blebbing and ruffles, similar to
cells incubated with α-lactalbumin RCM. However, a small amount of membrane
perturbations were observed for cells incubated with amorphous α-lactalbumin compared to
the cells incubated in the absence of protein.

Figure 5.10 Aggregated Htt e x1 46Q, α-synuclein, TDP-43, α-lactalbumin RCM and
amorphous proteins induce ruffles in the plasma membrane of NSC -34 cells. NSC-34 cells
were serum starved for 24 h and were incubated with PBS (control, no protein) or 20 μg/ml of aggregated
Httex146Q, α-synuclein, TDP-43, α-lactalbumin RCM and amorphous proteins for 2 h, fixed with 2.5%
glutaraldehyde/4% PFA in 0.1 M phosphate buffer for 3 h, postfixed in 2% OsO 4/ water, dehydrated using a
gradient of ethanol (30-100%, 30 min per treatment), critical point dried for 2 h and coated with graphite-gold.
Increases in membrane perturbations can be observed, such as ruffles and blebs. Slides were analysed by field
emission scanning electron microscopy. Bars represent 2 µm. Results are representative of n = 2.
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Since activation of the Rho GTPase RAC1 is involved in regulating macropinocytosis, the
activation of RAC1, via cellular interaction with protein aggregates was next assessed. To
investigate whether Httex146Q, α-synuclein, and TDP-43 protein aggregates induce the
activation of RAC1 upon entry into NSC-34 cells, cells were incubated with these aggregates
and RAC1 activation was probed for using a G-LISA based assay (Figure 5.11). Compared to
control cells, a significantly increased amount of activated RAC1 was detected in cells
incubated with Httex146Q, α-synuclein, and TDP-43 aggregates. However, while the mean
level of activated RAC1 was increased when cells were incubated with α-lactalbumin RCM
and amorphous aggregates, this increase was not significant.

Figure 5.11 RAC1 also has an important role in Htt e x 1 46Q, TDP-43, α-lactalbumin RCM
and a morphous proteins entry into NSC -34 cells. NSC-34 cells were serum starved 24 h, incubated
with PBS alone (control) or 20 μg/ml of Httex146Q, α-synuclein, TDP-43, α-lactalbumin RCM and amorphous
proteins for 30 min at 37°C and lysed. RAC1 activation was measured using a RAC1 activation G-LISA kit
activation assay that probes for RAC1-GDP. Absorbance values of anti- RAC1 HRP at 490 nm were determined
by spectrometry and results are shown as mean absorbances (490 nm) ± SD of 6 experiments, ***P < 0.001 or *P
< 0.05, compared to corresponding control (mock).

Finally, to investigate whether the interaction of a variety of protein aggregates with cells
triggers fluid phase uptake (Figure 5.12), NSC-34 cells were incubated in the presence of
both Httex146Q, α-synuclein, α-lactalbumin, and TDP-43 with 10 kDa 647-dextran and
assessed by confocal microscopy (Figure 5.12A) and flow cytometry (Figure 5.12B).
Incubation with all protein aggregates including the model proteins α-lactalbumin fibrillar
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and amorphous aggregates induced significant uptake of fluid (dextran- ALEXA-647), with
significantly greater amounts of dextran detected in cells incubated with Httex146Q, TDP-43,
α-lactalbumin and α-synuclein compared to cells compared to cells treated in the absence of
protein aggregates.

Figure 5.12 Htt e x 1 46Q, α-synuclein, TDP-43, α-lactalbumin RCM and amorphous protein
aggregates trigger fluid phase uptake using fluorescently labelled dextran. NSC-34 cells were
incubated with PBS alone (mock) or 20 μg/ml of Httex146Q , α-synuclein, TDP-43, α-lactalbumin RCM and
amorphous proteins for 30 min at 37°C, co-incubated with dextran Alexa-647 for 15 min, fixed with 4% PFA,
permeabilised and labelled with Alexa Fluor 488 streptavidin. Slides were analysed by confocal microscopy.
Outline of cells are indicated with white dashed lines. Bars represent 10 µm. Results are representative of at
least n = 3. (B) Cells were firstly gated on forward (FSC) and side (SSC) scatter to exclude dead cells and the
mean fluorescence intensities (MFI) of dextran Alexa-647 in NSC-34 cells was determined by flow cytometry.
Results shown as means ± SD, n = 6; ***P < 0.001 or **P < 0.01 compared to corresponding control.
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5.4 Discussion
The current study demonstrates that SOD1 aggregates can be internalised via
macropinocytosis-like pathways into human primary neurons and more importantly human
motor neurons derived from iPSCs. The addition of pharmacological inhibitors of
macropinocytosis including EIPA and W56 disrupted the uptake of SOD1 aggregates into
these cells. SOD1-mediated activation of macropinocytosis-like pathways in these primary
cells induced membrane perturbations in the forms of ruffles and blebs, and subsequent fluid
uptake, which are characteristic of macropinocytosis. The current study also confirmed for
the first time that other protein aggregates associated with ALS, Huntington’s and Parkinson's
diseases, including purified TDP-43, Httex146Q and α-synuclein protein aggregates
respectively, trigger the activation of the Rho GTPase RAC1. This results in the formation of
membrane ruffles on the cell surface and fluid phase uptake in NSC-34 cells, facilitating the
entry of large fibrillary or amorphous protein aggregates. Together, the current study
indicates that SOD1 aggregates can stimulate macropinocytosis in human neurons and
suggests a role for macropinocytosis in the uptake of a protein aggregates more generally.
Previous work had shown that exogenously applied misfolded mutant SOD1 could be taken
up by cell lines and material found in conditioned media was shown to be internalised into
human WT SOD1‐expressing murine primary spinal cord cultures, derived from embryonic
spinal cord of transgenic mice (Grad et al., 2014). In the work presented here, the ability of
human neurons to take up SOD1 aggregates was observed for the first time, supporting
previous observations which suggest that extracellular misfolded or aggregated SOD1 may
have an active role in the spread of pathology among cells in vitro and motor neurons in vivo
(Ayers et al., 2014). Thus, SOD1 aggregates may contribute to disease progression via
interactions with both the cell surface and internalisation into cells, which may occur in both
fALS and sALS (Grad et al., 2014; Münch et al., 2011; Sundaramoorthy et al., 2013).
199

Furthermore, the uptake of purified TDP-43, Huntington and α-synuclein aggregates into
NSC-34 motor neuron cells was observed similar to uptake of SOD1 in Chapter 2. This is
consistent with cellular uptake of TDP-43 into microfluidic neuronal cultures as reported by
Feiler et al (Feiler et al., 2015). In the context of Parkinson’s disease, cell culture studies have
shown that extracellular α-synuclein in various forms (fibrils, oligomers, and monomers) can
be internalised by cultured neuronal cells (Lee et al., 2008). Furthermore, α-synuclein is
known to directly interact with lipids and membranes to facilitate its entry into neuronal cells
(Lee et al., 2008). Similarly, in a Huntington’s disease model, large polyglutamine aggregates
were shown to internalise into cultured cells (Yang et al., 2002). However, the precise
mechanisms for entry of these proteins into cells remain to be determined.
A role for macropinocytosis in the uptake of extracellular native and aggregated WT and
mutant SOD1 into neuronal cells has been previously suggested (Grad et al., 2014; Münch et
al., 2011; Sundaramoorthy et al., 2013). In these studies, cell lines were treated by the
addition of small molecules that inhibit actin rearrangement, or Na+/H+ exchangers, Pak-1,
PI3K, and PKC was reported to impair the uptake of SOD1 aggregates (Grad et al., 2014;
Münch et al., 2011; Sundaramoorthy et al., 2013) consistent with macropinocytosis. In the
current study, EIPA (inhibitor of Na+/H+ exchanger) which has previously been used as the
main diagnostic test to identify macropinocytosis from other forms of endocytosis (West et
al., 1989) and the RAC1 inhibitor W56 were used to confirm the involvement of
macropinocytosis-like pathways in the uptake of SOD1 aggregates into human neurons. EIPA
and RAC1 W56 inhibited the uptake of SOD1 aggregates into human iPSC derived motor
neurons and primary neurons, similar to the study in Chapter 2 and previous observations
(Grad et al., 2014; Münch et al., 2011; Sundaramoorthy et al., 2013). Similarly, the level of
TDP-43 and Httex146Q uptake into NSC-34 cells were significantly suppressed by EIPA.
Other fibrils such as Tau associated with Alzheimer’s disease have also been shown to enter
200

cells via macropinocytosis (Holmes et al., 2013). Taken together, these data suggest that
SOD1, TDP-43 and Httex146Q and Tau are taken up by a similar mechanism, consistent with
a generic mechanism of protein aggregate uptake. However, in the current study while αsynuclein aggregates triggered ruffling and fluid uptake, characteristic of macropinocytosis,
the uptake of α-synuclein was not significantly affected by EIPA. This might suggest the
involvement of distinct pathways, or it could suggest a higher concentration of EIPA is
needed in this model, as α-synuclein aggregates are small in size and could potentially be
interacting and internalising in a different manner. However, future investigations into the
role of α-synuclein, and indeed Httex146Q, α-syn and TDP-43- aggregates in the induction of
macropinocytosis is clearly warranted.
Triggering the activation of macropinocytosis leads to the entry of large amounts of solute,
and because of the large size of macropinosomes macromolecules or particles too large for
other forms of endocytosis are able to enter the cell (Swanson and Watts, 1995). Activation
of macropinocytosis has been reported to induce a number of downstream signaling events
including the activation of the Rho GTPase, RAC1 (Ridley et al., 1992), which contributes to
the modulation of actin-mediated membrane ruffle formation in the form of lamellipodia,
circular-shaped membrane extensions (ruffles) and large plasma membrane extrusions
(blebs), macropinosome closure forming large intracellular vacuoles (0.5–10 μM) and
membrane trafficking (Lanzetti et al., 2004; Mercer and Helenius, 2012). In the current study,
SOD1,

TDP-43,

Httex146Q

and

α-synuclein

aggregate-mediated

activation

of

macropinocytosis thus internalisation into human primary neurons or NSC-34 cells
respectively, was demonstrated. Incubation with SOD1, TDP-43, Httex146Q and α-synuclein
aggregates induced membrane protrusions, including macropinocytic ruffling and systemic
blebbing, consistent with the formation macropinosomes at the plasma membrane. Thus, it is
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likely that motor neurons internalise extracellular aggregates directly via dynamic membrane
rearrangements that eventually form large endocytic macropinosomes.
Activated RAC1 has previously been identified as an important and central player in
triggering membrane ruffles and blebbing (Mercer and Helenius, 2009) associated with virus
entry into cells, and has been found to do so by activating downstream effectors of actin
polymerisation (Sanchez et al., 2012). While the precise role of PKC in virus entry is still
unclear, its activation with PMA (as used in this current study and in Chapter 2) can induce
ruffling and fluid uptake in the absence of ligands that bind the cell surface (Swanson, 1989).
The activation of RAC1 by TDP-43, Httex146Q and α-synuclein aggregates and subsequent
membrane ruffling was supported by results presented in the current study. Although SOD1mediated activation of RAC1 in human iPSC derived motor neurons and primary neurons
was not directly investigated in the current study, inhibition of RAC1 supressed the uptake of
SOD1 aggregates into these cells, thus suggesting a role for RAC1 activation in aggregate
entry. Of note, the study in chapter 1 confirmed that activation of RAC1 is upstream of
membrane ruffling, thus consistent with triggering the increased perturbation in the plasma
membrane of human iPSC derived motor neurons and primary neurons upon incubation with
SOD1 aggregates.
Macropinocytosis is a form of fluid phase endocytosis, characterised by internalisation of
extracellular fluids and solutes at whatever concentrations they are found in the extracellular
medium, rather than concentrating ligands at the cell surface (Swanson and Watts, 1995). The
data presented here shows that the activation of macropinocytosis mediated by SOD1
aggregates in human iPSC derived motor neurons and primary neurons, and TDP-43,
Httex146Q and α-syn in NSC-34 cells induced fluid uptake (dextran-Alexa 647 to quantify
fluid-phase endocytosis), coinciding with the formation of membrane ruffling. Similarly,
previous work has demonstrated that incubation with tau fibrils increased dextran uptake,
202

consistent with activation of macropinocytosis (Holmes et al., 2013). The model proteins αlactalbumin RCM and amorphous proteins were also able to induce membrane perturbations
that facilitate their cellular uptake in a similar manner to that of SOD1, suggesting that a
broad range of aggregated proteins, both amorphous and amyloid-like, are able to induce
membrane perturbations that facilitate their cellular uptake.
In addition to TDP-43, Httex146Q and α-synuclein aggregate, various viruses, such as the
vaccinia virus, adenovirus 3, herpes simplex virus 1 and HIV, utilize macropinocytosis to
gain entry to cells. This phenomenon is likely to be due to the fact that macropinosomes are
not restricted in size, enabling even large virions to be internalised, and that many cell types,
not just professional phagocytes (such as macrophages), have the ability to activate the
macropinocytosis pathways (Swanson and Watts, 1995). Indeed, macropinocytosis can be
activated in neurons by interactions with large viral particles (Kalia et al., 2013). Of note,
amyloid fibrils including those associated with Alzheimer's disease (Aβ1-40) and Parkinson’s
disease (α-synuclein) and can enhance human immunodeficiency virus type 1 infection
(Munch et al., 2007; Wojtowicz et al., 2002). Thus, it is interesting to speculate that this
behaviour could be due to the potent ability of such aggregates to stimulate macropinocytosis
and facilitate increased viral uptake. Recently, accumulating evidence suggests that the
transcellular propagation of a wide range of disease-associated proteins, including SOD1,
TDP-43, huntingtin with poly-Q repeats, α-synuclein, Aβ, tau mediate the progression of
disease in a prion-like manner (reviewed in Ayers et al., 2016). Likewise, cellular uptake of
the pathological prion protein has been reported to occur via by stimulated lipid-raft mediated
macropinocytosis (Wadia et al., 2008)
In conclusion, this study represents the first report of SOD1 mediated activation of
macropinocytosis in human neurons, consistent with the notion that protein aggregates could
be an active part of ALS disease progression, possibly through secondary nucleation (Buell et
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al., 2014), or another prion-like aggregate propagation process. In addition, the current study
highlights the ability of neurons to undergo stimulated macropinocytosis. Furthermore, the
current study suggests that aggregate induction of macropinocytosis may be a more generic
principle and not restricted to one type of aggregate (Holmes et al., 2013). While further
investigations are required to determine the exact mechanisms of TDP-43, huntingtin and αsynuclein uptake in vivo, additional mechanisms may also operate to facilitate their entry.
Overall, the data is consistent with protein aggregates exploiting macropinocytosis as a novel
route for entry into cells. It may therefore prove important to elucidate intracellular pathways
that result in macropinosome formation and closure to generate effective therapeutic targets
for halting the propagation of aggregation in these disorders.
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Chapter 6
CONCLUSIONS AND
SIGNIFICANCE

205

6.1 Overview
Amyotrophic lateral sclerosis (ALS) is a devastating neuromuscular degenerative disease that
currently has no effective treatments or therapeutics. ALS is characterised by a focal onset of
motor neuron loss, followed by contiguous outward spreading of pathology throughout the
nervous system, resulting in paralysis and death within a few years after diagnosis. The
aetiology of ALS is poorly defined and the complexity of the pathogenic mechanisms
responsible for disease initiation and progression are not completely understood. However,
multiple factors and cellular pathways including; protein aggregation and seeding of
endogenous native proteins, aberrant secretion and the subsequent internalisation of
aggregated proteins by neighbouring cells are implicated in disease pathogenesis. Both
copper-zinc superoxide dismutase 1 (SOD1) and the 43-kDa trans-activating response region
DNA-binding protein (TDP-43) have been implicated in these disease mechanisms, with
recent evidence demonstrating a role for macropinocytosis in ALS disease progression. Thus,
this thesis aimed to examine the prion-like activity of SOD1 and TDP-43, and determine the
role of macropinocytosis in the propagation of ALS pathology, in cell lines and human
neurons. From this, potential therapeutic targets may be identified and strategies developed.
6.2 Conclusions and Significance
The work presented in this thesis suggests that aggregates of SOD1 can stimulate
macropinocytosis and result in the subsequent prion-like propagation of misfolding, both
findings that may help explain patterns of ALS disease progression. Misfolded SOD1 is
capable of transferring between neuronal cells, through release from cells via active and
passive mechanisms and uptake via macropinocytosis–like pathways. In Chapter 2, the
uptake of SOD1 aggregates by the murine motor-neuron like cell line (NSC-34) was
confirmed. Furthermore, Chapter 2 demonstrated that inhibiting key regulators of
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macropinocytosis in NSC-34 motor neurons, using pharmacological inhibitors significantly
reduced the uptake of SOD1 aggregates into NSC-34 cells. This is consistent with previous
evidence in the same and similar cell lines (N2a neuroblastoma cells) using misfolded SOD1.
In these previous studies, similar pharmacological inhibitors of macropinocytosis resulted in
a significant reduction in SOD1 internalisation (Grad et al., 2014; Münch et al., 2011;
Sundaramoorthy et al., 2013) and subsequent induction of endoplasmic reticulum (ER) stress
in neuronal cells (Sundaramoorthy et al., 2013). Although ER stress was not directly
investigated in the current study, expression of misfolded WT and mutant SOD1 have been
observed to induce ER stress, and when prolonged can promote and pro-apoptotic pathways
in motor neurons reminiscent of ALS pathology (Nishitoh et al., 2008; Sundaramoorthy et al.,
2013).
Furthermore, although these studies suggest a role for stimulated macropinocytosis in SOD1
uptake, the exact mechanisms that underlie internalisation via macropinocytosis are
unknown. It is therefore possible that misfolded SOD1 may trigger macropinocytosis through
a direct interaction with receptors on the cell surface. Therefore, further analysis into the
specific pathways leading up to the activation of macropinocytosis will assist in identifying
how SOD1 utilises macropinocytosis for entry into cells. Incubation of NSC-34 cells with
SOD1 aggregates induced the activation of the signalling molecule RAC1 which in turn
resulted in the induction of membrane perturbations in the form of ruffles and blebs in the
plasma membrane and subsequent fluid-phase uptake into NSC-34 cells was also observed.
Given that there is no evidence of activated macropinocytosis in the absence of aggregates, it
is therefore reasonable to conclude that aggregated SOD1 triggered these signaling pathways
to activate a macropinocytosis-like pathway. The above represents new evidence for the
SOD1 aggregate mediated activation of macropinocytosis in ALS, however viruses have been
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shown in prior studies to activate these same macropinocytosis-like pathways to facilitate
cellular infection (Sanchez et al., 2012).
The murine motor neuron cell line NSC-34 is a hybrid cell line originally developed by
fusing mouse derived neuron-enriched primary embryonic spinal cord cells and N18TG2
neuroblastoma cells (Cashman et al., 1992). Although the NSC-34 cell model may provide
information that may not be completely applicable to human ALS disease, it is likely that
misfolded toxic SOD1 proteins may also activate macropinocytosis in a similar manner in
vivo to facilitate their entry into motor neurons. For decades, transgenic rodent models of
ALS have been widely available for use and have provided important information on a range
of areas including pathogenesis and disease progression in ALS disease. However, given that
there are differences between humans and rodents, particularly genetically engineered rodents
which develop ALS-like disease phenotypes, other physiologically relevant models should be
used to strengthen the validity of the data obtained. The development of reprogramming
biology and humanised models of ALS have been established in recent years to allow for
complementary, and arguably more relevant, models. The generation of patient specific
induced pluripotent stem cells (iPSCs) derived from reprogrammed somatic cells from a
range familial and sporadic ALS patients now represent an effective model disease model of
ALS (Hedges et al., 2016; Lee and Huang, 2015). A range of disease-relevant cell types
including neurons and motor neurons can be differentiated from human induced pluripotent
stem cells and used to study pathogenic mechanisms and elucidate specific drug targets.
Humanised models of ALS including iPSC derived motor neurons and human primary
neurons were therefore used to investigate the role of SOD1 in triggering macropinocytosis
(Chapter 5). In Chapter 5, internalisation of exogenously added WT and mutant SOD1
aggregates were also shown to be reduced in the presence of pharmacological inhibitors that
interfere with regulators of the macropinocytosis pathway and signaling molecules. In
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addition, SOD1 aggregates induced membrane ruffling and blebbing in the plasma membrane
and subsequent fluid uptake into human neurons coinciding with the activation of
macropinocytosis. Although the activation of the signalling molecule RAC1 was not
investigated, inhibition of RAC1 reduced the uptake of SOD1 aggregates consistent with a
role for RAC1 activation in this process. Although these human models provide relevant
insight into the mechanisms of exogenous SOD1 aggregate uptake, future studies could focus
on investigating the role of macropinocytosis in SOD1 internalisation in animal models,
including zebra fish which provide many advantages such as they are transparent and
therefore can visualise fluorescence in real time and are easy to handle and house.
Given the consistent structure and large size of most protein aggregates, it is likely that
similar mechanisms are used by neurons to engulf such large aggregates. Intuitively, the large
size of the protein aggregates argues against neuronal entry by most forms of endocytosis
given their size limitations. Therefore, the process of macropinocytosis could potentially
explain the uptake of such large structures. Thus, it reasonable to speculate that a wide range
of proteins associated with other common neurodegenerative diseases including TDP-43, αsynuclein and fibrillar polyQ aggregates (e.g. Huntingtin protein) in ALS, Parkinson’s and
Huntington’s disease respectively, may also trigger the activation of macropinocytosis in
neuronal cells. In Chapter 5, exogenously applied TDP-43, α-synuclein and Huntingtin (Htt46Q) protein aggregates were shown to be internalised by murine NSC‐34 motor neurons via
activated macropinocytosis, as similarly observed for SOD1 aggregates. This is consistent
with previous reports that implicate fluid-phase endocytosis in the cellular uptake of αsynuclein and Tau (Alzheimer’s Disease) aggregates (Holmes et al., 2013; Lee et al., 2008).
The panel of pharmacological inhibitors of macropinocytosis used in this study was sufficient
for confirming the involvement of macropinocytosis, specifically the use of amiloride (EIPA)
which is reported to specifically (in the context of other endocytosis pathways) inhibit
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macropinocytosis (West et al., 1989) (Chapter 2 and Chapter 5). Given the effectiveness of
EIPA, it may be worth investigating the effects of this drug in ALS mice or other animal
models. However, it may also be worth utilising other available inhibitors specific to
macropinocytosis or possibly developing new drugs for future experiments, to identify select
processes that may be directly involved in the uptake of aggregates into neuronal cells among
proteinopathies. However, macropinocytosis is important in a range of physiological
processes, including its contribution to antigen presentation by the immune system (Kerr and
Teasdale, 2009). Therefore a side effect of inhibiting macropinocytosis could be
compromised immune function.
In addition, given that this study presents for the first time, evidence for the activation of
macropinocytosis mediated by aggregates of SOD1, TDP-43, α-synuclein and Huntingtin
proteins, it will be interesting to determine whether these proteins interact with a specific
receptor upon cell contact and whether this receptor is the same among proteinopathies.
Although there is no evidence in the context of protein aggregate activated macropinocytosis,
previous work would suggest that receptor tyrosine kinases are involved in activation of
macropinocytosis (Kerr and Teasdale, 2009). Activation of receptor tyrosine kinases causes
an increase in actin polymerisation at the cell surface, resulting in an elevation in actinmediated ruffling and therefore an increase in macropinosome formation, which is the
mechanism distinguishing it from other endocytic pathways (Kerr and Teasdale, 2009). This
cell surface receptor triggering activation of macropinocytosis may therefore represent a
therapeutic target. Recent work suggests heparan sulfate proteoglycans are involved in the
entry of tau aggregates, but how this relates to activation of macropinocytosis and to entry of
other neurodegenerative disease associated aggregates is unclear (Holmes et al., 2013). In
addition to this, inhibition of RAC1 activity inhibits ruffle formation irrespective of receptor
tyrosine kinase signaling (Lanzetti et al., 2004). These are two examples of pathways that
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could potentially be exploited to slow or stop the progression of toxic protein aggregates that
enter cells via macropinocytosis. Furthermore, since macropinocytosis is incompletely
understood, it is possible that different types of macropinocytosis pathways may exist, and
therefore it will be interesting to investigate whether these proteins use the same or different
pathways and how they induce relevant responses in varying neuronal cells.
The ability of the SOD1 aggregates to escape membrane bound compartments and enter into
the cytosol is consistent with prion-like activity. By entering through macropinosomes, SOD1
aggregates can escape delivery into the endosomal compartments potentially due to the
‘leaky’ nature of macropinosomes, which is attributed to their lack of physical structure
(Conner and Schmid, 2003). Although the precise mechanism by which these SOD1
aggregates escape macropinosomes and the relationship between escape and induced
pathology is currently unknown. Given this, it may be worth investigating how SOD1
aggregates gain access to the cytosol and whether these aggregates interact with endogenous
proteins using real-time imaging techniques including Fluorescence Resonance Energy
Transfer (FRET) Microscopy which can be used to investigate molecular interactions
between SOD1 aggregates and endogenous proteins in real-time.
The release of SOD1 into conditioned media was observed from cultured NSC-34 cells
transiently expressing SOD1 proteins, coinciding with cell death (Chapter 3). However, how
the protein aggregates relate to toxicity is currently unknown and it will therefore be
interesting to determine whether misfolded and aggregated SOD1 proteins can directly
induce cell death or whether other factors are operating simultaneously. These factors include
deficient protein quality control, aberrant RNA metabolism, oxidative stress, endoplasmic
reticulum stress, glutamate excitotoxicity, mitochondrial dysfunction, fragmentation of the
Golgi apparatus, axonal transport defects and neuroinflammation. Furthermore, it is unknown
whether the secreted SOD1 proteins were mediated by cell death or by active secretion
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mechanisms. It is possible that both active and passive mechanisms of SOD1 secretion may
have occurred, via cell death and exosomes respectively, as previously reported (Grad et al.,
2014). Incubation of naïve neuronal cells with these conditioned media containing
extracellular WT and mutant SOD1 was shown to be internalised by murine NSC-34 motor
neurons. Toxicity and apoptotic cell death have been similarly observed in NSC-34 cells,
which have taken up extracellular misfolded and aggregated WT and mutant SOD1 protein
(Sundaramoorthy et al., 2013).
The prion-like propagation of a range protein aggregates mentioned above associated with
neurodegenerative diseases is a hypothesis gaining much attention. Prior studies suggests that
injection of brain/spinal cord extracts from symptomatic transgenic mice expressing human
SOD1, Tau, or α-synuclein can seed pathology in the sites of injection and spread to other
regions of the nervous system (Ayers et al., 2014; Clavaguera et al., 2009; Mougenot et al.,
2012). Moreover, cell culture experiments also show that insoluble material from brain tissue
can seed aggregation of neuropathological TDP-43, whose cytoplasmic accumulation is
associated with ALS (Furukawa et al., 2011). However, only until very recently has ALS
been implicated in the prion-like paradigm.
Cell-to-cell transfer of SOD1 aggregates between murine NSC-34 cells was observed here in
vivo (Chapter 3). In addition, the ability of WT and mutant SOD1 as well as TDP-43 to
induce the misfolding of native soluble proteins was quantified using a novel technique for
measuring inclusions; flow cytometric characterisation of inclusions and trafficking (FloIT)
(Chapter 3 and 4). Specifically, FloIT can be used to rapidly quantify cytosolic protein
inclusions, including small inclusions and can be used to investigate the co-aggregation of
different proteins into inclusions. Our data therefore, demonstrates the seeding of aggregation
in a prion-like manner. Consistent with this, recent work provides striking evidence that this
may indeed drive disease progression as focal injection of spinal cord homogenates from
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symptomatic G93A SOD1 triggers progressive motor neuron disease in mice expressing
G85R SOD1-YFP below the threshold for disease (Ayers et al., 2014). Furthermore, fibrils of
TDP-43 can induce templated aggregation of TDP-43 in cells expressing WT TDP-43 or
TDP-43 lacking nuclear localization signal (Shimonaka et al., 2016).
In vivo, aggregates of SOD1 were shown to induce TDP-43 mislocalisation NSC-34 cells and
rapid fragmentation consistent with TDP-43 pathology observed in sporadic disease.
Although the exact mechanism for this observation was not determined, it is likely that the
proteotoxic stress induced by aggregate uptake was sufficient to trigger the mislocalisation of
TDP-43. To the best of our knowledge, SOD1 induced TDP-43 pathology has not yet been
reported in humans, and the mislocalisation of TDP-43 in SOD1 mouse models is
contradictory (Shan et al., 2009; Turner et al., 2008) and therefore future investigations into
the mechanisms and role of SOD1 aggregates in the formation of pathological TDP-43 are
therefore warranted. This, however, provides a potential mechanistic link between sporadic
and familial ALS cases. Interestingly, TDP-43 aggregates are present in other
neurodegenerative diseases such as Huntington’s and Alzheimer’s disease and may reflect the
proteotoxic stress in these diseases.
The use of WT and mutant forms of SOD1 as well as other pathological proteins including
TDP-43 has been largely informative in the current study, given that these two proteins have
been largely implicated in ALS. However, the use of one mutant form of the SOD1 protein
(SOD1G93A) and TDP-43 (TDP-43G127X) may present a limitation of the study. Although the
G93A mutation is one of the more common and well characterised mutations used widely as
a model for familial ALS, future work should focus on a wider range of SOD1 mutations and
possibly more mutations in TDP-43 protein.
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6.3 Final remarks
Overall, this thesis demonstrated that misfolded SOD1 and other protein aggregates
associated with other common neurodegenerative disease including TDP-43, α-synuclein and
Huntingtin aggregates are capable of entering into NSC‐34 motor neurons and that
macropinocytosis plays a role in allowing the passage of protein aggregates into naïve cells.
The SOD1-mediated activation of macropinocytosis on these cells induced actin dependant
ruffling and blebbing in the plasma membrane triggered active RAC1 which lead to the
internalisation of the aggregates. Once internalised into macropinosomes, the aggregates were
capable of escaping into the cytosol, where the seeding of aggregation occurred, as detected
using FloIT. Furthermore, the release of SOD1 aggregates from neuronal cells via passive
and/or active mechanisms including cell death or potentially exosomes were observed and
this may represent an early event in ALS disease. These extracellular (released) aggregates
were able to internalise into other neighbouring motor neurons that may be more susceptible
to cell damage and/or death, propagating cellular stress and aggregation from cell to cell,
seeding aggregation consistent with previous evidence (Figure 6.1) (Grad et al., 2014; Münch
et al., 2011; Sundaramoorthy et al., 2013).
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Figure 6.1 Summary of important findings in this study and how they may explain the
role of macropinocytosis and SO D1 and TDP-43 protein aggregates in the pathogenic
disease cycle of amyotrophic lateral sclerosis . (i) In ALS, SOD1 or TDP-43 may form spontaneous
aggregates under non-physiological conditions or contain newly formed aggregates from seeded aggregation
reaction in motor neurons. (ii) These aggregates can be released from motor neurons either via cell death
(passive) or via exosomes (active) mechanisms. (iii) Once released into the extracellular environment, these can
internalise into neuronal cells via the activation of macropinocytosis, and enter through newly formed
macropinosomes, a process exploited by viruses. (iv) These aggregates may then escape these membrane bound
vesicles and enter into the cytosol (v) to potentially seed the aggregation of endogenous soluble proteins.
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Understanding neuron specific macropinocytosis mechanisms will be vital in identifying a
target to slow disease progression. In particular, the intracellular pathways that result in
activation of macropinocytosis, the formation and closure of macropinosomes, and
importantly potential disintegration of macropinosomes must be examined. Lastly, while the
ability of cellular uptake of misfolded SOD1 to induce TDP-43 pathology may be due to
cellular stress rather than a specific result of SOD1 misfolding, this notion further supports
the complex nature of ALS disease. However further study is required to decipher the
mechanisms involved in these interactions, and potentially identify other proteins or
processes that may be involved.
Given the prion-like properties of SOD1 and TDP-43 aggregates, an attractive therapeutic
target would be to block the cell-to-cell propagation. One way of doing this is to target the
aggregate entry mechanism. In an analogous situation, mechanisms underpinning Ebola virus
entry via macropinocytosis are being scrutinized, with promising compounds targeting
endocytosis and escape of viral particles from endosomes proving successful in mice (Sakurai
et al., 2015). Macropinocytosis may be a viable target given that other cell types such as
microglia that clear protein aggregates appear to be via different pathways (Roberts et al.,
2013). It may be possible then to redirect aggregates from entering neurons by supressing
macropinocytosis in pathological conditions while maintaining receptor mediated phagocytic
pathways utilized by microglia to engulf extracellular protein aggregates.
Overall, the work presented in this thesis presents data that is consistent with the notion that
protein aggregates could be an active part of ALS disease progression, possibly through
secondary nucleation (Buell et al., 2014), or another prion-like aggregate propagation
process. It presents novel data that now implicates the activation of macropinocytosis, a
process used by viruses during infection. Therefore, a better understanding of the
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pathological mechanisms involved and identifying targets may lead to halting the passage of
the toxic aggregates in a strategy analogous to drugs blocking viral entry.
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